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ABSTRACT

Coronary heart disease (CHD) is the single largest cause of death and disability in
most modern western societies and poor diet is a significant risk factor in the
pathogenesis of this disease. Despite significant advances in the treatment of
CHD, effective primary prevention approaches remain elusive largely due to the
difficulty of sustaining significant and long term dietary changes. In this doctoral
program, the hypothesis that the use of functional foods is an effective strategy in
the primary prevention of this lifestyle disease was examined. Methodological
approaches grounded in the field of nutrition science and behavioural psychology,
incorporating both quantitative and qualitative studies were used.
Results of a dietary trial in 25 patients, reflective of ‘free-living’ clinical practice
conditions, found that a functional food-led intervention using plant sterol enriched
margarine was an effective approach in the management of hypercholesterolemia.
Sixty percent of subjects counselled on the inclusion of 25g per day of plant sterols
achieved >15% reduction in total serum cholesterol, compared to none receiving
standard dietary advice. In another dietary trial that was a randomised placebo
controlled dietary intervention with parallel groups, 86 overweight, but otherwise
healthy, subjects where asked to choose at least eight serves per day from a
selection of either long chain omega-3 fatty acid (LCn-3) enriched foods (~125 mg
LCn-3 per serve) or matched control foods. After six-months, participants were
able to increase their dietary LCn-3 intake 4-fold (to ~1200 mg/day) and this was
confirmed by a corresponding increase in the erythrocyte LCn-3 levels by 20%.
This has implications for CHD reduction given the importance of dietary LCn-3.

xxxi
Consumer and social research also suggest that functional foods can have an
important role in public health. The Theory of Planned Behaviour (TPB) was used
as a theoretical framework for a study examining prediction of intention to use n-3
enriched functional foods, using a purpose designed questionnaire and follow up of
recorded intake. Regression analysis was able to show that the model was a
significant predictor of intention (R2 = 0.725, P < 0.001) and to a lesser extent
behaviour (R2 = 0.298, P < 0.001). Attitude was significantly positively associated
with intention, whereas subjective norms and control beliefs were not. These
results imply that the best prospects for modifying behaviour are likely to come
through a change in attitude. Beliefs and attitudes of key influencers are a
significant determinant of consumer attitude. Semi-structured interviews with
stakeholders (e.g. nutrition professionals, scientists, regulators, media personnel
and food industry representatives) revealed there are a number of areas of
agreement in their attitudes towards functional foods, including the need for safety,
taste, bioactivity and extensive evidence for claims. Divergent views were
expressed in relation to the regulation of health claims and the levels of evidence
required substantiating these claims. A strong feature of the areas of disagreement
was lack of clear scientific evidence available to form opinions, and stakeholders
often relied on pre-existing ideology. These differing views may impact negatively
on consumer attitude to the use of functional foods.
In conclusion, analysis of clinical and consumer research suggests that use of
functional foods can be an effective preventative health strategy for CHD as long
as the maintenance of positive consumer confidence can be achieved.
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CHAPTER 1

INTRODUCTION

Coronary heart diseases (CHD) collectively are the major cause of death and
disability in most modern western societies. Primary prevention strategies are
founded on the doctrine that prevention is better than cure. It has been
demonstrated that population-based healthy eating primary prevention programs
cost £14 - 560 (~AUD$ 34 -1373) per life year gained which is substantially
cheaper than the cost of treatment (1). This would suggest that effective primary
prevention strategies have the potential to reduce both the personal and financial
burden of many lifestyle diseases. However, primary prevention programs are seen
by many as achieving marginal gain at best and at worst are seen as ineffective
(2).
To date, approaches to reduce CHD which have been largely based on
educational and behavioural models of intervention, have met with limited success
(2). They are underpinned by the rational premise that people, once given
appropriate education and skills will make sound decisions regarding their longterm health status. Although there have been a number of programs which have
successfully demonstrated improvements in knowledge, skill application and
occasionally behaviour, they have seldom demonstrated improvements in risk
factor reduction or improvements in morbidity and mortality outcomes (2). With
tertiary treatment institutions under mounting resource and financial pressures,
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there needs to be a redress of effective strategies that can potentially prevent
these debilitating lifestyle diseases (3).
Recent advancements in food technology provide a new range of options for
intervention programs which are only beginning to be explored. At the forefront of
this technological boom are functional foods. These are foods which provide
nutritional benefits beyond basic nutrition (4, 5). Currently there is no universally
accepted definition. In its broadest definition functional foods can include not only
newly formulated foods but also traditional whole foods (e.g. oats and walnuts) (5).
Central to this research is the hypothesis that the use of functional foods is an
effective primary prevention strategy as it applies to CHD.
With the unlikelihood that functional foods singularly will prevent CHD, it is
important to place functional foods within an existing health promotion framework.
Egger and Swinburn urge us to view lifestyle diseases as an epidemic, and state
that epidemics historically have only been controlled after environmental factors
have been modified and that existing intervention strategies for lifestyle diseases
will only have limited impact if environmental factors are not addressed (6). There
proposed model (epidemiological triad) supports a devotion of effort into three
distinct, yet interrelating domains: host, environment and vector. For CHD, “host”
refers to the biological and behavioural influences on diet and other lifestyle
behaviours. “Environment” can be described in terms of the macro-environment
and the micro-environment which are located in the physical, economic and sociocultural environmental context (7). And finally the “vector” is represented by the
food and its associated nutritional profile. It is suggested that effective interventions
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need to address each of the components of the triad. By superimposing a
functional food-led intervention onto components of the epidemiological triad
model, effects of functional foods (vector) on biological and behavioural outcomes
(host) as well as the effects of these on the interface with policy and legislation
(environment) were investigated. In this thesis, evidence for the effectiveness of a
functional food-led approach was gathered using dietary intervention studies,
behavioural studies and a stakeholder analysis.
1.1

Methodological issues

Establishing evidence for effective CHD prevention using dietary intervention
studies provides a number of unique challenges. Firstly, the pathophysiology of
CHD develops over a long period of time and absolute rates of mortality in the
populations are relatively small. In order to detect the effect of an intervention on
mortality rates, trials require large sample sizes with long intervention and follow up
periods. This is usually cost prohibitive, leaving the definitive studies unavailable.
Secondly, there is no single cause for the development of this disease, and as
such a number of attributable risk factors have been described. These include dietrelated factors such as type 2 diabetes mellitus, obesity, elevated cholesterol,
particularly LDL-cholesterol and high triglyceride levels, lifestyle-related risk factors
such as physical inactivity and smoking and genetic factors such as gender and
family history (8) and more recently a low level of erythrocyte eicosapentaenoic
acid (EPA) + docosahexaenoic acid (DHA) (9). Often these intermediate markers
of disease do not necessarily answer questions of mortality. Despite our best
efforts to provide evidence of the effectiveness of primary prevention interventions,
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there will always be uncertainty because of the lack of definitive evidence related to
the disease endpoint itself. This should not lead to abandonment of research into
primary prevention programs, but does serve as a cautionary tale which needs
addressing through appropriate trial design and a reasoned approach to the
application of newly acquired knowledge.
Another concern for research design is that the utility of findings from the research
setting to a ‘real life – free living’ context is not always assured (10). Caution is
required when interpreting results from controlled clinical contexts and transferring
them into free-living settings. For this reason it is important to design intervention
trials that are grounded in a free-living context ensuring that the study outcomes
are not overly inflated due to the tightly controlled design where compliance is
assured. Also, extrapolating scientific evidence from one paradigm to another may
falsely raise expectations. For example, positive results obtained from a sample of
hypercholesterolaemic patients cannot be extrapolated to the general population.
Therefore, consideration of the use of functional foods for public health benefits or
as part of individual therapeutic regimens requires certain distinctions to be made.
Dietary interventions designed to promote health may be categorised two ways:
those that aim to modify dietary behaviour and reduce the level of risk factors in
individuals, and those that aim to address the underlying determinants of health in
populations as a whole (11). Each category of dietary intervention has specific
considerations with respect to study design as well as the conclusions which can
be drawn from the results. In relation to CHD, primary prevention interventions can
be categorised as those targeted toward individuals that aim to reverse the
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condition of diagnosed dyslipidaemia and those that aim to improve the dietary fat
intake (reduce saturated fat and increase essential fatty acids) in the population.
Despite the favourable results that individual counselling has on patients with
elevated cholesterol in controlled studies (where food is provided) the results in a
clinical environment are far less impressive (12). This has led to the undermining of
nutrition counselling as the front line treatment of dyslipidemia in favour of more
expensive drug therapy (13). However, the recent release of plant sterol/stanol
enriched food products has renewed interest in dietary therapy, culminating in the
recommendation of plant sterol/stanol use as part of medical nutrition therapy by
the authors of the US National Cholesterol Education Program (14). However,
there are no studies in the context of clinical practice that support this statement.
1.2

The utility of functional foods in clinical practice

In this thesis the first study was designed to test the hypothesis that specific dietary
prescription of margarine enriched with 2g/day of plant sterols/stanols is more
effective than standard dietetic advice in achieving an improved lipid and nutrient
profile in free-living subjects with hyperlipidaemia. A randomised parallel design
trial of comparative 12-week interventions was conducted with patients referred by
a general practitioner to a dietary outpatient clinic for the management of
hyperlipidaemia. In total, twenty-five patients (15 women and 10 men) completed
the study. The control group received counselling regarding diet for
hyperlipidaemia was based on the National Cholesterol Education Program
(NCEP) guidelines (14), whereas the intervention group was instructed to
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incorporate ~25 g/day of margarine containing plant sterols/stanols, which
delivered ~2 g of plant sterols/stanols. Changes in diet, body weight and serum
total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides were
measured and reported at baseline and at three months. The number needed to
treat (NNT), which is an index of effectiveness of the intervention, was calculated.
This study gave an indication of the utility of functional foods in clinical practice.
1.3

The utility of functional foods in population interventions

Independent of the favourable effect that a reduction of hypercholesterolemia has
on CHD risk, an adequate long chain omega-3 fatty acid (LCn-3) intake (EPA +
DHA) has also been found to be beneficial for the prevention of CHD (15-17).
Australians eat ~ 1/3 of the suggested intake of 650mg/day (18). Thus, from a
population perspective there could be significant population health benefits from
increasing the intake of this essential fatty acid in a large portion of the population.
Therefore, in this thesis a second study was designed, this time with a population
scope in mind, to test the hypothesis that a dietary strategy based on foods
enriched with microencapsulated LCn-3 (fish oil) is more effective than a diet with
non-enriched foods in achieving the target dietary recommendations of 1g/day of
LCn-3 as well as providing cardioprotective benefits. An evaluation of reported
dietary intakes in a 6-month randomised controlled parallel design supplemental
trial was carried out. 86 overweight men and women with elevated triglycerides
who reported low baseline fish intake were recruited and all subjects were supplied
with a range of processed foods enriched with LCn-3 and instructed to consume 8
serves per day (equivalent to ~ 1 g/day LCn-3), or matched control foods.

7

Reported energy, macronutrient and fatty acid intakes were measured by diet
history and 3-day food records in conjunction with red cell fatty acids and surrogate
markers of CHD. Food preferences were also determined along with the impact of
this style of eating on the whole diet. The effect that this functional food-led
intervention had on the total diet and dietary biomarkers was assessed and the
feasibility and practicalities of the widespread application of this approach
discussed.
The ability to extrapolate results from these studies is somewhat limited by their
design. In order to achieve the study design objective of placebo-controlled,
randomised interventions subjects were provided with all test foods. The relatively
high compliance in this study may not be achieved outside of the confines of such
a controlled environment. Therefore, two more studies were designed for this
thesis to investigate consumer beliefs, attitudes and ultimately predict the
consumer behaviour in relation to functional foods.
1.4

Consumers beliefs and behaviours with respect to functional foods

There are a number of theories which aim to explain and predict human behaviour.
These include, but are not limited to, the transtheoretical model (TTM), health
belief model (HBM) and theory of planned behaviour (TPB). All have valid use in
specific areas, with no one theory universally recognised. After a review of the
literature the TPB was chosen as the model of choice to help understand
consumer behaviour in relation to omega-3 (n-3) enriched functional foods. In brief
TPB suggests that the best predictor of human behavior is a person’s conscious
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decision to perform the behavior. This behavioural intention is determined by
several factors, including the attitude they hold towards the behavior, the degree of
social pressure felt by the person to perform or not perform the behavior, and the
degree of control that the person feels they have over performing the behaviour
(19). These three factors in turn are determined by a number of beliefs and
subsequently how each is evaluated. It has been demonstrated that the TPB, or
modified versions of it, is applicable in explaining consumers’ food choice (20-22),
including supplement use (23) and genetically modified products (24), however this
is the first time it has been applied to the area of functional foods.
The first step in testing the hypothesis that the TPB predicts intention and use of
functional foods enriched with n-3 was the implementation of exploratory focus
group research. As suggested by the authors who described the TPB, the first step
in exploring behaviour is to unveil the salient beliefs toward the behaviour of
interest, which in this case is toward functional foods enriched with n-3 fatty acids
(19). Focus group interviews were conducted with adult community based
residents living in the Illawarra region of New South Wales, Australia. Forty-two
participants (29 female; 13 male) aged 30-80y were recruited by advertisement
and attended one of six focus groups which were recorded and transcribed
verbatim. Content analysis was carried out and sub-categories were developed to
capture the emerging themes according to the TPB model. Each aspect of the
model was explored and salient behavioural, normative and control beliefs were
discussed and reported. The consumer attitudes and purchase intentions identified
in this study will be helpful to educators as they plan messages and strategies to
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guide dietary choices related to products with n-3 fatty acids. In addition the beliefs
identified and categorised from this study were then used to formulate a 54 item
questionnaire which was used in the subsequent study. The questionnaire, in
conjunction with information on dietary intake, was used to quantify responses
regarding intention to use, beliefs and attitude toward n-3 enriched functional
foods. A cross-sectional self-administered questionnaire was completed by
community based residents living in the Illawarra region of New South Wales,
Australia. Two sub-samples were surveyed via questionnaire: community members
who responded to a local media advertisement (n = 79), and subjects in a dietary
intervention trial for type 2 diabetes mellitus (n = 50). Using dietary intake data in
conjunction with the TPB variables, questionnaire items were constructed to
measure behaviour as well as intention to consume n-3 enriched functional foods.
Results from sub-samples did not differ and were combined for analysis. Using
regression analysis it was demonstrated that the model was a significant predictor
of intention as well as being externally valid when intake data was considered. This
work will help identify cognitive targets for the promotion of n-3 enriched foods,
which are important to identify if we are to increase the population intake of n-3
through the addition of this active ingredient through a range of processed foods.
However, primary prevention strategies based on education and promotion alone
will be ineffective if the environmental factors highlighted in the epidemiological
triad are not addressed (6).
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1.5

Environmental influences on the utility of functional foods

In order for a functional food-led intervention to have a significant impact on CHD a
supportive environment through effective policy and legislation is required.
McConnon et al (2002) argue that the success of functional foods in both
commercial and health promoting terms is reliant on the resolution of incongruence
between stakeholder beliefs and attitudes towards these foods as this will have an
effect of consumer confidence (25).
The final study of this thesis tested the hypothesis that beliefs about functional
foods are related to underlying ideology. Using semi-structured interviews the
beliefs and attitudes of stakeholders towards the development and promotion of
functional foods were unveiled. A sampling frame was drawn up of potential
stakeholders in Australia using the categories as outlined by McConnon et al (25).
A purposive sample of individuals was used representing general practitioners
(GP’s), nutritionists, industry, media, regulatory bodies and authoritative
organisations from various States. Interviews were audio taped and later
transcribed to allow systematic analysis of the discussion. Using the theoretical
framework proposed by McConnon et al (2002)(25) as well as reviewing the
literature pertinent to this area (26, 27), ten open ended questions were devised to
determine stakeholder awareness, beliefs, attitude issues regarding the
development and promotion of functional foods. The results of the stakeholder
interviews are discussed in relation to current national and international trends in
food policy and regulation. Outcomes from this study provide a better
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understanding of the areas of agreement and disagreement between the various
stakeholders, and ways to reconcile incongruence are suggested.
1.6

Summary

The primary prevention of CHD presents us with two challenges: to treat those with
overt symptomatic risk factors and to prevent CHD in people with no identifiable
risk factors. Neither of these challenges is currently being met with any widespread
effect (28). The studies reported here present an alternative primary prevention
paradigm using innovations in food technology as an underlying driver. To answer
the question as to the effectiveness of a functional food-led intervention this work
has gone beyond the traditional approach of controlled clinical studies to
incorporate dietary and behavioural psychology methodologies. In addition, the
interface between functional foods, consumer behaviour and policy has been
investigated and some of the implications of this intervention approach for food
regulation have been discussed.
1.6.1 Hypotheses
The advent of functional foods is an important technological innovation which has
the potential to help overcome the natural aversions humans have to dietary
change. However, evidence of the effectiveness of a functional foods-led
intervention is required. In addition, the use of functional foods by consumers must
be congruent with the socio-cultural beliefs of the target population and supported
by appropriate public policy. To confirm the central hypothesis that the use of
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functional foods is an effective primary prevention strategy, the following
hypotheses were tested:
1. Specific dietary prescription of margarine enriched with 2g/day of plant
sterols/stanols is more effective than standard dietetic advice in achieving
an improved lipid and nutrient profile in free-living subjects with
hyperlipidaemia.
2. A dietary strategy based on foods enriched with microencapsulated fish oil
is more effective than a diet with non-enriched foods in achieving the target
dietary recommendations of 1g/day of LCn-3 and providing the
cardioprotective benefits of fish oils.
3. The behaviour model, Theory of Planned Behaviour, can be used to predict
consumer’s intention and use of functional foods enriched with LCn-3.
4. Stakeholder beliefs about functional foods will influence the consumer
environment.
1.6.2 Aims
More specifically the aims of this thesis are to:
i.

Determine the effectiveness of prescribing 25g of margarine per day
(containing 2 g plant sterols/stanols) to hypercholesterolaemic patients
referred to an outpatient clinic on biochemical and dietary outcomes.
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ii.

Describe the feasibility of incorporating LCn-3 enriched foods in the diets of
people with low fish intakes and the subsequent impact on the total diet,
making clear reference to the quality and validity of the dietary data through
the use of biomarkers.

iii.

Gain an understanding of the salient beliefs underlying Australian consumer
attitudes and purchase intentions with regard to n-3 enriched functional
foods using focus group discussions.

iv.

Identify the nature, strength and relative importance of influences on
intentions to consume foods that are good sources of n-3 fatty acids using
the Theory of Planned Behaviour (TPB).

v.

Ascertain the beliefs and attitudes of key leaders (stakeholders) towards the
development and communication of functional foods.
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CHAPTER 2

LITERATURE REVIEW1

2.1

Coronary Heart Diseases

Coronary heart diseases (CHD), also known as coronary occlusion, ischemic heart
disease (IHD), atherosclerotic heart disease or coronary thrombosis, are the
leading cause of death in most Western societies including Australia (29). This has
wide public health implications. In 2002, CHD was the single largest cause of death
and the most common cause of sudden death, and accounted for 26,063 deaths
which represent 19.5% of the total number of deaths and accounted for 51.8% of
cardiovascular deaths in Australia (29). Over half of the CHD deaths were from
sudden heart attacks (acute myocardial infarction) (29). Overall, males are twice as
likely as females to die from CHD (29). From the results of the Australian 2001
National Health survey, 1.9% (355,600) of those surveyed individuals reported
having manifestations of CHD (29), whereas in 2001-02 it was estimated that there
were 48,700 fatal and non-fatal CHD events (29). Cardiovascular diseases are the
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most costly disease for the health system and in 1993-94 it accounted for $3,719
million or 12% of total direct health system costs in that year (29). Coronary heart
diseases were the major contributor to this cost, accounting for 25% ($894 million)
of the total (29). Furthermore cardiovascular drugs accounted for 16.8% of all costs
of prescription drugs listed on the Pharmaceutical Benefits Scheme in 1994 ($27.3
million per year) (29). From 1992-1994, there was an average increase of 4.0% per
year in these prescription drugs (29).
The clinical manifestations of CHD are chronic arterial obstructions or acute arterial
occlusions in various territories, which ultimately lead to the condition where there
is an inadequate supply of blood to the heart muscle leading to ischemia (30). In
some cases ischemia may become so severe that it causes a myocardial infarction
(coronary infarction, coronary thrombosis, or heart attack). This may result from the
progression of atherosclerosis within the coronary arteries, or result from the
formation of a blood clot within the arteries (thrombosis), or most likely a
combination of both that ultimately leads to a necrosis of the cardiac muscle cells
(30). Atherosclerosis is a disease of the tunica intima (arterial inner lining of the
lumen) of the large and medium sized arteries, characterised by the development
of fibrous, fatty deposits called plaques or atheromas (31). These atheromas
eventually become calcified, rendering them rigid and narrow.
The pathogenesis is only understood in part as yet. The development of an
atheroma (or plaque) in the intima of the major arteries marks the development of
the pathogenesis of atherosclerosis. Arterial wall abnormalities, blood composition
abnormalities and haemodynamic alterations are generally accepted to be
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causative (Virchow’s triad) (8). There is strong support for a causative relationship
between hypercholesterolaemia and atherosclerosis originally evidenced by the
premature development of CHD in younger individuals with familial
hypercholesterolaemia (32). There is also direct evidence from animal models of
the effect of elevated LDL-cholesterol on atherogenesis (32). Research suggests
this forms a cytotoxic compound and initiates the cascade of events eventually
leading to atherosclerosis (33). Shear-stress induced micro injuries of the
endothelium in hemodynamically compromised regions together with local
coagulation activation associated with microinflammation of the plaque are
currently thought to cause plaque rupture (8). The resultant local clot formation is
the ultimate reason for organ failure.
2.2

Dietary risk factors

No authentic cause of atherosclerosis has been isolated, but is believed to be
multifactorial (34). To date, aetiologic research has only established risk factors
which provide the basis for some efficient but incomplete means for prevention.
Most of this evidence relating to risk factors is epidemiologic and therefore consists
of statistical evidence for probability of evidence (34). The three factors most
consistently associated with an increase in the incidence of CHD include
hypertension, hypercholesterolemia and cigarette smoking. Other modifiable risk
factors include obesity, lack of exercise, hypertriglycerideaemia and low HDL
cholesterol levels. There are also a number of non-modifiable risk factors such as
male sex, diabetes mellitus, and family history of premature CHD and the presence
of definitive atherosclerosis.
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There is considerable evidence that dietary fats lead to increases in blood levels of
cholesterol, and ultimately to atherosclerosis, and in the past this has been the
theoretical underpinning to many health promoting and dietary prevention
strategies (35). Initially, expert committees from major scientific associations such
as the National Heart, Lung and Blood Institute and the American Heart
Association initiated clinical trials with the aim of decreasing plasma cholesterol
levels in an attempt to decrease the risk of atherosclerotic disease (the diet-heart
hypothesis) (36). However it is now becoming apparent that the role of diet in the
prevention of CHD is more complicated than this simple cause and effect
relationship would suggest.
2.3

The diet-heart disease hypothesis

Keys et al first suggested the link between serum cholesterol, dietary fat intake and
cardiovascular disease in the landmark Seven Countries study (37). Populations
living in Japan and Crete were shown to have the lowest rates of CHD and tended
to have a lower serum cholesterol and consume a diet low in saturated fat, while
being high in polyunsaturated fatty acids (PUFA) (38). However, it is apparent that
although there was a positive relationship between serum cholesterol and rates of
CHD, there was wide inter-population variation in CHD rates at all levels of serum
cholesterol. For example, at a cholesterol level of 6.00mmol/l, the US and Finland
had an incidence of cardiovascular disease (CVD) between 30-45%, whereas
Japan and Crete had an incidence of <10% (39).
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In addition to elevated levels of plasma cholesterol (TC), increased levels of
triglycerides (TG), as well as a reduced level of high-density lipoprotein cholesterol
(HDL) have been linked to the development of premature CHD (40-42). In a
prospective observational study, the Framingham Study, it was concluded that
coronary risk starts to increase with total cholesterol values over about 5.00
mmol/L (41). In addition, for patients with established CHD, elevated lipids and
lipoprotein remain predictive of future CHD events and even death (43). Elevated
triglycerides have also been suggested as having a predictive role in CHD (44).
The authors concluded that high plasma cholesterol; high blood pressure and
cigarette smoking are predictors of coronary risk. In addition, the Strong Heart
Study (2003) found the ratio of total and HDL cholesterol to be a good predictor of
CVD in both male and female type 2 diabetics, although a stronger predictor in
men (45). However the investigators acknowledged that they could only
demonstrate ‘guilt by association’ and could not prove that they cause CHD (46).
Hu et al followed 85,941 women from 1980 to 1994 from the Nurses’ Health study
and investigated the incidence of CHD (15). The age specific incidence rates of
coronary disease showed a decline in over time. The relative risk of all coronary
disease decreased by 31% from 1980 – 1992. This model suggested that an
improvement in diet explained a 16% decrease while the increase in body-mass
index explained an 8% increase in the incidence of CHD. Researchers noted that
the dietary changes were from a decrease in the intake of saturated and trans fatty
acids, whereas the intake of polyunsaturated fatty acids (PUFA), cereal fibre,
marine n-3 polyunsaturated fatty acids (LCn-3) and folate increased (15). In
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summary they concluded that a 10% decrease in serum cholesterol levels is
associated with a 30% reduction in CHD after adjusting for confounders and
measurement errors (47) which is consistent with earlier risk modelling which
reported a 2-3% relative risk reduction with each 1% reduction in serum cholesterol
(37). In addition, there is a wealth of observational, experimental and genetic
evidence to suggest that increasing HDL cholesterol will also lower the risk of CHD
(48-51). The ratio of total to HDL cholesterol is now considered more important
than these individual factors alone in estimating the risk of CHD (52-54). Therefore
it is important to assess the effects of dietary interventions on both of these
biomarkers.
Using these epidemiological associations as a theoretical base, drug intervention
trials have been carried out since the 1970’s. In 1994, the Scandinavian
Simvastatin Survival Study conducted a double-blind trial using 4444 patients with
existing CHD (55). Those patients receiving 3-hydroxy-3-methylglutaryl coenzyme
A reductase inhibitors (HMGCoA reductase inhibitor (statin)) showed total
cholesterol, LDL-cholesterol, HDL- cholesterol changes of –25%, –35% and +8%
respectively. Using the combined end-points of coronary deaths and nonfatal
myocardial infarct (MI), a reduction in incidence of 37% was achieved over the
entire study (5.4 years) (55). Comparable results were reported by using
Pravastatin (56). Similarly, dietary studies into the secondary prevention of heart
disease have shown a reduction in serum cholesterol by 8 -12% through dietary
manipulation – aiming for low saturated fats, high n-3, high fruit and vegetables –
has resulted in a 25 - 45% reduction in cardiovascular mortality (57-59).
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Can the same benefits be achieved with dietary interventions aimed at reducing
total cholesterol in primary prevention? Epidemiological and experimental evidence
indicate that a diet high in SFA is associated with high levels of serum cholesterol
which are in turn related to CHD, although there are some significant anomalies in
the evidence where some of the earlier intervention studies failed to improve CHD
prognosis (60). However, it can be noted that the trials were conducted on low risk
patients and used high fat diets (~ 40% of energy as lipids), comprising of low
saturated fat and cholesterol levels, but very high level of PUFA (15 to 20% of
energy), particularly n-6 (60). An epidemiological investigation into the relationship
between dietary intake and CHD mortality could not find any significant association
between any of the dietary components and mortality (61). It was concluded that a
better understanding of the pathway between dietary intake and coronary disease
is needed, as the current diet-lipid-heart hypothesis may be overly simplistic (61).
Furthermore a number of primary prevention trials failed to determine this
association. In the Multiple Risk Factor Intervention Trial, 12,866 high risk males
between the ages of 35 and 57years were recruited to a randomised primary
prevention trial (62). Men randomly assigned to the intervention group were
counselled on lowering cholesterol, received dietary advice for reducing
hypertension, and instructed to cease smoking, whereas those in the usual care
group were referred to usual community follow up. After an average of 7 years, and
despite significant reductions in risk factors in the intervention group, both CHD
mortality and total mortality did not differ between groups (62).
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In summary, the diet – heart disease hypothesis is characterised by the following
syllogism: that an elevated intake of saturated fat, and total fat, and dietary
cholesterol will raise serum cholesterol, which in turn leads to atherosclerosis and
ultimately results in CHD morbidity and mortality (63). As this hypothesis would
suggest, a reduction in dietary saturated and total fat should result in a reduction in
morbidity and mortality from CHD. It is the lack of direct evidence that is missing in
order to prove the hypothesis that has prompted others to question its validity (64).
2.4

The diet – heart disease hypothesis revised

Although research has focused on the role of SFA, serum lipids and
atherosclerosis for the last 3 decades, more recent attention has turned to the role
of specific dietary fats, and in particular n-3 on specific manifestations on CHD,
namely sudden death (65-67). N-3 fatty acids are a family of naturally occurring
PUFA. It is in the position of the double bonds within their hydrocarbon chain that
gives n-3 fatty acids their name and also their physical and physiological
properties. For example, in n-3 the terminal double bond (i.e. closest to the methyl
end of the hydrocarbon chain) is on C3. In n-6 the terminal double bond is on C6.
The n-6 and n-3 families of PUFA have a range of members, ranging from linoleic
acid (LA; 18:2n-6) and α-linolenic acid (ALA; 18:3n-3), both of which are plantderived oils. In fact, n-6 and n-3 double bonds can not be inserted into fatty acids
by animal enzymes, only by plants through the action of the ∆12- and ∆15desaturase respectively (68). Although animals cannot derive these fatty acids,
mammals have a requirement for these, and thus they are regarded as essential
fatty acids. Although mammalian cells cannot synthesis these fats, they can
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metabolise them by further saturation and elongation. For example linoleic acid can
be converted to γ-linolenic acid (18:3n-6) by ∆6-desaturase and then γ-linolenic
acid can be elongated to dihomo- γ-linolenic (68). This can be further desaturated
by ∆5-desaturase to yield arachidonic acid (20:4n-6). Using the same series of
enzymes α-linolenic acid is converted to EPA (20:5n-3) (68). Because the n-6 and
n-3 series utilise the same enzymatic pathways (∆6-desaturase reaction) which is
a rate limiting step, there is competition between these fatty acid families.
Further metabolism of EPA to DHA (22:6n-3) is mediated by the formation of
docosapentaenoic acid (DPA; 22:5n-3), then the addition of two additional carbons
(24:5n-3) and desaturation at the ∆6 position to form 24:6n-3 and finally β-oxidation
to yield DHA (69). It is important to note that recent studies have revealed that the
conversion of ALA into its longer chain derivatives is not efficient in humans, and
some suggest that conversion of ALA to DHA is around 15% (70-72). Similarly
arachidonic acid can be metabolized by the same enzymatic series to yield, in turn,
22:4n-6, 24:4n-6, 24:5n-6 and 22:5n-6 (73).
The long-chain derivatives of LA and ALA acid (AA and EPA respectively) are
important biologically as they exert potent physiological effects (68). EPA and AA
are competitively metabolized via the cyclooxygenase, lipoxygenase and
cytochrome P450 pathways to eicosanoids such as prostaglandins (PG),
thromboxanes (TX) and leukotrienes (LT) (74). Arachidonic acid is the substrate for
the synthesis of 2-series PG, 2-series TX and 4-series LT, whereas EPA is the
substrate for the 3-series PG, 3-series TX and 5-series LT. The competitive
metabolism of these substrates has important implications in the regulation of
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smooth muscle contraction, platelet aggregation, inflammation, immune function
and cell proliferation (74). For example, EPA-derived TXA 3 shows reduced
proaggregatory and vasoconstricitive properties compared to the AA-derived TXA
2, while the antiaggregatory and vasodilative efficacy of PGI 3 equals that of PGI 2
(74). Because ALA and LA compete for the ∆-6-desaturase enzyme in the
desaturation chain elongation pathway, both incorporation of ALA into the tissues
and plasma as well as the conversion of EPA and DHA, are influenced by LA
levels. The net result of a higher ALA levels and subsequent EPA metabolite is the
suppression of TXA 2 (and promotion of TXA 3) which has a proaggregatory
vasoconstrictor, as LA conversion to arachidonic acid is decreased (64). In
addition, PGI 3, the antiaggregatory prostaglandin derived from EPA, has effects
comparable to those AA-derived PGI 2 (75). Subsequent research revealed that
the other 3-series eicosanoids derived from EPA (e.g. PGE 3, LTB 5) also have
reduced physiological activity compared to their 2-series counterparts (75).
Thus the net results in prostanoid synthesis from n-3 results in reduced
proaggregatory and vasodilatory effects (74). The differences between the EPA
and AA metabolism are likely to be the basis for the observed reduction in
thrombosis and anti-inflammatory properties of dietary n-3 fats (75). Thus it is
thought that a lower n-6:n-3 ratio has a beneficial effect on primary and secondary
prevention of atherosclerosis, thrombosis and embolic phenomena,
hypertriglyceridaemia and hypertension (74).
Presently most Western countries consume diets with relatively low levels of this
LCn-3. A good dietary source of LCn-3 is fish. Fish can be classified as either lean
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fish, where fat is stored in the liver (e.g. whiting, cod) or fatty fish, where the oil is
contained in the flesh (e.g. salmon, tuna, herring, mackerel). Essentially all fish oil
is high in LCn-3, although the proportions of EPA, DPA and DHA can vary. The
major dietary source of AA is from meat and meat products, but most AA comes
from the conversion of LA rather than from the diet (76). In contrast, major sources
of LA come in the form of cooking oils (e.g. corn oil, sunflower oil and rapeseed oil)
and margarines made from these oils, which make a significant contribution to the
intakes of these fatty acids (68). This results in a higher intake of n-6 in modern
Western societies over the last 35 years (68). For example in the UK the average
intake of LA among adults increased from ≈ 11g in 1970 to ≈ 14g in 1990 (68).
However, more recently margarines derived from canola and flax have been
introduced into the food supply and contain more ALA. ALA can be metabolized to
EPA and DHA through the desaturation chain elongation pathway (64). The
physiological action of the n-6 series is interwoven with the actions of the n-3
series, and it is an imbalance between the two that has a detrimental effect on
vascular health. The correction of this n-3 imbalance and LCn-3 deficiency in the
modern diet is a key step to improving the cardiovascular risk in our population
(77).
Interest in n-3 and their health benefits were stimulated by earlier research into the
dietary habits of Greenland Eskimos. It was suggested that the reasons for the low
cardiovascular disease rate, which was <10% of that predicted given their high
intake of fat, was due to a diet which was high in seal meat and whale blubber (17,
78). The suggested cardioprotective component was LCn-3, with the intakes being
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estimated to average as much as 5-15g/day (78). In comparison to Danes,
Eskimos ate a diet that was lower in linoleic acid (LA) and higher in n-3; had
platelet phospholipids that contains proportionately less LA, less AA, and more
EPA; and had a lower mean platelet count and longer mean bleeding (79). The
Japanese also exhibit a low mortality from CHD, with fatty fish also contributing
significantly to the traditional Japanese diet (80). These results have been
replicated in population studies that have found a positive association between
communities with a high fish intake and lower rates of CHD (17, 81). Data from a
number of epidemiological and case-controlled studies dating from the 1960’s have
strongly supported the inverse relationship between high LCn-3 blood
concentration and intake on CHD mortality rates in Western countries (65-67, 79,
82-100). For example, the Zutphen study provided early epidemiological evidence
of the importance of fish oil in the prevention of CVD (100). This study, conducted
in 1960, observed a cohort of 852 middle aged men who had no history or
symptoms of heart disease. After 20 years the incidence of heart disease was
inversely related to fish intake. The authors concluded that 35 g fish/day equated to
a 50% reduction in mortality from coronary artery disease (100). However, this
area is not without controversy as others have failed to show significant benefits of
modest intakes of fish oil on CHD rates (96, 101, 102).
Further support for an increase in LCn-3 comes from research into Paleolithic
nutrition. N-3 fats were abundant in the diet of our Paleolithic ancestors (103). The
original sources of n-3 in the food supply were from ubiquitous algae in the sea and
of grasses and leaves on the land (104). This small amount of n-3 in the algae and
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grasses became more concentrated as it was consumed up the food chain,
particularly in fish and larger grazing animals (104). With modern domestic animal
generally being fed on cereal based products, meat is generally low in these
essential fatty acids (105). Although interesting, evidence from controlled
intervention trial is needed to substantiate the hypothesis.
A secondary prevention study, the Diet and Reinfarction Trial (DART) randomised
2033 survivors of myocardial infarction who were at very high risk of dying from a
heart attack with the next few years into a low fat diet or high fibre diet. The
intervention group consumed ~2.3g EPA/day, whereas the control group
consumed ~0.7g EPA/day. After 2 years of intervention the low dose fish oil group
had a reduced mortality (29%), with no effect on blood pressure, serum lipids and
no difference in ischaemic events, and the authors concluded that this suggests an
antiarrhythmic effect (58, 106). Similar results have been reported by Singh et al
(1992) (107). The clinical effectiveness of fish oil was most strikingly demonstrated
in the GISSI Prevenzione study (108). This was also a secondary prevention study,
but this time using a fish oil supplement, Marchioli et al (2002) randomised 11,323
survivors of myocardial infarction to either n-3 supplements (885mg of EPA +
DHA/day), vitamin E (300mg/day), both or neither (control) (108, 109). After 12
months, compared to the control group, they demonstrated a significant reduction
of cardiovascular deaths by 30% and a significant reduction of sudden death by
45% in the fish oil group, but not the others (108). There were no effects on
cholesterol, blood pressure and a small reduction in triglyceride. Survival curves for
the n-3 treatment group diverged early after randomisation and mortality was
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significantly lowered after 3 months of treatment. The authors concluded that the
early effect of low-dose (~1g/day) n-3 on total mortality and sudden death supports
the hypothesis of an antiarrhythmic effect of this therapy (108). Equally impressive
results have been reported with ALA. The Lyon heart study was a prospective,
randomised single-blinded secondary prevention trial and compared the effect of a
Mediterranean diet rich in ALA (precursor of long chain n-3 fatty acids) rich diet to
the usual post-infarct prudent diet. Overall mortality was reduced and an adjusted
risk ratio of 0.30 achieved (38, 110). An interesting addendum in these studies was
the finding that significant reductions in CHD death were observed with little or no
reduction in serum cholesterol (111).
When comparing these results to those obtained through drug interventions, the
clinical validity of fish oils therapy in the secondary prevention of CHD becomes
apparent. A recent meta-analysis of patients with CHD to determine the
effectiveness of HMGCoA inhibitor (Statin) therapy concluded that there was a
reduction in CHD mortality or non-fatal myocardial infarction of 25% (RR, 0.75;
95% CI 0.71-0.79), all cause mortality 16% (RR, 0.84; 95% CI, 0.79-0.89), and
CHD mortality 23% (RR, 0.77; 95% CI, 0.71-0.83) (112). These values are no
better that the results achieved in the fish oil supplementation trials.
There are a number of mechanisms via which LCn-3 may reduce the risk of heart
disease. It may protect against both the pathological processes leading to the
disease (i.e. atherosclerosis) and the process leading to death (i.e. stroke and
myocardial infarction). Dietary n-6 and n-3 reduce triglyceride accumulation in the
skeletal muscle and potentially in the cardiomyocytes and β cells (75, 113-116).
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Elevated triglycerides are regarded as an independent risk factor of CVD and has
been outlined in a number of reviews (117-119). The resultant lower tissue lipid
levels are associated with an increase in insulin sensitivity (120). PUFA
concomitantly suppress lipid synthesis in the liver, up regulating fatty acid oxidation
in liver and skeletal muscle and increasing body glycogen (120). This repartitioning
activity of PUFA has been observed in both animal and human models (120-122).
LCn-3 are also anti-inflammatory (123), which is recognized to be a contributing
factor to atherosclerosis, starting off the cascade of vessel wall intima damage
culminating in leukocyte and smooth muscle migration (124). Further down
regulatory pathways, protective actions attributed to LCn-3 include decreasing
growth factor (125) and adhesion molecules (126-128). Long chain n-3 have also
been found to reduce blood pressure (129-131) and as revealed in a recent metaanalysis, an intake of a median dose of 3.7g/day of LCn-3 can reduce systolic and
diastolic blood pressure of 1.7 mmHg (95% CI: 0.3, 3.1) and 1.5 mmHg (95% CI:
0.6, 2.3), respectively (132). LCn-3 have also been shown to promote arterial
compliance which is also an athero-protective benefit (133). Finally, as
demonstrated in a recent study by Erkkila et al (2004) fish intake is associated with
a reduced progression of coronary artery atherosclerosis (134).
In addition to the beneficial effects of PUFA which are exerted through changes in
vascular membrane fatty acid composition and subsequent alterations in hormone
signaling, fatty acids exert a direct effect within the heart. For example diets rich in
PUFA from both plant (n-6) or marine (n-3) origin reduce the incidence of fatal
cardiac arrhythmias after induced simulated myocardial ischemia in rat models
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(135-138) and in the marmoset monkey (139). Also, a comparison of the effect of
the different PUFA indicates an enhanced antiarrhythmic effect of dietary fish oils
(140). Fish oils typically contain 30-40% PUFA, mainly as EPA or DHA, and
provide the greatest antiarrhythmic protection (67, 141, 142). Furthermore, due the
preferential accumulation of DHA in myocardial cell membranes, its association
with arrhythmia prevention and metabolic efficiency and the selective ability of pure
DHA to prevent ventricular fibrillation, suggest that DHA is the bioactive component
of fish oil in the heart (143). There is also strong evidence to suggest that these
effects rely on the incorporation of DHA into the myocardial cell membranes and
are dependent upon habitual intake (143). Given that sudden ventricular fibrillation
accounts for up to 50% of cardiovascular deaths in developed nations (29) coupled
with the fact that prior symptoms often do not occur, prevention may best be
approached through community wide nutritional changes (141).
For a putative risk factor to be clinically useful several requirements need to be met
(144) and LCn-3 fulfils many of these (9). There is substantial epidemiological data
(145). A relationship between membrane EPA + DHA and cardiac death is also
biologically plausible which is characterised by the following hypothesised
relationship: 1. dietary n-3 intake increases cell membrane and free fatty acid n-3
levels, 2. higher n-3 levels favourably alter cardiac ion channel function, 3. altered
ion channel function modifies the cardiac action potential, and 4. alteration in the
action potential reduces myocardial vulnerability to ventricular fibrillation, which is
the major life threatening arrhythmia that results in sudden cardiac death (67). In
addition, LCn-3 may enhance plaque stability as well as being anti-atherosclerotic
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via other mechanisms (146, 147). Most importantly secondary prevention trials
have shown that by changing a risk factor a disease outcome is altered (109).
These results culminate in a strong association between this biomarker and
disease which is independent of other risk factors (87) and systematic review
evidence concludes that dietary advice to those with CHD can reduce morbidity
and mortality (148).
Although these results provide substantial evidence for the LCn-3 in secondary
prevention of CHD, the prevention of sudden cardiac death in the community in
patients without clinically recognised CHD remains a challenge. Currently there is
no primary prevention intervention trial linking fish intake or fish oil and the reduced
incidence of CHD and this area is not without conflict. For example, the Cochrane
Collaboration published a review on the role of n-3 for the prevention of CVD and
concluded that it was not clear that n-3 alter cardiovascular mortality in high risk
populations (149). Nevertheless there is enough evidence to support populationwide guidelines about fish consumption (150).
2.5

Summary of dietary risk factors for CHD

What is emerging from the literature is that there are a number of dietary factors
which have been implicated in either the promotion or prevention of CHD via two
potential mechanisms – atherogenicity and thrombogenicity. Saturated fatty acids
(SFA) have been shown to be cholesterol raising (and by inference atherogenic) as
well as thrombogenic (30, 151). PUFA of the n-6 series, and PUFA of the n-3
series (152), monounsaturated fatty acids (MUFA), dietary fibre (153, 154) and

31
antioxidants (155) have demonstrated protective effects. In addition, both clinical
and animal-experimental evidence suggests that the effect of n-3 on the risk of
sudden cardiac death relates primarily to reduced vulnerability to ventricular
fibrillation, rather than to a reduction in atherosclerosis or nonfatal myocardial
infarction (63). Doses of 3-5g/d of EPA + DHA have been shown in experimental
studies to decrease triglycerides (75, 113-116), decrease inflammation (123) and
blood pressure (132), whilst increasing vessel relaxation and increasing
erythrocyte deformability (133). However, excessive n-6 intake, through direct
competition, has been shown to increase thrombogenicity via the promotion of
platelet aggregation (126-128) and decreasing levels of growth factor (125). It is
worthy of noting that all of the doses in these studies that have been shown to be
effective are significantly higher than what is usually associated with prevention of
heart disease, suggesting that it may be the combined, or even synergistic effects
of all of these marginal effects that is important, although this is yet to be fully
understood. With this basis of scientific evidence a number of authoritative
organisations, using expert panels, have published dietary recommendations to
guide dietary therapy.
2.6

Dietary recommendations for the primary prevention of CHD

In a recently published review of some 150 studies on the link between diet and
cardiovascular health, the authors concluded by suggesting three major
approaches as being the most effective in preventing cardiovascular health: 1.
replacing SFA and trans-fats (solid fats produced artificially by heating liquid
vegetable oils and has similar effects to SFA) with MUFA and PUFA; 2. Increasing
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consumption of n-3 from either fish or plant sources such as nuts; and 3. eating a
diet high in a variety of fruits, vegetables, wholegrain, nuts and avoiding foods with
a high glycaemic load (156).
The Adult Treatment Panel (ATPIII) of the National Cholesterol Education Program
(NCEP) recommend as part of their Therapeutic Lifestyle Changes for the
reduction of CVD risk, a diet which contains 25 - 30% of total calories from fat (<
7% SFA, up to 10% PUFA, and up to 20% MUFA, 50 - 60% of total calories from
carbohydrates (CHO), ~ 15% of total energy from protein (PRO), < 200mg
cholesterol/day, dietary fibre 20 –30g/day and total energy to be balanced with
energy expenditure to maintain desirable body weight or prevent weight gain (14).
There is a recommendation to include 2g per day of plant sterols into the diet for
those with elevated serum cholesterol (14).
In addition, the International Society for the Study of Fatty Acids and Lipids
(ISSFAL) makes the official statement that the consumption of LCn-3 may reduce
the risk of CHD (157). More recently the Food and Drug Administration in the US
(FDA) has agreed to a qualified health claim for n-3, stating “supportive but not
conclusive research shows that consumption of EPA and DHA omega-3 fatty acids
may reduce the risk of coronary heart disease” (158). Although to date there are no
human studies that support the direct effect of LCn-3 and the primary prevention of
CHD, these uncertainties have been addressed by a number of secondary
prevention randomised controlled trials (RCT). Therefore, based on the balance of
evidence ISSFAL supports the use of LCn-3 in the prevention of CHD, and intakes
of 800-1000 mg per day appear to be a prudent approach (75). Safety of intakes
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up to 3000 mg per day of DHA/EPA has been approved by the FDA and this level
in generally regarded as safe (GRAS) in the American food supply (75).
Recommendations from the UK and Europe after an experts meeting suggested
values of up to 650 mg per day for the general population (75). In fact, recently the
American Heart Association recommended that n-3 be consumed as a supplement
if the diet contained an insufficient amount of this fat (159). In summary, for a
8360kJ (2000kcal) diet, ISSFAL recommends a daily intake of n-3 fatty acids of
0.65g EPA + DHA and 2.22g ALA, with the n-6:n-3 ratio reduced to substantially
less than 10 (157, 160).
2.7

Behaviour change theory in dietary interventions to prevent CHD

The goal of primary prevention is defined as the treatment of risk factors when no
clinical manifestations of atherosclerosis are apparent yet (8). Primary prevention
of CHD can either be individually oriented involving screening for and treating risk
factors (high-risk approach) or it can be directed to the whole population (161).
Although the priorities of primary prevention programs are to: 1. educate people
about risk factors and lifestyle changes to reduce risk; 2. identify and alter risk
factors to prevent the onset of CHD leading to heart attack or stroke, primary
prevention strategies in the past have taken on many forms which have resulted in
mixed results, therefore undermining the perceived benefits of this approach.
Much progress has been made in recent years in improving the cardiovascular
health of Australians. Death rates from CHD have fallen substantially, by around
70% since the late 1960’s (29). However, despite this CHD remains Australia’s
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greatest health concern. As most of the improvements in this rate have been on
the impact of cardiac survival (advances in treatment and care) there are huge
gains to be obtained through primary health care strategies (28).
Epidemiological observational studies, both prospective and case control, show
repeatedly that dietary factors are associated with CHD (79, 162-164), and
therefore contribute substantially to the preventable burden of this lifestyle disease.
Clinical trials have confirmed many of these associations leading to the notion that
people’s dietary intake can affect health (68). The scientific consensus is
supportive of an approach to improving dietary intake, and as dietary change
remains an important modifiable behaviour, it follows that primary prevention
intervention is advisable (165). However, non-pharmacological treatments such as
smoking cessation, exercise and improved nutritional habits are generally poorly
followed and their effectiveness is widely questioned (166, 167).
Nutrition intervention programs focus on foods people eat (168) as well as
employing behavioural science theory and methods to understand dietary
behaviour and design and evaluate dietary change programs (169). Early
behavioural nutrition research used basic learning theory to address issues of how
much and when a person chose to eat (169). These interventions included
nutritional counselling and adult learning theory in program design.
More recently, nutritionists and nutrition researchers have been exploring
behaviour change models and intervention strategies to find ways of having a
greater impact on behaviour change (170). The theories most commonly employed
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in primary prevention nutrition programs include Social Cognitive Theory (SCT)
also sometimes called Self Efficacy Theory and previously called Social Learning
Theory; Theory of Planned Behaviour; Health Belief Model (HBM); the
Transtheoretical Model (TTM), also called the stages of change; Health Belief
Model; and Self Control Theory (170). Population approaches have also been
employed using a number of theories from Community Education Theory to Health
Education and more recently Social Marketing (170). Each of these will be
reviewed briefly.
2.7.1 Nutritional counselling
Nutrition counselling is the process of guiding a client toward a healthy nutrition
lifestyle by meeting normal nutritional needs and solving problems that are barriers
to change (170). To alter food habit successfully, counsellors work with clients to
change behaviour based on a range of psychological, socio-cultural and
physiological factors. During the 1980’s, the focus was on behaviour modification,
giving way to goal setting and client centered counselling in the 1990’s (170).
There is an array of counselling philosophies, theories and models that are
available to deal with the complex field of behaviour change. The range includes
Person-centered therapy which involves clients actively participating in clarifying
needs and exploring potential solutions (171); Behaviours therapy which is based
on the premise that behaviours are learned and therefore new behaviours can be
re-conditioned (170); Gestalt therapy which operates in the present and aims for
clients to take responsibility for their own actions (172); Cognitive therapy which is
based on the premise that negative self-talk and irrational ideas are self-deflating
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learned behaviours and most frequently the source of their problems (173); and
Family therapy which aims to assist the individuals within the context of the family
to change themselves (174).
2.7.2 Adult Learning Theory
Historically, adult learning theory was regarded as an extension of childhood
learning theory. Approximately 25 years ago the concept of andragogy was
introduced into the field of education (175). Andragogy, “the art and science of
helping adults learn”, was contrasted with pedagogy, the art and science of helping
children learn (175). Adults can learn from a continuum of approaches from
teacher-directed learning to student-directed learning depending on the situation
(175).
2.7.3 Theory of Planned Behaviour
The Theory of Planned Behaviour (TPB) provides a model that can help explain
behaviour and intention to perform a given behaviour. In turn, a person’s
behavioural intention is determined by the attitude they hold towards the behaviour,
the degree of social pressure felt by the person to perform or not perform the
behaviour as well as the degree of control felt by a person over performing the
behaviour (19). These three factors are determined by a number of beliefs and
subsequently how each is evaluated. The TPB, or modified versions of it, has been
applied to a range of health related behaviours (20-22).
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2.7.4 Health Belief Model
This is probably one of the most influential models governing health related
interventions. It postulates that cognitive factors influence an individual’s decision
to make and maintain a specific health behaviour change. The individual’s
behaviour will change if they believe that they are susceptible to a health concern
which will impact on their life, and they are capable of making the necessary
behavioural changes to reduce the risk (176). Traditional approaches to dietary
management of cholesterol lowering are largely based on this premise.
2.7.5 Transtheoretical Model (TTM)
The TTM (also known as the stages of change model) states that people progress
through five distinct motivational stages in attempting to change their behaviour:
pre-contemplation, contemplation, preparation, action and maintenance (177). In
addition to helping understand behaviour, this model can be used as a counselling
guide, as strategies will have varying effectiveness depending on the stage of
change the individual is at. In addition this model can be used as a measure of
outcome effectiveness. For example, an intervention may be considered effective if
a client moved from “I do not need to make a change” to “maybe I should give
some thought to change”.
2.7.6 Self-Efficacy Theory
Self-efficacy has been used as a stand alone model, as well as incorporated into
other behavioural change models. Self-efficacy has been defined as “our personal
belief of how capable we are of exercising control over events in our life” (178). As
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strong self-efficacy has been found to correlate with the attainment of health
behaviour change, it is believed that a person’s confidence in ability to accomplish
behavioural change is more important than the skill per se (179).
2.7.7 Social Cognitive/Learning Theory
Social cognitive theory states that people are neither driven by inner forces nor
automatically shaped and controlled by external stimuli. Rather, human functioning
is explained in terms of a model of triadic reciprocally in which behaviour, cognitive
and other personal factors, and environmental events all operate as interacting
determinants of each other (180). Here, it is said, that behaviour change occurs
through taking action, observations of others taking action, and evaluation of the
results of those actions.
2.7.8 Social Marketing Theory
Kotler et al (2002) define social marketing as “the use of marketing principles and
techniques to influence a target audience to voluntarily accept, reject, modify or
abandon a behaviour for the benefit of individuals, groups or society as a whole”
(181). This relies on the voluntary compliance of consumers and often cannot
promise a direct benefit for this change. Despite distinctions in scope, social
marketing shares many similar techniques with commercial sector marketing.
A review of some of the individual randomised trials and other individual-level
intervention studies that have examined the effectiveness of various nutrition
interventions will be presented, including those conducted with healthy individuals
as well as at risk individuals. Also, a review of interventions focusing on both
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community groups (e.g. family, providers, worksites, point-of-purchase) and entire
communities will be presented. These studies will be presented with reference to
the theoretical model underpinning the intervention and discussed in relation to the
outcome achieved.
2.8

Individual-level dietary intervention studies

A large number of individual-randomised studies have been conducted to test the
efficacy on outcome measures such as food based outcomes (e.g. fish intake or
fruit and vegetable intake), dietary goal based outcomes (e.g. percent fat intake)
and CHD biomarker outcomes (e.g. serum cholesterol levels).
The 1990’s saw a large number of individual interventions aiming to increase fruits
and vegetables reporting largely positive results. Significant increases in fruit and
vegetable (F/V) intake were reported in an individual case study using behavioural
therapy over a relatively short time frame of 5 months (182) as well as in a 6 month
intervention with 33 women with low F/V intake (183). Lutz et al (1999) conducted
a 6 month intervention using 710 males and females using interventions based on
social cognitive theory and transtheoretical model with the aim of increasing F/V
intake (184). Subjects were randomised to receive regular newsletters, tailored
messages or goal setting advice at monthly intervals. Significant increases in F/V
intake in all intervention groups was achieved (184). Similar results have been
reported using telephone calls (185), nutritional counselling (186), coupons along
with educational programs (187), messages about change (188), and multiple
mailed contacts which resulted in significant decreases in fat scores (an indirect
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measure of fat intake) (189). Another personalised health promotion program using
targeted counselling demonstrated improvements in diet scores over a 2 year
period, but not 5 years (190). In the Netherlands, significant increases in fish
consumption were achieved in both group sessions and tailored letters after a 16
week intervention (191).
Similarly there have been a number of studies which have reported similar
successful outcomes in reducing both total and saturated fat intake. The MRFIT
trial was a randomised intervention of 12,866 males at high risk of CHD who
received nutrition counselling to reduce total fat, saturated fat and low fat foods or
control and were followed up for an average of 6 years. The intervention group
achieved significantly greater decreases in all outcome measures (192). Large
reductions in fat consumption in relation to controls have been reported by Boyd et
al (1997) after a two year period of nutrition counselling of 220 premenopausal
women (193), by Coates et al (1999) after 18 months provision of group education
to 2208 women (194) and in trials on men undergoing nutritional counselling (195)
and a prescription of dietary plans (196). Another trial found that dietitian-led
interventions produced significant reductions in dietary fat and cholesterol intake
compared with material and videotape intervention groups (197). While these
studies predominately used nutrition counselling as a theoretical underpinning,
White et al (1994) investigated the effect of using a program based in cognitive
theory (198). Using group sessions with self monitoring tools in conjunction with
nutritional and behavioural strategies they were able to demonstrate significant,
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large reductions in fat intake, which was maintained for at least one year after
intervention in 1050 women aged between 45-69 years (198).
Several studies have targeted individuals with risk factors for chronic disease. The
Oslo Study found that regular dietary counselling produced significant long-term
declines in serum cholesterol compared to control participants (199). However, a
community-wide screening and follow-up project in a low-socioeconomic area
produced significant changes in diet following group education compared with
pamphlet intervention, but no difference in serum lipids or CHD risk (200).
Metabolic ward studies have shown that dietary changes can reduce blood total
cholesterol concentration by 10-15% in settings with very strict dietary control (201204). However these results should be used with caution when extrapolating to
free-living populations. For example, Denke et al (1995) showed that dietary
counselling could achieve cholesterol reductions of up to 10%, and therefore would
prove value as a clinical treatment option (205). However, a study published in
1991 suggested that dietary advice to individuals produced small reductions in total
cholesterol concentration (less than 4%) rendering it of little value in clinical
management (206). Tang et al (1998) published a systematic review of 19
randomised controlled dietary intervention trials under free-living conditions aimed
at lowering total cholesterol (12). The overall weighted mean reduction in blood
cholesterol across all dietary comparisons was only 5.3%, using trials of at least six
months duration (12).
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A meta-analysis of randomised controlled trials of dietary interventions of at least
3-months concluded that dietary interventions in primary prevention can achieve
only modest improvements in diet and cardiovascular disease risk status that are
maintained for 9 – 18 months (207). For example, after 3 – 6 months dietary fat as
a percentage of energy reduced by -2.5% (CI - -3.9%, -1.1%) in the intervention
groups and serum cholesterol, -0.22 (CI = -0.39,-0.05) mmol/L in the intervention
groups (207). Dietitians are specifically trained and motivated to provide highquality dietary advice. Having a battery of approaches available for individual
clients, dietitians appear to achieve better outcomes than doctors at lowering
cholesterol in the short to medium term, though clinically the difference is small,
and there is no evidence to suggest that this strategy is better than self-help
resources or nurses (208).
2.9

Community-level dietary intervention studies

Community level interventions using a range of theoretical models such as SLT
(209), TTM (210-212), participatory strategies model (213), community
organisation (214, 215), socio-ecological (216), social marketing theory (217) and a
multitude of models (218) appear successful in improving fruit and vegetable
intakes as well as the selection of low fat products. Some studies, although not
stating the theoretical underpinning of the study, but using similar techniques such
as counselling, print material, advertising and food policy changes, have reported
similar positive effects of interventions (219-224), although others using similar
approaches and theoretical behaviour change models have reported little or no
effect (225-232). Also, a large number of interventions designed to reduce total fat
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and saturated fat intake as a percent of energy have all achieved positive
outcomes using TTM and Educational theory (233-235) and without an underlying
intervention strategy specified (236-239).
Now turning attention to population interventions targeting a reduction of serum
cholesterol, of the 6 published studies, half showed a positive effect whereas the
other half showed no significant impact of the intervention. In 1994, Luepker et al
used an intervention based on SLT employing mass media, health professional
training, screening and education across three separate communities and found no
sustained differential change in total cholesterol (240). Two subsequent
interventions using nutrition education and training in counselling found a similar
result (241, 242). However, positive effects have been reported in interventions
using mass media campaigns in 5 cities (243), community counselling and
screening (244) and food policy changes along with educational programs in a
contained community of a Kibbutz in Israel (245).
Several community interventions aimed at reducing CHD have not achieved
desired outcomes that would be predicted from the individual dietary behaviour
change interventions. In the Malmö preventive project (2000) between 1974 and
1992, a total of 22 444 men and 10 902 women attended screening. Around 25%
of the screened subjects underwent various interventions (lifestyle modification and
drug therapy) aimed at treatment of hypertension, hyperlipidaemia, IGT etc (161).
The behavioural approach was an individually oriented, high-risk approach with
resources for both screening and intervention. Although positive effects on risk
factors such as hyperlipidaemia were found, no effect of intervention on mortality
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and cardiovascular morbidity in the intervention group as a whole was reported
(246, 247). The authors concluded that risk factor screening and intervention in an
urban setting such as the one in Malmö, and the use of contemporary methods of
the trial, are not enough to reduce all cause mortality more than implied by the
population trends. They did note that it is important to consider the heterogeneity in
the determinants of disease, as people living in more socially deprived areas have
more risk factors and a higher incidence of CHD than found in the less deprived
areas (161). In a similar trial in another part of Sweden, middle aged men were
screened and treated for cardiovascular risk factors (248). However, no overall
beneficial effect could be detected in total or CHD mortality in comparison with a
predetermined control group. The MARGARIN study (2000) investigated the
impact of an intensive group education on the Mediterranean diet and after oneyear of intervention a posted leaflet with dietary guidelines was provided (249).
Beneficial changes in dietary habits were recorded in the intervention group,
however, saturated fat and total fat was still too high. Of the 262
hypercholesterolaemic persons with at least 2 other cardiovascular risk factors, the
intensive program of dietary education did not significantly lower cholesterol (-3%)
more that the control (-2%) and after 1 year both groups gained ~1% body weight.
2.10 Limitations of primary prevention strategies
With this background in mind it reinforces the fact that changing life-long behaviour
is a complex process, and the results are often disappointing. Despite the
increasing knowledge about the pathophysiological processes and resultant risk
factors of CHD and subsequent awareness and education about nutrition and
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exercise, CHD remains our number one lifestyle disease. Evidence from lifestyle
trials, in which both individual and population based preventative strategies have
been successful is limited (161). With the absence of disease symptoms it may be
difficult for individuals to change and adhere to a prescribed treatment. A large gap
exists between research and practice in the effective implementation of validated
lifestyle primary health initiatives to reduce the incidence of CHD.
Prevention of CHD represents a great challenge with the potential to reduce a
considerable portion of the global burden of this disease (250). Results obtained
from a number of trials (248, 251) lead us to believe that a hospital-based
prevention program alone is not effective in reducing the incidence of CHD, nor is
individual screening due to the vast numbers of at-risk individuals and lack of long
term resources (251). Therefore an individual approach is encouraged to be
combined with population-based approaches (161). These programs are required
to be based on evidence, noting that evaluation of larger scale community projects
will always be much more difficult than evaluation of individually targeted projects.
This raises the question about why primary prevention strategies fail. Possibly
there is a lack of compliance thus rendering interventions ineffective. In part this
can be attributed to the lack of knowledge of the psychological and social
mechanisms involved in changing attitudes and behaviours, not only of individuals
but of the entire population (161). Similar concerns have been raised by others,
and in part, this was the reason why a long term primary prevention trial was
abandoned because of the poor ability of free-living subjects to adhere to long-term
dietary recommendations to reduce saturated fat, highlighting the perceived
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difficulty of achieving dietary change (161). In addition the resource burden of
primary prevention strategies may be too great for patients, clinicians and the
health care system (252). Finally, lifestyle trials have traditionally been narrow in
their scope. They rely on singular contexts (individual or community) are based on
singular theoretical models (TTM, SCM, social marketing) and rarely consider the
wider political or environmental factors. To this end, the World Health Organisation
(WHO), the National Institute for Heart , Lung and Blood Disease (NHBLI), as well
as other organisations have all recommended radical changes in diet and lifestyle
interventions (161). The authors recognise that population-based interventions
need the development of a new methodology, not least within the social and
behavioural processes involved in preventive efforts in the population. Thus a new
intervention paradigm is required that helps individuals overcome the natural
aversion to dietary change and one that is going to be supported by a large portion
of the population.
2.11 A new paradigm for the primary prevention of CHD
Mortality from several causes has been reduced through prevention programs that
changed population behaviours (7). Examples in Australia and New Zealand are
smoking related diseases (253), road deaths (254), lung cancer (255), cervix
cancer (256) and sudden infant death syndrome (SIDS) (257). Mortality rates from
CVD provide a mixed picture. Mortality rates peaked in 1968 and have since fallen
by over 60%, and this is consistent in industrialised countries (29). However, it has
been reported that more than 70% of this overall decline in mortality has occurred
amongst patients with existing coronary heart disease (258). Evidence suggests
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that emergency care, medical (259) and surgical treatment and follow-up care (58,
260, 261) have influenced this rate due to the survival of cardiac events which
underscores the importance of secondary prevention (15). However, it is much
more difficult to detect a positive preventative effect of interventions directed
toward relatively healthy populations (192, 240, 248, 262).
Of the range of theoretical frameworks in common usage in health promotion for
influencing population behaviours and disease end-points the ‘epidemiological
triad’ has been widely used in addressing both communicable and noncommunicable epidemics and only recently has it been applied to lifestyle diseases
(7). Figure 2-1 shows how it relates to CHD specifically (7). The agent (the final
common pathway) for CHD is an imbalance of dietary fatty acids. Host factors are
a combination of non-modifiable, such as, genetic factors, age, gender, whereas
others such as beliefs, attitudes and behaviours are modifiable.
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Host

Education; behavioural & medical
interventions

Technology

Vectors

Policy, social change

Environment

Figure 2-1 The epidemiological triad as it applies to cardiovascular disease (the ‘agent’ is
dietary fatty acid imbalance) (6)

Behaviours are a complex interaction of psychological factors, including habits,
emotions, beliefs and attitudes developed through a background of learning history
(263). The vectors for a poor dietary profile are high saturated fat foods (264) and
foods low in n-3 (265). The environment is external to the individuals and provide a
structure within which people live and is considered a powerful determinant of
behaviours (7).
Host-related activities to date have been the focus of primary prevention strategies,
and tend to be education based (individuals or group education) or medical
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(pharmaceutical). Technological innovations such as novel food enriched with
bioactive ingredients or modified in fat content provide vector-related solutions.
These novel foods are commonly referred to as functional foods. A functional food
is defined as “… any modified food or food ingredient that may provide a health
benefit beyond that conferred by traditional nutrients the food contains” (266) or
“foods with health benefits beyond basic nutrition” (267). In this instance, vectorrelated solutions could be physical (making functional foods widely available),
economic (making the costs of functional foods affordable), policy (altering rules
related to the promotion of these foods i.e. health claims) and sociocultural
(influencing attitudes, beliefs and perceptions). Whilst there is overlap between the
different sectors of the triad, interventions historically focus on one corner.
What has been learned from ameliorating other epidemics is that population
behaviour change can be achieved knowing that: knowledge itself is a weak
determinant of behaviour but well communicated, action specific messages
influence behaviours; television-based communications are effective but
expensive; and environmental strategies are powerful. All elements of the triad
must be addressed simultaneously. In the case of CHD, vector innovations such as
low fat food were the first phase; now food innovations which include bioactive
ingredients provide new opportunities. Social attitudes are influenced and shaped
by policy changes (again nutrition claims and fat claims provided first phase
opportunities, now health claims legislation changes offer new opportunities); here
advocacy from powerful commercial groups often influence policy. Finally, the
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normalisation of consumers’ behaviours (e.g. acceptance of eating novel foods
enriched with fish oil) is powerful in sustaining long term behaviour changes.
2.11.1 Vector-based innovations
There has been an incremental increase in research into the bioavailability and
application of functional foods and food ingredients (268). Interest in functional
foods is increasing because of higher health care cost and recent scientific
discoveries linking dietary habits with the development of many diseases (269).
Functional foods have been designed with health improvement in mind.
Dietary guidelines are pointing nutrition educators to two priorities in the prevention
of CHD, namely promoting dietary habits that reduce serum cholesterol as well as
increasing their dietary LCn-3 intake. However, it has been widely acknowledged
that individuals find it difficult to adhere to stringent dietary goals for elevated
cholesterol (12) and the there is an inability of the population at large to consume
enough LCn-3 from fish alone (18). Thus the combined efforts of food
technologists, scientists, nutritionists and food industry have led to the
development of a number of functional foods, of particular note products enriched
with plant sterol/stanol and LCn-3.
Since the 1950’s plant sterols were found to have cholesterol-lowering properties.
The major plant sterols in the diet are β-sitosterol, campesterol and stigmasterol.
Research over the past decade has focused on the esterified form of plant sterols
which is added to food products - for reasons of effectiveness and safety.
Esterification renders plant sterols soluble in dietary fat which is the most effective
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vehicle to deliver sterols to the small intestine where cholesterol absorption occurs
(270). Plant sterols reduce the absorption of both dietary and biliary cholesterol
from the intestinal tract by 30-50% (271). The exact mechanism is yet to be
elucidated, however it is generally assumed that the presence of increased
quantities of plant sterols in the gut lowers the micellar solubility of cholesterol
thereby, lowering the amount of cholesterol available for absorption. Recent
advancements in food technology have seen the emergence of food products such
as margarine, milk, yoghurt and cereal products being enriched with plant
sterols/stanols and promoted as a food which can help lower serum cholesterol.
Another food innovation has been the development of LCn-3 enriched foods such
as margarine, bread, eggs and yoghurt. This has been made possible by the
advent of microencapsulation which allows for LCn-3 to be added to a range of
food stuffs (272). Microencapsulation is the process whereby small particles of oil
are encased in a secondary material (encapsulent) which is usually a complex
carbohydrate compound (272). This increases the shelf life of the oil as it reduces
exposure to the environment which would oxidise the n-3 and eliminates the ‘fishy’
taste that is accompanied by LCn-3 (272, 273). This has the net effect of protecting
the organic structure throughout all phases of the processing and in addition to
ensuring that taste and texture is not affected (272, 273). Both the bioavailability
and taste is not affected by oil that is microencapsulated (272-274).
There is little doubt that these two food types are a triumph of food technology,
however their effectiveness in promoting health is yet to be confirmed. There is
therefore an opportunity to use these recent advances in food technology and the
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development of functional foods (Vector) and test them against the elements of the
theoretical model. To demonstrate the effectiveness of these products in a
functional food-led intervention, an examination of both the biological and
psychological effects of these foods (Host) is required along with the consideration
of the wider social context (Environment).
2.11.2 Host-based considerations
Clinical studies on the effects of spreads enriched with plant-sterol-esters or plantstanol-esters (hydrogenated form of sterols) have consistently shown reductions in
serum total and LDL-cholesterol, with little or no change in serum HDL-cholesterol
or triglyceride. In controlled situations, plant sterol intake of up to 2g per day added to products such as margarine, oils, spreads and milk - have been shown to
reduce serum cholesterol by up to 15% (270, 275-278). The cholesterol lowering
effects of plant sterols is independent of, and additive to, the effects of dietary
manipulation and cholesterol lowering medication. A recent study showed that the
reduction in LDL-cholesterol by 10% achieved by a low-fat diet was enhanced by a
further 12% when plant sterols were added to the diet through salad dressing
(279). Since the hypercholesterolaemic action of sterols is mechanistically different
from the statin class of drugs, it might be expected that the effects are also additive
to those of drug therapy, however one study comparing the efficacy of sterolenriched spreads between subjects with and without cholesterol lowering
medication revealed that the relative fall in LDL-cholesterol was the same in both
groups (280). Despite the favourable results reported so far, all studies to date
have been in controlled settings where subjects have been supplied with sterol
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containing products. Translation of these efficacy trials into the clinical setting has
been slow. One reason is that evidence is still required from studies investigating
subjects who assemble the diets for themselves on a routine basis, thus
determining the true applicability of this strategy in the clinical setting (281).
Despite the body of evidence suggesting the importance of LCn-3, dietary goals
are difficult to achieve through the consumption from fish alone (18). Although
there have been a wide range of foods enriched with this essential fatty acid, only a
few studies have investigated their efficacy. A study by Mantzioris et al (2000)
investigated the effectiveness of a diet that incorporated foods rich in n-3 fatty
acids (282). Healthy male volunteers were supplied with foods enriched with α–
linolenic acid (cooking oil, margarine, salad dressing, and mayonnaise) and EPA
and DHA (sausages and savory dip) as well as foods naturally high in n-3 (flaxseed
and fish). Intake averaged 9.0 g/day of ALA and 1.8 g/day of EPA and DHA which
was confirmed by an increase in plasma, platelet and monocellular phospholipids
(282). However, this was a pre test – post test study, with 15 subjects over 4
weeks (282). Metcalf et al (2003) took this concept one step further and tested the
effects of providing a wide range of foodstuffs containing n-3 from fortification
(283). Foods enriched with LCn-3 included margarine spread, milk, sausages,
luncheon meat and French onion dip was provided to 16 subjects. Again this was a
before-after study for duration of 4-weeks. The consumption of ALA increased from
1.4 to 4.1 g/day and EPA and DHA increased from 1.2 to 1.52 g/day which was
confirmed by corresponding increases in serum and platelets (283). There has
been a suggestion by these authors and others that a range of novel foods
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provides the opportunity for wider public consumption of LCn-3 (282, 283), but this
may be a little premature. Although Mantzioris et al reported positive effects on
monocyte-derived eicosanoids and cytokine production, the design of these studies
require caution in interpretation of these results. The short time frame limits the
assertion that these foods could “support large-scale programs on the basis of the
therapeutic and disease-preventive effects of n-3 fatty acids”(282). Finally, the
effects of these foods on the composition of the total diet as well as other
biomarkers of CHD warrant attention.
A general principle in relation to vectors is that small changes in high volume
vectors can have significant population impacts (7). However at the core of this
principle is the assumption that a modified vector will be widely accepted by
consumers as well as being accessible in terms of location and cost. In this case
there is an assumption that these foods will be incorporated into the diet such that
the other dietary considerations are not compromised. Therefore for this class of
functional food to support large scale programs for the primary prevention of CHD
an understanding of consumer acceptance is fundamentally important. Factors that
promote or constrain the use of these foods need to be understood. The unveiling
of psychosocial variables can be used to maximise interventions, predict the
potential impact of an intervention and help guide future interventions. Whilst there
have been a few studies that have investigated consumer views towards functional
foods in general, (284-288) there are no studies that have investigated the factors
that prevent or promote the use of LCn-3 functional foods in the wider community.
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2.11.3 Environment – based considerations
To date the food industry has responded to public health guidelines and has
contributed to influencing the food supply (Vectors) in several ways. For example,
in response to a rapid rise in CHD there was a national call in Finland for the
Government to intervene (289). The results were a removal of saturated fat from
the food supply or its replacement with unsaturated fats. The results were exciting;
with mean cholesterol levels in Finland dropping by 15% along with rates of CHD
by about 75% of their peak levels (289). In many westernised countries farmers
and processors have responded more recently by producing leaner meat and dairy
whilst manufacturers have provided a number of foods substantially reduced in
harmful components. At the heart of this issue is the ability of companies to gain a
marketing advantage from nutritionally enhanced foods and nutrition and health
claims are one way to achieve this (11, 26). Countries such as the US, Canada,
UK, Europe, Japan have established processes for the management of health
claims. In contrast Australia has been slower in adopting this policy, with the Health
ministers of the Australian New Zealand Food Standards Council (ANZFSC)
agreeing in May 2002 and again in December 2003 to set policy principles for a
new regulatory system that will allow the use of health claims within a risk
management framework (290).
Health claims bring with them the concerns about the level of honesty and
accuracy of claims and label information generally (291). Examples show us that
the regulators are often behind the marketers in this regard (292, 293). In Australia,
where health claims are currently prohibited with one exception, a study found that
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7.4% of food and drink advertisements contained illegal health claims (26). In
addition, a major threat to the effective use of functional foods is the exaggerated
and often contradictory health claims observed in Europe, Asia and the US. For
example, only 1% of Japan’s functional foods are directed at the significant health
problems such as high blood pressure, with adequate scientific justification (294).
In part the problems relate to the strength of the evidence base for these claimed
benefits which range from very strong, based on multiple clinical trials, to the
merely suggestive, relying on epidemiological or in vitro studies (295). A strong
scientific base is a necessary requirement for any health claims about functional
foods (295). Furthermore consideration needs to be given to the ethical and social
consequences of their introduction into the food supply (296). For example, who
has access to these foods and what will be the cost to the consumer? Thus, careful
consideration is required about our future regulatory frameworks to ensure that
consumers are not misled about the potential benefits of functional foods.
McConnon et al suggests that in order for functional foods to reach their maximum
potential the food industry, government and health professionals must work
together to improve communication between themselves and consumers (25). An
initial step in this process is the clear articulation of the beliefs and attitudes of
these stakeholders and the identification of incongruence which may ultimately
affect this communication process.
In summary, in this thesis the effectiveness of a functional food-led intervention will
be measured against each component of the epidemiological triad model. Two
dietary interventions, behavioural studies using both qualitative and quantitative
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methods and a stakeholder analysis were conducted and the methodological
considerations will now be discussed.
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CHAPTER 3

METHODOLOGY

3.1

The concept of ‘evidence’ in relation to primary prevention interventions

Despite the postulation that functional foods can be used to improve health, it is
highly unlikely that these novel foods alone will be the solution. For functional foods
to be effective they must be placed within the context of current primary health
intervention frameworks. Thus an important conceptual issue concerns the type of
scientific evidence required to substantiate the effects of primary prevention
strategies (297).
Traditionally, in evidenced based medicine there has been an emphasis on a
hierarchy of evidence to rank recommendations according to the available type and
amount of evidence, of which the randomised controlled trial carries the greatest
weight (298). There is little doubt that the push by medical societies and federal
agencies to ensure practice was governed by this type of evidence in clinical and
pharmaceutical research has improved the quality of clinical practice. Unfortunately
this has motivated medical and nutrition societies to try to apply this scheme to all
research questions in the medical field, including public health.
A critical evaluation of these hierarchies of evidence and their application is
required. Because they were originally developed out of a specific type of research
question – mainly the evaluation of therapeutic treatments – their utility in the
evaluation of primary prevention strategies is questioned (297). The hierarchies are
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based on the ranking of studies according to their susceptibility to bias (297). This
means that hierarchy refers to the internal validity of the study designs. Although
internal validity is important in terms of experimental design, its external validity is
the relevance to the research question (297). For example, a randomised
controlled trial can be designed to test the effects of eating 10 tubs of yoghurt a
day on health, but obviously very few people would actually eat this. There is thus
a trade off between vulnerability to bias and external validity (297). The question
here is whether existing schemes for levels of evidence and grading
recommendations are appropriate for recommendations /guidelines dealing with
behavioural lifestyle modifications. To answer this question we firstly have to
differentiate between studies on therapeutic effectiveness or clinical preventive
measures on the one hand and observational studies on the relationship between
lifestyle and disease on the other (297).
A clinical preventive measure such as a vaccine or a clinical treatment or the
prescription of a pharmaceutical has to be applied before the treatment can be
evaluated. Therefore, assessment via an experimental study is appropriate. In
contrast, primary behaviour change interventions usually advise people how to
modify their behaviour (such as eating low fat foods or more fish or abstaining from
alcohol) within a common range of behaviours. For example, the recommendation
to stop smoking for lung cancer prevention was implemented without the support of
a RCT. Because lifestyle behaviours are observable in populations it suggests that
the assessment of the overall effect of specific patterns can often be obtained from
observational studies (297). In addition, there are significant barriers if an
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experimental design were required to prove insights from observation. For
example, apart from ethical barriers of exposing some individuals to an adverse
behaviour (e.g. smoking) some studies take years if not decades to complete
because of the latency periods of many of these lifestyle diseases. There is also an
inherent impossibility of blinding of many nutrition or other lifestyle interventions.
Finally, dietary interventions that may involve the increase of one food group (e.g.
fish) will inevitably result in the decrease of another, for example red meat. Thus
the effects of the whole diet are important and often it is difficult to disentangle
whether benefits are due to an increase in one food or the corresponding decrease
in another.
Reliance solely on RCTs is both not feasible and not able to provide adequate
answers for the effectiveness of dietary primary prevention interventions. Recently
levels of evidence have been published which take into account that different
medical areas require a different set of levels of evidence (299). However this
approach relies heavily on Cohort design studies. Another approach to cope with
the uncertainty in evaluating observational study results on disease relationships is
the application of causal criteria that includes aspects such as consistency,
temporality, biological gradient, biological plausibility and coherence (300). It has
been suggested that contemporary approaches to evaluation of evidence are
based on systematic summaries of all available data on a given topic rather than
on single studies or results from single study types (297). In addition innovative
designs, models and methodologies are needed for each research setting including
consumer research (301).
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In summary, RCTs are not available to establish the effectiveness of most primary
prevention interventions, but still an answer is needed and recommendations are
required. In order to assess the effectiveness of a functional foods-led intervention
as a primary prevention strategy a different set of research questions need to be
answered and therefore different types of study design are required. A paradigm
shift from the traditional hierarchy of evidence to an application of causal criteria is
required for guiding public health interventions.
This research drew from medical, dietetic, psychological and sociological
methodologies to answer the antecedent hypotheses. Firstly, in order to evaluate
the effectiveness of functional foods, trial design resembled ’free-living’ conditions
as this is the context where these products will exert their potential health benefits.
It was therefore important in evaluating effectiveness to design trials as close to
free-living conditions as practical. Secondly, dietary assessment approaches
needed to quantify not only the functional nutrient of interest, but also the total diet,
and here attention to dietary methodology was given. Also, in order to ascertain
consumer beliefs and attitudes toward functional foods as well as determinants of
behaviour, both a qualitative and quantitative approach were applied to fully
understand the reaction of consumers. Finally, to understand the wider political
environment, qualitative methodology provided useful tools in investigating
stakeholder views. Each of these approaches will be considered in turn.

62

3.2

Dietary interventions

Generally, evidence-based dietary interventions are hampered by 3 factors: a lack
of nutritional intervention studies; the difficulty of translating nutritional interventions
into practice; and the difficulty of translating interventions into a primary prevention
setting (302). Compared with research into the efficacy and safety of
pharmaceuticals, which is based on hard clinical endpoints, the study of food and
mixed diets is more complex. In fact, due to the heterogeneity of the population
and the different amounts and compositions of foods used by different populations,
objective definitive trials are almost unfeasible (303). Providing proof of
effectiveness is difficult due to the delay between the application of an intervention
and the observation of its effects, which may be many years (303).Therefore
upstream pathophysiological (304) and nutritional indicators (73, 305) may be used
as surrogate endpoints.
While evidence of the efficacy of dietary components are required from clinical
trials, it is equally important that evidence of the effectiveness from research in
practice environments is obtained, since the applicability of controlled studies to
general community settings needs to be confirmed (10). It is often believed that the
positive results obtained in controlled trials can be extrapolated into a free-living
context, as it is assumed that efficacy equates to effectiveness. However, efficacy
aims to establish a relationship between a bioactive component and therapeutic
benefit, whereas effectiveness also establishes this relationship whilst considering
the question of compliance. In order to determine the effectiveness of functional
foods, behavioural issues relating to the belief in the benefit of use, taste,
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preference and price need to be investigated as they can ultimately affect
compliance (20, 22). In addition, the net effect on the whole diet needs to be
considered given the importance of other dietary aspects involved in reducing CHD
risk (306).
3.2.1 Trial design
Historically dietary interventions have been evaluated on the basis of a hierarchy of
evidence, such as that of the National Health & Medical Research Council
(NH&MRC) (298). Because of the unique ability of randomised controlled trials to
control for confounders, which are either known or unknown, they provide the best
evidence of efficacy for interventions. Traditionally clinical nutrition practice has
used results to from RCT research to develop health promotion strategies.
However, this has not always led to the outcomes that have been promised. In part
this is due to the assumption that efficacy equates to effectiveness. This is an
important distinction if we are to determine the effectiveness of interventions for
diseases with a multitude of aetiologies. For example, confounders such as
compliance and the total diet profile can markedly reduce the predicted viability of
an intervention under investigation.
It is for these reasons that the dietary intervention studies that were used in this
research were designed to resemble as close to a free-living context as possible.
The first dietary trial investigated the effectiveness of plant sterol prescription within
a clinical context (Chapter 4). As previously summarised, although there were
numerous publications of the efficacy of plant sterols/stanols in reducing serum
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cholesterol and LDL, no studies had investigated effectiveness in a free-living
context where subjects had to purchase and consume products containing this
functional ingredient. The design used an existing outpatient clinic to recruit,
manage and follow up subjects. All outcome measures were those obtained
through routine practice (i.e. blood chemistry was collected by accredited
laboratories at the direction of the medical practitioner) which would be used as
markers for clinical decision making. The second dietary trial (Chapter 5)
investigated the effectiveness of LCn-3 enriched foods on biomarkers of
cardiovascular health. Within the study design considerations ensured that
subjects were free to incorporate these foods into their diet at will. There was no
specific counselling other than a brief instruction on how much of the products they
should consume. Also, to increase the power of this study, a variety of prototype n3 enriched food products were provided free to the subjects as additional foods not
currently available on the market.
Despite the very best of intentions to design trials that mimic real life situations
there will always be limitations. For example, recruitment bias, where certain
individuals are more likely to participate in trials because of a personality trait can
lead to an overestimation of compliance and ultimate effectiveness of a treatment.
In the fish oil trial, food products were provided and as a result real life barriers
such as cost, access and availability of these foods were removed.
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3.2.2 Dietary recording methods
In order to address secondary questions about the adherence to intervention goals,
and about the differences in observed outcomes between groups in trials, the
accurate assessment of diet is important (301). To do this there is a reliance on
dietary assessment methods such as the DH and FR. The DH is considered to be
the benchmark method used to assess dietary intakes (307). The DH is designed
to estimate subjects’ usual intake over a specified period of time, usually 3-months
(308). It has an established place as a dietary assessment method and lends itself
well to clinical practice (309). The DH method is also valuable in intervention trials
where dietary manipulation is required at the time of assessment (310).
Furthermore, the DH method has demonstrated its ability to produce reliable group
means for energy and macronutrients (309, 311). The FR on the other hand has a
greater precision in determining food amounts, is cheaper to administer and has
less reliance on memory (312).
It is common practice to validate methods for measuring intakes of a particular
nutrient on the basis of a positive correlation between individuals using different
dietary assessment techniques (313-315). However, measurement errors
associated with multiple assessments are most likely to also be correlated, making
an accurate assessment of nutrient exposure problematic (301). For example,
limitations in the DH method include interviewer bias, inaccuracy of portion size
reporting, errors in reporting of frequency, and a need for subjects to follow regular
eating habits (316). In contrast, FRs tend to underreport dietary intake, are a poor
representation of usual diet due to the limited number of days recorded, and distort
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food habits due to the recording process (317). Despite these obvious limitations,
the use of multiple dietary assessment measures, combined with the use of
biomarkers allow for comprehensive assessment of dietary intake that is less likely
to be skewed by common biases or errors.
With error in self-report of dietary intake being the single greatest impediment to
understanding the effect of diet on disease risk, the reliance on biomarkers has
received recent attention (301). The Women’s’ Health Initiative program in the US
was designed to demonstrate the feasibility of collecting a comprehensive panel of
biological markers of dietary intake (318). That study reviewed biomarkers for
energy (doubly labelled water), protein (24-hour urine collections) and
carbohydrate (plasma vaccenic acid). The authors propose that fat (and alcohol)
intake should be determined by subtracting protein and carbohydrate (as
measured by biomarkers) from the estimation of energy (318). Our primary dietary
outcome of interest was n-3 intake, and as such a biomarker for this fatty acid
class was required.
Biochemical validations make it possible to compare assessed dietary intake of
some nutrients against biochemical markers (319). In the case of fatty acid
compounds, demonstrated correlations between dietary intake and erythrocyte cell
membrane concentrations have been found, and provide a useful biomarker which
was used in the fish oil study (Chapter 5) (319-321). However, It is important to be
aware that the biochemical marker method itself is prone to error with results often
confounded by the fact that they reflect relative percentage and not absolute
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amounts as well as different methods of collection, sampling site and analytical
technique used (322).
In the sterol/stanol study no biomarkers were used to validate dietary data or
determine plant sterol/stanol intake. This obvious limitation was a trade off with the
experimental design which was to replicate real-life clinical conditions.
3.2.3 Sample
Two trials were used to look at the important primary prevention strategies aimed
at reducing the prevalence of CHD, namely cholesterol reduction in those with
hypercholesterolemia and increasing LCn-3 in low fish eaters. For the plant sterol
study, those identified as ‘at risk’ groups but with no overt cardiovascular
comorbidities provided the basis for investigation. Samples have been drawn from
patients identified with hypercholesterolaemia (TC ≥ 5.50 mmol/L) by General
Practitioners. Those who were of non-English speaking background, taking lipid
lowering medication for less than 3-months prior to referral or had changed dosage
within the last 3-month period were excluded, along with subjects following dietary
regimens for allergy or intolerance, renal disease and diabetes mellitus.
For the fish oil study, low fish eaters who had a BMI ≥ 25 kg/m2 and plasma
triglycerides > 1.6 mmol/L were included. Although healthy subjects were selected,
a criterion of elevated triglycerides was included as a triglyceride lowering effect of
LCn-3 is considered as a potentially important cardiovascular biomarker. Potential
subjects with a diagnosis of diabetes, recent symptomatic heart disease; angina
pectoris; history of myocardial infarction or stroke; peripheral vascular disease;
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major surgery within the last 3-months; BP >170/100; liver or renal disease
(plasma creatinine >120 mmol/L); regular non-steroidal anti-inflammatory drug
therapy; antihypertensive drugs, lipid lowering or other drugs affecting lipid
metabolism; those eating more than one fish meal per week or regularly taking fish
oil supplements; or an inability to consume the test foods were excluded. Both of
these samples represent sub-sets of the population which have well established
risk factors for CHD for whom targeted primary prevention strategies are
advocated.
3.3

Consumer research

In this thesis the primary interest in consumer research was to predict behaviour in
relation to the use of functional foods. Qualitative research methods have long
been used in the social sciences and are the principle methods used by
researchers interested in studying behaviours as well as customs. They are
particularly useful in answering complex questions confronting health researchers
and health care practitioners. The term “qualitative research” refers to specific
research techniques used to gather data about the social world (such as
questionnaires in survey research or focus groups) (323). Although qualitative
research may appear neither unified nor well defined, it is often characterised by
three distinguishing features. Firstly, qualitative research generally deals with talk
text or words rather than numbers, which does not preclude measurement, or that
it cannot be explanatory. A second feature is that it studies people in their natural
setting, rather than an experimental situation. This has particular relevance to this
research given the importance of establishing evidence in a ‘real life’ context. And
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finally, the use of a “multi-method” approach where questions are asked of social
phenomena from a range of perspectives is also a distinguishing feature. In a
health behaviour context, such as the use of functional foods, we have therefore
added a range of qualitative research methods to address the important questions
about this social phenomenon.
A frequent criticism is that qualitative methods are necessarily subjective (and,
therefore biased) and that such research is difficult to replicate and amounts to little
more than anecdote, personal impression or conjecture (323). This concern can be
allayed by ensuring that these techniques are applied appropriately and interpreted
cautiously (324).This research uses qualitative techniques to play a role in both
validating quantitative research findings as well as providing a alternate
perspective on the same social phenomena. So instead of viewing quantitative and
qualitative approaches as methodological opposites, each can be used to
complement the other.
An important feature of qualitative research is the link between theory and method.
The choice of research methods is inextricably linked to a particular theoretical
perspective or set of explanatory concepts that provide a framework for thinking
about the issue of consumer research.
3.3.1 Theoretical model of behaviour
The Theory of Planned Behaviour (TPB) (325) was used in this thesis and provides
a model that can help explain consumers’ purchase behaviours in relation to
functional food products. It has been demonstrated that the TPB, or modified
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versions of it, has been applied to areas of consumers’ food choice (20-22),
supplement use (23) and genetically modified products (24). In addition,
Baranowski et al (1999) published a review article on the psychosocial correlates
of dietary intake and concluded that models with psychosocial variables predicting
dietary fat and fruit and vegetable intake had a generally low predictive power (R2 <
0.30), with no single model out predicting others (168). However, they went on to
note that when models predicted narrower categories of behaviour such as the
TPB (e.g. milk consumption), predictive power tended to be higher (168). Thus it
could be predicted that this model will perform well against single action behaviour
such as consumption of n-3 enriched functional foods. It was also suggested by the
authors that in order to increase the predictive power of models, future research
should combine variables from separate theories and incorporate variables that
moderate the relationship of psychosocial to dietary behaviour (e.g. genetics of
taste, stage in the life course).
3.3.2 Qualitative methods
As the TPB model had not been applied to consumer behaviour related to
functional food use, beliefs and attitudes need to be determined. It has been
suggest that for each behaviour under investigation it is important to determine the
salient beliefs related to the behaviour in question (19). Focus group methodology
is recommended and others have reported using this technique to assist with
questionnaire design when using the TPB (23, 326, 327). Therefore, results
obtained from a set of focus group interviews served to define the parameters of
the TPB model and to test the language for questionnaire design.
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Focus groups are a form of group interview that capitalises on communication
between research participants in order to generate data. Here people are
encouraged to talk to one another as well as the researcher, exchanging questions
concerns and anecdotes to express points of view (328). Group work also assists
in understanding an issue through the different ways people communicate with one
another through the use of jokes, arguments and teasing which is useful as
people’s attitudes are not necessarily encapsulated in reasoned, logical responses
to direct questions (328).
In this research, focus group procedures adhered to the guidelines as suggested
by Krueger (1994) (329). Firstly, an interview guide was developed using the TPB
theoretical framework. Questions were devised to determine consumer awareness,
beliefs, attitude and barriers to using n-3 fatty acid functional foods. All focus
groups interviews were conducted in a neutral setting (a community hall). Each
group was heterogeneous for age, sex, socioeconomic status and occupation. All
focus groups were recorded and transcribed verbatim and transcripts were
analysed using a computer software package (Chapter 6).
3.3.3 Focus group sample and group composition
Focus groups studies consist of anything from half a dozen to over 50 groups,
depending on the aims of the study and the resources available (328). It was
reasoned that a sample of 12 groups would generate enough data to suit our
needs. The aim of the study was to work with a representative sample of
consumers with each group composition being heterogeneous in order to explore
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the different perspectives within each group setting. It is inappropriate to assume
that these group data are representative of the population, in the sense that these
views would be expressed in the community independent of the group structure. In
this sense the data obtained from the groups can be viewed metaphorically as a
“guidepost” rather than a “landmark”.
Using the TPB model, transcribed focus group conversation was categorised into
one of the three areas of belief related to behaviour: behavioural beliefs, which are
assumed to influence attitudes toward the behaviour; normative beliefs, which
constitute the underlying determinants of subjective norms; and control beliefs,
which provide the basis for perceptions of behavioural control. Content analysis
was carried out and sub-categories were developed to capture the emerging
themes. These themes provided the basis for questionnaire design.
3.3.4 Quantitative methods
To be able to test the ability of the model to predict behaviour a questionnaire
needed to be developed. Questionnaire development followed the process outlined
by Ajzen & Fishbein (1980). As recommended by the authors, clarity of the single
action behaviour is critically important (325). The behavioural criteria are
comprised of four elements: the action, the target at which the action is directed,
the context in which it occurs, and the time at which is performed. In this study the
single target behaviour was defined as “eating foods enriched with omega-3 fats in
the proceeding 2 weeks”. Even though clinical research points to LCn-3 (from fish)
as being more bioactive than ALA (from plants), this distinction was not made in
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the questionnaire as it was apparent from focus group research that consumers did
not distinguish the different classes of n-3. In order to measure behaviour we
surveyed the subjects 2 weeks after completion of the survey to ascertain the
behaviour under question, namely the consumption of n-3 enriched foods.
One of the advantages of this model is the ability to predict behaviour from
intention. Although intentions are immediate antecedents of actions, the observed
relationship between intention and behaviour depends on two factors: first, the
measure of intention has to correspond to the behavioural criterion in action, target,
context, and time; second, a measure of intention will predict behaviour only if the
intention does not change before the behaviour is observed. Here the careful
selection of intention is required. For this research intention was ascertained using
the following measure of intention, “I intend to eat one or more foods with added
omega-3 oils over the next two weeks”.
As outlined by the theory, a person’s intention to perform a given behaviour is the
immediate determinant of that behaviour. According to the TPB model, a personal
or attitudinal component, a social or normative component and a control
component determine behavioural intention (325). To assess a person’s attitude
toward behaviour a standard 7-point Likert scaling system was used. This alone
does little to explain the complexity of behaviour, therefore the factors that
determine these intentions are of interest. Beliefs can be viewed as underlying a
person’s attitudes, subjective norms and control that may ultimately determine
intention and behaviour (325). A number of possible salient beliefs obtained from
focus group interviews were used and converted into statements, anchored on a 7-
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point bi-polar Likert scale. The implementation of the questionnaire was via postal
survey and is also reported in detail in Chapter 7.
Whilst the reduction of behaviour to a set of statistical relationships is tempting,
caution in interpreting these results is required. At best statistical models have
been shown to explain about 30% of behaviour (168, 330). With the area of
functional foods being a contemporary issue, very little research has been
published on the psychosocial correlates which determine behaviours about their
use. For these reasons this research is as much exploratory as it is explanatory.
3.3.5 Questionnaire sample
As with the dietary intervention studies this research drew samples from an adult
population that would benefit most from the introduction of n-3 enriched functional
foods in reducing CHD risk. In addition, recruitment targeted a mixture of both
consumers without existing disease as well as with morbidities that may increase
the likelihood of developing CHD (e.g. diabetes mellitus), varieties of
socioeconomic backgrounds, age brackets and income ranges. The literature has
suggested that these factors may be independent determinants of healthy foods
choice (331).
Samples meeting these criteria were drawn from the general community of
interested consumer’s via media (print and radio) as well as subjects with type 2
diabetes mellitus (otherwise healthy) participating in an unrelated dietary
intervention trial. Stratifying the sample based on co morbidities as well as
recruiting from a general sample facilitated the investigation of socioeconomic and
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health factors, in addition to beliefs and attitudinal factors about functional food
use.
3.4

Stakeholder study

Although the collaboration of the food industry, government and health
professionals is regarded as being important for functional foods to reach their
maximum potential, no studies have investigated the attitudes of these stakeholder
groups in the Australian context. Theoretically stakeholders are of interest because
their needs, wants, desires, perceptions and conceptualisations differ (324). We
can view stakeholders as networks of human beings, actors or agents with distinct
roles to play based on distinct ideology which is defined as “scheme of ideas at
basis of political etc. theory or system” (332). It is the interest in the underlying
assumptions of these ideologies which is fundamental to this research. A
qualitative methodology was used to expose and challenge underlying
assumptions and making ideologies explicit.
3.4.1 Analytical strategy
From the literature five key domains which were derived which are regarded as
being key issues of likely controversy between stakeholders. These were related to
issues surrounding processing and production, the ability of functional foods to
achieve tangible health benefits, evidence required for health claims, the regulatory
environment (including substantiation authority, health claim wording authority and
public disclosure of evidence) and intellectual property and propriety issues (25,
333). This framework provided a foundation for analysis.
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Although focus group methodology could be used in this study, semi-structured
interviews have been suggested as a more viable option for eliciting views from
professional groups (324). Reasons cited are that professionals tend to be less
likely to express true beliefs in an open forum, and there is a strong probability that
discussion will end in verbal point scoring between opposing views, as opposed to
an exploration of these issues (324). An interview guide was developed using the
theoretical groupings of McConnon et al (2002) and Kwak et al (2001) to develop
the categorisation of key issues to be investigated with stakeholders (25, 333). All
interviews (except for two face-to-face interviews) were conducted over the phone,
recorded and transcribed verbatim by an independent third person. Transcripts
were analysed using a computer software package for qualitative research
analysis, NVivo 2.0 (2002, QSR International Pty Ltd), which was used for data
management and coding (334).
Stakeholders may present themselves as people, as role occupants, as groupings,
as occupational groupings and pressure groups and many more categories.
Identifying stakeholders for this research presented a number of hurdles. The
general guideline is that a stakeholder is any interest group affected by or affecting
the phenomena, which in this case is the development and communication of
functional foods. In addition, the stakeholder grouping is usually constructed based
on those having a relatively consistent experience and point of view. Practically,
where an imagined stakeholder interest group (e.g. dietitians/nutritionists) has
significant internal differences of opinion (e.g. between dietitians employed in
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clinical, public health and food industry settings) the grouping should be further
broken down.
The process of conducting qualitative, stakeholder analysis, involves making
continuous skilled researcher craft judgments – whom to talk to and what to ask
(324). When researching complex social areas orientating advice can be
significantly shaped by these fine judgments. Furthermore, this research, as in any
kind of applied research, is sponsored by, and intended to serve the interests of,
one or more of the stakeholders. Whilst this does not automatically invalidate the
process it needs to be stated and considered when drawing conclusions from the
research. Perhaps stakeholder analysis is a clearer method than many other forms
of research about these difficult but crucial underlying choices.
3.4.2 Sample
Stakeholders were first identified, using the literature as a guide. McConnon et al
(2002) identified key stakeholders when considering the development of functional
foods (25). These were defined as the food industry, consumers, health sector and
government. These categories were further subdivided into eleven categories
regarded as representing the key stakeholders in relation to functional food
development in Australia. Key leaders in the field of Nutrition and Dietetics were
consulted to structure a sampling frame based on these key groupings. The
objective was twofold; firstly to sample a wide range of views from a variety of
states and territories within Australia, and secondly to recruit equal numbers of
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subjects presumed to have positive and negative views about functional food
development.
One approach to identifying stakeholders identified in the literature is to follow a
process of sequential sampling. This process involves collecting information from
one interested party who will identify other stakeholders who can be followed up.
This process is followed until nothing new turns up (324). This process was
rejected in favor of a more structured form of sampling described above for two
reasons. Firstly, the sequential sampling approach can be regarded as an optimal
but requiring considerable effort and resources that were not available within the
time frame (324). Secondly, with the recently established National Centre of
Excellence in Functional Foods, there was the unique opportunity to draw on the
expertise of Centre members in identifying key stakeholders within the Australian
context. Specific details of the stratification are outlined in Chapter 8.
3.4.3 Limitations and quality issues in qualitative research
Qualitative research suffers from the “stigma of the small n” (335) because of the
small samples under investigation and due to not seeking statistical
representiveness. However this feature is irrelevant to the strength of this approach
(335). Nonetheless, as with all forms of research attention to the quality of research
is important.
The first issue of quality is with validation. There are no easy methods of validating
qualitative research. There are ways to improve the validity which requires the
exercise of judgment on the researcher. Firstly, since methods used in research
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influence the objects of enquiry, it is important to provide a clear account of the
process of data collection and analysis. This helps the reader judge the
conclusions made from the methods used and the way the data was collected.
These details have been included in the methods section of the qualitative studies
presented in this thesis.
Closely related to this concept is the issue of reflexivity. This means the ways in
which the researcher and the research process have shaped the data collection,
including the role of prior assumptions and experience, which may influence the
interpretation of the results (335). In view of this, personal and intellectual biases
are declared at the outset of any research reports, which enhance the credibility of
the findings. The final technique that has been employed to reduce bias is termed
“fair dealing”. By this the researcher ensures that the research design explicitly
incorporates a wide range of different perspectives so that the viewpoint of one
group or person is not presented as if it represents the sole truth of the situation
(336).
An additional dimension of relevance is the extent to which findings can be
generalised beyond the research setting. In this sense forms of stratified sampling
were used in order to ensure that the range of settings chosen was representative
as well as the reporting of results with sufficient descriptive detail for the reader to
be able to judge whether or not the findings apply to other situations.
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CHAPTER 4

FUNCTIONAL FOODS ARE RELEVANT FOR INDIVIDUALS IN MANAGING
CHD RISK2

4.1

Introduction

Despite extensive evidence for the efficacy of plant sterols/stanols in reducing
serum cholesterol, evidence of effectiveness in a practice setting is absent. Fortyone clinical trials have studied the efficacy of plant sterol esters and plant stanol
esters in reducing mean total cholesterol (TC) and low-density lipoprotein
cholesterol (LDL) (337). When plant sterols/stanols are added to foods such as
margarine, up to a 15% reduction in serum TC and LDL has been reported and the
effect is additive with diet and drug interventions (337). To this end the Adult
Treatment Panel (ATP III) of the National Cholesterol Education Program (NCEP)
recommend the addition of plant sterols (2g/day) to the diet (14). However, all
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studies to date have been in controlled settings using willing volunteers and
providing subjects with sterol containing products. These results are yet to be
replicated in subjects who assemble the diets for themselves on a routine basis,
thus determining the true effectiveness of this strategy in the clinical setting (281).
It is commonplace when determining evidence for functional foods to equate
efficacy with effectiveness. Whereas efficacy aims to establish a relationship
between a bioactive component and a therapeutic benefit, effectiveness goes one
step further in answering the question of compliance i.e. do subjects comply with
the therapy and does the therapeutic relationship hold. Whilst it may be correct to
assume that efficacy often equates to effectiveness with therapeutic drugs, with
functional foods, issues relating to the belief in the benefit of use, taste, preference
and price may affect intake and ultimately compliance (20, 22). In addition, the net
effect on the whole diet needs to be considered in those who select functional
foods, given the importance of other dietary aspects such as restricting saturated
fat and cholesterol and increasing n-3 fatty acids, in reducing CHD risk (306). It is
therefore important in evaluating effectiveness to design trials in free-living
contexts.
A clinical setting with standard practices is a useful setting for this research.
However, the problem associated with recruitment in clinical trials has been
acknowledged in the literature and obtaining the numbers needed to achieve
statistically significant results can be problematic (338). The Number Needed to
Treat (NNT) is becoming increasingly popular as an index for reporting results of
randomised controlled trials and other clinical trials (339). The NNT represents the
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clinical effort that is required by treatment in order to achieve a positive outcome,
compared to the expected response in a control group. This provides a useful
measure of effectiveness and overcomes some of the issues of recruitment of
large numbers of subjects.
The aim of this study was to test the effectiveness of plant sterol/stanol prescription
in consenting patients referred to an outpatient clinic that were randomised to
either standard practice (a low fat, low saturated fat, high fibre diet) or standard
practice with the additional prescription of 25g of a plant sterol or plant stanol
containing margarine. This was a free-living trial. No food products were supplied
to subjects, and the margarines prescribed were available commercially.
4.2

Methods

4.2.1 Participants and Study Design
Subjects were recruited through an established dietary outpatient clinic over an 18
- month period (Appendix A & B), from February 2001 to August 2002. Subjects
were included if they were aged between 30 - 75 years and had a fasting serum
total cholesterol concentration > 5.50 mmol/L. Those who were of non-English
speaking background, taking lipid lowering medication for less than 3 months prior
to referral or had changed dosage within the last 3-month period were excluded,
along with subjects following dietary regimens for allergy or intolerance, renal
disease and diabetes mellitus. Details of the study were explained to all subjects
and written informed consent provided before participation in the study. The goal
was to recruit 80 participants (allowing for 10 drop outs); on a sequential basis
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using a blocking protocol for total serum cholesterol to ensure the cholesterol
levels at baseline did not differ between the groups. Within each block, the
allocation to treatment or control group was random. The study was conducted on
an outpatient basis over 12 weeks and no foods or supplements were provided to
subjects. At baseline (week 0) and week 12 subjects filled out a 3-day food record
(two week days and 1 weekend day). One week later (week 1 and 13) a detailed
dietary history was conducted along with weight, waist circumference
measurement and an activity questionnaire. Fasting blood samples were collected
prior to baseline ~2-3 weeks and at 12 weeks. The human research ethics
committee of the University of Wollongong and the Illawarra Area Health Service
approved the study (Appendix C).
4.2.2 Treatment Conditions
Control group
Subjects were individually instructed by the same Accredited Practising Dietitian to
consume a diet low in saturated fat, consistent with the Therapeutic Lifestyle
Changes dietary approach as outlined by NCEP (14). In summary, the diet aims for
25 - 30% of total calories from fat (<7% saturated fatty acids, up to 10%
polyunsaturated fatty acids, and up to 20% monounsaturated fatty acids), 50 - 60%
of total calories from carbohydrates, ~15% of total energy from protein, <200mg
cholesterol/day, fibre 20 – 30g/day and total energy balanced with energy
expenditure to maintain desirable body weight or prevent weight gain (14).
Sterol/stanol use was not included as part of dietary instruction, however if subjects
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were currently using plant sterol/stanol containing margarine they were
encouraged to continue. This was regarded as standard practice and there would
be ethical implications to actively discouraging the use of these products. Subjects
were provided with information sheets offering practical suggestions and an
individual diet plan. Furthermore, all subjects were encouraged to exercise (e.g.
30-minute brisk walking) at least 3 sessions per week. Counselling sessions
consisted of a 1-hour session at week 1 and two 30-minute sessions at week 3 and
6.
Intervention group
The intervention diet was identical to the control diet in all but one aspect. All
subjects on the intervention diet were instructed to consumer 25g (5 teaspoons) of
either Flora’s Pro-active® (Unilever Australasia, Sydney, Australia) or Meadow
Lea’s Logicol™ (Goodman Fielder, Sydney, Australia) margarine (these were the
only plant sterol and plant stanol containing products respectively on the Australian
market at the time of the study). The information sheets and diet plans explicitly
stated these products and the amount to be consumed each day (Appendix D).
Subjects were instructed to modify their fat intake to accommodate the sterol/stanol
dosing and encouraged to consume additional carotenoid containing vegetables to
prevent a possible decrease in plasma carotenoids as a result of the sterol/stanol
intake (340). This message was the focus of each follow-up clinic visit.
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4.2.3 Dietary Measurement
A dietary history (DH) (Appendix E) interview was conducted by the same dietitian
(CP) at baseline and at 12 weeks. The DH method lends itself well to clinical
practice where it provides clinicians with an opportunity to subjectively examine
meal patterns and provide dietary advice while the patient is still present (309).
Furthermore the utility of this method has been demonstrated in a number of
sample groups, including short-term intervention studies (311, 341, 342). The
approach taken was a narrative style DH interview (open-ended) described in
detail elsewhere (341). In summary, the meal based diet history interview noted the
types, amounts and frequency of consumption of all foods consumed routinely
within a 3-month reference time. The interview was completed with a food
frequency checklist of major food categories, snack and drink items (including
alcohol), and sources of n-3 fatty acids (fish, nuts, soy foods), as well as questions
on food preparation practices. The same assessor was the interventionist in this
study; therefore the DH was not blinded. Subjects were also required to keep an
estimated 3-day food record (FR) (Appendix F) (two weekdays and one weekend
day) after the collection of the DH. Forms were provided along with instructions on
how to estimate food portion sizes using standard kitchen measuring equipment.
Food records were checked for missing values and clarification.
4.2.4 Anthropometric Measurement
Weight and height was recorded at each interview using calibrated balance scales
and a wall mounted stadiometer. All subjects were clothed (light shirt). Height was
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measured to the nearest 0.5cm and weight to the nearest 0.1kg. Waist and hip
circumferences were measured at each time point. Waist circumference was
measured using a standard cloth measuring tape (units in centimeters and inches);
at natural waist when clearly identifiable or midway between the lower rib and iliac
crest) and hip circumference measured at the greater trochanter. For each
circumference, measurements were recorded to the nearest 0.5 cm. Activity level
was obtained from a self-reported description of usual activity, including details of
number of sessions a week of activity, the duration of each session and the
intensity of each activity.
4.2.5 Biochemical Measurement
In keeping with standard clinical practice, a trained phlebotomist at accredited
pathology laboratories within the Illawarra region (Southern IML Pathology) drew
blood samples from subjects after an overnight fast. Subsequently, samples were
analysed for concentrations of total cholesterol, HDL cholesterol, LDL cholesterol,
and triglyceride. The pathology laboratories were fully accredited with the National
Association of Testing Authorities (NATA) and the Royal College of Pathologists of
Australasia (RCPA), which is a mandatory requirement for pathology laboratories
in Australia.
4.2.6 Analysis and Statistics
Dietary data were analysed with Foodworks nutrient analysis software package
(Professional Version 3.1, Xyris Software, Highgate Hill, Brisbane Australia), which
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is based on the Australian Nutrient Database (AUSNUT 2000, Department of
Human Services and Health, Canberra).
The required sample calculation of n = 80 was based on detecting a difference in
TC between the groups of 10% at 80% power. A Bland Altman plot (343) was
prepared to determine possible bias between actual and recalled total fat (%kJ)
with the two dietary assessment methods. As described by Bland and Altman (343)
the average of the reported fat intake in the DH and the FR (x axis) are plotted
against the difference between the DH and FR recorded fat intake (y axis). The
limits of agreement were set at 2 s.d. of the difference above and below the mean.
Comparing the reported intake using the DH and FR using Pearson’s correlation
coefficient assessed the validity of sterol/stanol intake. Changes between week 0
and week 12 were studied for all variables. Dietary data and baseline
measurements were assessed using a two-factor analysis of variance with diet and
sex as fixed factors. The effect of dietary intervention was assessed using paired
Student’s t-tests when comparing the change in variables (dietary, anthropometric
and biochemical data) between groups. For non-normally distributed data,
Wilcoxon signed ranks test was used for within group comparisons, and MannWhitney U test were conducted to determine the proportion of subjects reaching
dietary and biochemical goals between the groups. Changes in clinical outcomes
were analysed with an intention to treat model-using analysis of variance i.e.
subjects were included in the analysis whether or not they consumed the
prescribed dose of plant sterol/stanol. The relationship between plant sterol intake
and serum cholesterol was determined using Pearson’s correlation coefficient. The
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number needed to treat (NNT) index as described elsewhere was used to report
effectiveness of the intervention (339). The NNT was calculated using the
proportions of subjects on the control or experimental treatment who achieve a
total cholesterol reduction of ≥ 15%. NNT is defined as (339):

1
NNT =
π1 - π2

Here π1 and π2 are defined as the proportions of subjects on the control or
experimental treatment (respectively) that experience the defined outcome. A P value less than 0.05 were considered to be statistically significant. SPSS for
Windows (version 10.0, 1999, Chicago, IL) was used for all statistical analyses.
4.3

Results

4.3.1 Subject demographics
During the 18-month time course of the study forty-two participants met the
eligibility criteria, 32 agreed to participate producing a group randomisation of 15
control and 17 intervention subjects. Twenty-five subjects (15 women, 10 men)
completed the study producing a group randomisation of 11 control and 14
intervention subjects. One subject withdrew after a myocardial infarct, another
subject was hospitalised for psychiatric illness and was unable to complete the final
assessment phase, the clinic lost contact with another subject, and four withdrew
after the initial assessment. Baseline characteristics of all subjects admitted to the
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study are shown in Table 4-1. The groups did not differ in terms of age, sex, body
mass index, level activity, and waist: hip ratio, medication use, or serum lipid
levels.
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Table 4-1 Participant characteristics at baseline

Control Group

Intervention Group

(n = 15)

(n = 17)

Age (y) (mean ± s.d.)

59.2 (±13.2)

55.2 (±13.4)

Female/Male

11/4

8/9

BMI (kg/m2) (mean ± s.d.)

29.8 (±3.3)

31.4 (±5.9)

Waist/Hip ratio (mean ± s.d.)

0.92 (±0.1)

0.94 (±0.12)

Cholesterol lowering medication (n)†

2

3

Nil

5

6

1-2 times per week

3

3

3-4 times per week

2

2

5-6 times per week

1

2

>6/7 times per week

0

1

Total cholesterol (mmol/L) (mean ± s.d.)

6.64 (±0.8)

6.89 (±1.1)

*

4.25 (±0.6)

4.35 (±0.8)

2.40 (±1.4)

2.28 (±1.1)

1.27 (±0.3)

1.26 (±0.3)

Frequency of activity

LDL cholesterol (mmol/L) (mean ± s.d.)

**

Triglyceride (mmol/L) (mean ± s.d.)

***

HDL cholesterol (mmol/L) (mean ± s.d.)

*

n = 23, **n = 30, ***n = 27

There were no significant differences between any of the groups at baseline using Student’s t-test
for normally distributed data and Wilcoxon sign ranked test for categorical data.
†

Refers to number of patients taking cholesterol lowering medication who had not reported a

change in dose for >3 months.

4.3.2 Dietary data
Using the Bland-Altman plot there was no relationship between the average of the
reported fat intake using DH and FR with the difference between the two methods
(Figure 4-1). All but one value was within the 2 s.d. confidence limits as
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recommended by Bland and Altman (343) indicating that there was no systematic
bias. Strong correlations were found between the DH and FR method (r = 0.782, P
< 0.001) for plant sterol/stanol consumption. Results of the dietary analyses using
DH data are reported in Table 4-2. Overall, nutrient intakes were not significantly
different between the two groups at baseline and at the end of the study (12
weeks). However, the change in protein was higher in the intervention group (22%)
compared to the control group (5%) as well as the change in alcohol intake (7g/day, 2g/day in the intervention and control group respectively). The average
intake of plant sterols/stanols increased by 1.3g/day in the intervention group and
reduced by 0.3g/day in the control group (P < 0.05), and 20% achieved the goal
intake of ≥ 2g/day compared to none in the control (P < 0.05). After the intervention
period, 43% (P < 0.05) of the intervention subjects achieved a polyunsaturated fat
intake within the NCEP Step 1 diet recommendations (≥ 7%kJ) whereas none
achieved this goal in the control. There were no other differences between the
groups in achieving the NCEP recommendations (Table 4-3).
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Figure 4-1 Bland-Altman plot of the mean difference between the DH and FR for fat (%kJ)
versus the mean of the DH and FR, with limits of agreement of 2 s.d. from the mean
difference
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Table 4-2 Mean (± s.d.) of dietary composition at week 0 and 12 as determined by DH

Lipid

Control group

Intervention group

(n = 11 )

(n = 14)

Week 0 (kJ)

8059 (±2658)

8899 (±3298)

Week 12 (kJ)

7700 (±2395)

7219 (±1718)

^Change %

-4.5 (±21)

-18.9 (±30)

Week 0 (%kJ)

19.7 (±2.3)

17.2 (±3.2)

Week 12 (%kJ)

20.7 (±2.0)

21.0 (±3.0)

^Change %

5.2 (±13.8) *

21.9 (±21.4) *

Week 0 (%kJ)

29.7 (±5.3)

31.9 (±8.9)

Week 12 (%kJ)

27.4 (±5.4)

29.9 (±6.4)

^Change %

-8.0 (±14.8)

-6.4 (±34.3)

Week 0 (%kJ)

47.4 (±4.8)

44.4 (±6.8)

Week 12 (%kJ)

48.0 (±4.7)

44.1 (±7.0)

^Change %

1.2 (±8.7)

-0.7 (±31.2)

Week 0 (%kJ)

10.1 (±2.9)

10.9 (±6.9)

Week 12 (%kJ)

8.0 (±2.3)

7.3 (±2.1)

^Change %

-20.8 (±27.5)

-32.1 (±37.5)

Week 0 (%kJ)

12.4 (±2.6)

12.9 (±3.3)

Week 12 (%kJ)

11.7 (±2.6)

13.3 (±3.6)

^Change %

-5.6 (±17.8)

2.9 (±37.9)

Energy

Protein

Fat

CHO

SFA

MUFA
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PUFA
Week 0 (%kJ)

4.4 (±1.1)

5.3 (±1.5)

Week 12 (%kJ)

4.0 (±1.2)

6.3 (±2.4)

^Change %

10.1 (±32.4)

18.6 (±56.2)

Week 0 (mg)

201.3 (±106.4)

236.7 (±166.1)

Week 12 (mg)

170.8 (±58.4)

153.1 (±64.9)

^Change %

-15.1 (±34.6)

-35.3 (±41.4)

Week 0 (g/day)

28.5 (±10.1)

24.2 (±8.5)

Week 12 (g/day)

35.3 (±17.3)

26.5 (±8.9)

^Change %

24.1 (±69.4)

9.5 (±40.9)

Week 0 (g/day)

3.4 (±6.1)

15.2 (±24.1)

Week 12 (g/day)

5.6 (±8.8)

8.4 (±16.7)

^^Change (g/day)

2.2 (±3.9) *

-6.8 (±10.7) *

Week 0 (g/day)

0.8 (±1.0)

0.2 (±0.5)

Week 12 (g/day)

0.5 (±0.8)

1.5 (±0.8)

^^Change (g/day)

-0.32 (±0.7) *

1.26 (±0.9) *

Cholesterol

Dietary fibre

Alcohol

Sterol/stanol intake

*

P < 0.05, **P < 0.01, significantly different between the groups

^Change % =

week 12 – week 0
week 0

^^Change = week 12 – week 0

X 100%.
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Table 4-3 Number of subjects meeting selected fatty acid targets at baseline and 12 weeks
(n = 25)

Time

Baseline

12 weeks

Group

Plant sterol/stanol

Saturated fat intake

Polyunsaturated fat
intake

≥ 2g/day

< 2g/day

≥ 10%kJ

< 10%kJ

≥ 7%kJ

< 7%kJ

Control

0

0

4

7

0

11

Intervention

0

0

7

7

2

12

Control

0*

11

2

9

0*

11

Intervention

3*

11

2

12

6*

8

*

P < 0.05, **P < 0.01, significantly different between the groups, Mann-Whitney U Test.

4.3.3 Serum lipids in response to treatment
Total cholesterol, plasma triglyceride, HDL cholesterol and LDL cholesterol
concentrations did not differ significantly over time or between groups.
Concentrations of plasma lipids at the beginning and end of the trial are shown in
Table 4-4 and Figure 4-2. After the 12-week intervention the reductions in total
cholesterol and LDL cholesterol were more than double in the intervention group
compared to the control group, but these differences did not reach statistical
significance. There was a strong inverse relationship between 12-week dietary
sterol/stanol intake and change in serum cholesterol (r = -0.62; P = 0.001) and
serum LDL cholesterol (r = -0.58; P = 0.019).
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Table 4-4 Mean (± s.d.) plasma lipid concentrations at week 0 and 12 with each dietary
intervention.

Lipid

Control group

Intervention group)

Week 0 (mmol/L)

6.64 (± 0.8)

6.89 (± 1.1)

Week 12 (mmol/L)

6.29 (± 0.7)

6.10 (± 1.0)

Change %

-5.3 (± 11.5)

-11.5 (± 13.9)

Week 0 (mmol/L)

4.25 (± 0.6)

4.35 (± 0.8)

Week 12 (mmol/L)

4.06 (± 0.9)

3.82 (± 0.9)

^

-4.5 (± 15.7)

-12.2 (± 13.1)

Week 0 (mmol/L)

2.40 (± 1.4)

2.28 (± 1.1)

Week 12 (mmol/L)

2.20 (± 1.3)

2.20 (± 0.9)

^

-8.3 (± 28.7)

-3.5 (± 34.7)

Week 0 (mmol/L)

1.27 (± 0.3)

1.26 (± 0.3)

Week 12 (mmol/L)

1.29 (± 0.3)

1.27 (± 0.3)

^

1.6 (± 8.7)

0.7 (± 13.1)

Week 0 (mmol/L)

3.37 (± 0.9)

3.49 (± 1.0)

Week 12 (mmol/L)

3.29 (± 1.1)

3.21 (± 1.1)

Change %

-2.4 (± 14.7)

-8.0 (± 10.0)

Total cholesterol

LDL cholesterol (n = 17)

Change %

Triglyceride (n = 24)

Change %

HDL cholesterol (n = 19)

Change %

LDL:HDL ratio (n = 18)

*

P < 0.05, **P < 0.01, significantly different from baseline

^Change % =

week 12 – week 0
week 0

X 100%.
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Figure 4-2 Mean (± SEM) percentage change in serum lipids from baseline to the end of the
12 week dietary intervention.

4.3.4 Clinical indexes
At the completion of the 12-week study 5 of 14 subjects in the intervention group
achieved ≥ 15% change in total cholesterol compared to 0 of 11 in the control (P <
0.05). No other significant changes were observed between the groups. Both
groups showed a mean weight change of < 1.0 kg and there were no significant
differences in body weight from the baseline to the end of the study. The NNT was
calculated to be 2.8.
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4.4

Discussion

This present study is the first to investigate the utility of using plant sterol/stanol
enriched margarine in a free-living clinical context. While evidence-based nutrition
recommendations attempt to translate research data into nutrition care (344),
research in clinical settings are paramount, as the applicability of controlled studies
to the general community is often questioned (10). For example, in the effective
management of hyperlipidaemia there are a number of dietary approaches that can
achieve moderate results; these include reducing the saturated fat in the diet,
increasing n-3 polyunsaturated diet and increasing dietary fibre (345). It is
important that the introduction of novel dietary strategies do not adversely affect
the dietary profile.
In conjunction with dietary advice consistent with the NCEP guidelines, the
inclusion of ~1.5-2g/d of plant sterol in margarine did not adversely affect the
dietary fat or plasma lipid profiles (Tables 4-2 and 4-4). Of particular interest was
the increase in the proportion of fats coming from polyunsaturated fat in the
intervention group. Intervention trials have shown that visible fats (such as
margarine and nuts) are often excluded from the diet in preference to hidden fats
that are often saturated (346). The net effect is a decrease in the P:S ratio. There
is increasing evidence of the importance of polyunsaturated fats as an important
dietary component in reducing the risk of CVD and the need to increase the P:S
ratio is of importance (347). A serendipitous result of prescribing a daily dose of
plant sterol/stanol enriched margarine was the delivery of extra n-3
polyunsaturated fatty acids. As plant sterols/stanols have an additive effect with
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other dietary modifications (348), prescribing enriched margarine is an effective
strategy to achieve both of these targets.
The dietary assessment measures had some limitations. In pursuit of designing a
study resembling ‘real life’ conditions there was a trade off by un-blinding the DH,
as the assessor was also the interventionist. The impact of this on the
interpretation of data is marginal as it was demonstrated that there was a strong
agreement between the DH and FR methods for dietary fats and sterol/stanols,
indicating relative validity.
Although compliance to the dietary regimen is a key component of determining
effectiveness, the ability to show the therapeutic benefit is also important. The
mean percent reduction in total cholesterol and LDL cholesterol in the intervention
group was ~11% and ~12% respectively compared to ~5% and ~4% in the control
group. This difference however was not statistically significant either within groups
or between groups over time, probably because the final sample size was
significantly smaller (n = 25) compared to the original sample size power
calculations (n = 80). The study was underpowered to reject the null hypothesis
that is, there was not enough evidence to say there was a significant difference
between the groups.
Results showed that dietary prescription of plant sterol/stanol margarines in
conjunction with the NCEP guidelines for the management of blood lipids resulted
in an intake of 1.3g sterol/day, whereas in the control group plant sterols reduced
their intake by 0.4g/day. Although studies have shown that 2g/day of plant sterol is
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the therapeutic optimal dose, the response curve is linear suggesting that an intake
of around 1.5g/day is still clinically useful and the levels achieved would be
predicted to achieve a change of ~10% in total serum cholesterol and LDL
cholesterol (348).
A significant limitation to clinical practice in the dietary management of
hyperlipidaemia is that despite studies in controlled environments achieving up to
15% reductions in total cholesterol, results in a free-living context have at best
shown a 5% reduction (12). This study showed that 5 of 11 (36%) in the
intervention group achieved a reduction in serum cholesterol levels ≥ 15%
compared to none in the control. This has an important clinical implication, which
can be summarised using the NNT statistic. Using this index one can predict that if
clinicians routinely prescribe 2g/day of plant sterol/stanol margarine, then for every
2.8 patients given this advice, an extra patient will achieve cholesterol reducing
effect ≥ 15%, compared to a more conventional approach to dietary therapy.
However, these results can only be viewed as preliminary at this stage as the small
sample size makes generalising beyond the bounds of this clinical context
inappropriate. Further research is required in this area which would involve a larger
sample, drawn over multiple clinical sites before conclusive evidence can be
provided.
What has been known for many years regarding the efficacy of plant sterol/stanol
enriched food products in the management of hyperlipidaemia can now be
extrapolated into a free-living, clinical context. Plant sterol/stanol margarines
provide a useful and significant adjunct to medical nutrition therapy. However,
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while these positive results may be relevant to at-risk individuals, the utility of
functional foods applied to a population approach needs to be verified. The
following study investigated the effectiveness of n-3 enriched functional foods in a
lower-risk group.
4.5
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CHAPTER 5

FUNCTIONAL FOODS ARE RELEVANT TO POPULATION BASED APPROACH
TO MANAGING CHD RISK3,4

5.1

Introduction

Population intakes of fatty fish remain suboptimal and functional foods enriched
with LCn-3 may be an effective population approach in managing this risk. Diets
high in fish has been found in epidemiological studies to protect against heart
disease (15-17). In addition, a number of experimental studies have demonstrated
the efficacy of LCn-3, which is found in fish, in reducing triglycerides, blood
pressure, arrhythmia and thrombotic risk (145, 349, 350), and it is this combined
effect that is believed to be cardioprotective (147). This study was a 6-month
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nutritional intervention study investigating the effects of foods enriched with (LCn3) on cardiovascular biomarkers. In order to substantiate the dietary effects of
these processed enriched foods, evidence of actual changes in fatty acid intakes is
required. In addition, the net effect on the whole diet needs to be considered in
those who select these foods, given the importance of other dietary aspects on
cardiovascular disease risk. For example, authorities recommend 25 - 30% of total
calories from fat (< 7% saturated fatty acids (SFA), up to 10% polyunsaturated fatty
acids (PUFA), and up to 20% monounsaturated fatty acids (MUFA)), 50 - 60% of
total calories from carbohydrates (CHO), ~15% of total energy from protein (PRO),
< 200mg cholesterol/day, fibre 20 –30g/day and total energy to be balanced with
energy expenditure to maintain desirable body weight or prevent weight gain (14)
and for a 8360kJ (2000kcal) diet, a daily intake of n-3 fatty acids of 0.65g
eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) and 2.22g α-linolenic
acid (ALA), with the n-6:n-3 ratio reduced to substantially less than 10 (160).
Therefore, in assessing dietary interventions, proper dietary assessment
methodology is essential as a cornerstone to evaluating the overall dietary profile.
The DH is considered to be the gold standard of methods used to assess dietary
intakes (307). It has an established place as a dietary assessment method and
lends itself well to clinical practice (309). The DH method is also valuable in
intervention trials where dietary manipulation is required at the time of assessment
(310). However, as with all dietary assessment methods there are limitations,
which include interviewer bias, inaccuracy of portion size reporting, errors in
reporting of frequency, and a need for subjects to follow regular eating habits
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(316). Due to the limitations of collecting intake data, the quality of dietary
assessment methods needs to be assessed in the context of each study (310).
This can be assessed using a number of methods such as reporting the degree of
over- and underreporting, assessing bias to over- or under report and the relative
validity between dietary intake data and erythrocyte fatty acid biomarker data. In
this study we developed multiple strategies to determine dietary intake. The aim of
this study was to evaluate the impact of incorporating LCn-3 enriched foods in the
diets of individuals, whose usual diet was low in fish, making clear reference to the
quality and validity of the dietary data.
5.2

Methods

5.2.1 Recruitment and screening
The study was approved by the Human Research Ethics Committees at the
University of Western Australia, the University of Adelaide and the CSIRO
(Appendix G). Ninety-four overweight men and women were recruited, age range
between 20 to 65 years through local media advertisements at two sites – Perth
and Adelaide (Australia). During a screening interview those who had plasma
triglycerides < 1.6 mmol/L, a diagnosis of diabetes, recent symptomatic heart
disease; angina pectoris; history of myocardial infarction or stroke; peripheral
vascular disease; major surgery within the last 3-months; BP > 170/100 mmHg;
liver or renal disease (plasma creatinine > 120 µmol/L); regular non-steroidal antiinflammatory drug therapy; antihypertensive drugs, lipid lowering or other drugs
affecting lipid metabolism; eating more than one fish meal per month or taking fish
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oil supplements; or an inability to consume the test foods were excluded. All
participants gave their written informed consent. Of the 94 volunteers who attended
screening, 86 volunteers were randomly allocated to either the intervention group
(n = 42) or the control group (n = 44). A block randomization scheme was used to
balance groups according to baseline triglyceride concentration and body mass
index (BMI).
5.2.2 Study procedures
The goal of the intervention was to consume 8 serves of study foods per day
equivalent to 1g LCn-3. Each serve of the enriched foods provided 125mg EPA +
DHA The objective was for subjects to replace current foods with study food
equivalents. A variety of LCn-3 enriched foods and matching control foods, which
included cheese spread, chocolates, instant oats, milk, dip (pepper, tzatziki, salsa),
biscuits (Anzac and ginger), pancakes, muffins, bread, salad dressing and soup
(chicken laksa and vegetable) were prepared by Goodman Fielder Ltd Sydney,
Australia. The fatty acid composition of the n-3 enriched foods provided to the
participants is detailed in Table 5-1. Intervention foods (enriched with LCn-3) and
equivalent control foods (not enriched) were supplied to all subjects in unmarked
packages with one of two codes. The content of the study foods was blinded to
subjects as well as researchers. Subjects were provided with two weeks supply of
study foods and instructed on how to incorporate at least 8 portions of study foods
into their daily eating pattern (Appendix H), but were not prescribed menus. The
background diet was ad libitum, however after the first month of the study, those
subjects who gained weight were advised by a qualified dietitian on ways to reduce
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their energy intake whilst accommodating the study foods. This was monitored
throughout the study.

1
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Table 5-1 Estimated fatty acid content of the study foods provided to subjects in the intervention and control groups
Food (Serve size)
a

Oleic (18:1n-9)

Linoleic (18:2n-6)

α-linolenic (18:3n-3)

Eicosapentaenoic (20:5n-3)

Docosahexaenoic (22:6n-3)

mg/ serve

mg/ 100g

mg/ serve

mg/ 100g

mg/ serve

mg/ 100g

mg/ serve

mg/ 100g

mg/ serve

mg/ 100g

Biscuit

Intervention

2.04

5.43

0.45

1.19

0.09

0.23

0.05

0.14

0.07

0.20

(2 biscuits ~ 40g)

Group

1.95

5.19

0.44

1.16

0.08

0.21

0.00

0.00

0.00

0.00

Bread

Intervention

0.53

0.63

0.71

0.85

0.06

0.07

0.05

0.06

0.07

0.09

(2 slices ~ 90g)

Group

0.44

0.52

0.70

0.83

0.05

0.06

0.00

0.00

0.00

0.00

Cheese spread

Intervention

2.30

9.19

1.20

4.80

0.29

1.15

0.05

0.21

0.07

0.30

(25g)

Group

2.21

8.84

1.19

4.76

0.28

1.12

0.00

0.00

0.00

0.00

Chocolate

Intervention

2.01

8.37

0.19

0.79

0.03

0.11

0.05

0.22

0.07

0.31

(25g)

Group

1.92

8.00

0.18

0.75

0.02

0.83

0.00

0.00

0.00

0.00

Dip

Intervention

1.12

3.69

1.23

4.10

0.13

2.34

0.05

0.18

0.07

0.25

(30g)

Group

1.02

3.40

1.22

4.07

0.12

0.40

0.00

0.00

0.00

0.00

Egg

Intervention

2.41

2.68

1.06

1.18

0.63

0.70

0.00

0.00

0.15

0.17

(2 ~ 90g)

Group

4.35

4.83

1.00

1.11

0.02

0.02

0.00

0.00

0.04

0.04

Margarine

Intervention

5.53

27.65

2.19

10.96

0.97

4.85

0.05

0.24

0.07

0.36

(20g)

Group

5.42

27.10

2.18

10.90

0.96

4.80

0.00

0.00

0.00

0.00

Milk

Intervention

0.98

0.39

0.06

0.02

0.04

0.02

0.05

0.02

0.07

0.03

(250ml)

Group

0.89

0.36

0.05

0.02

0.03

0.01

0.00

0.00

0.00

0.00

Muesli

Intervention

0.95

2.11

0.91

2.02

0.07

0.15

0.05

0.12

0.07

0.16

(30g)

Group

0.86

1.91

0.90

2.00

0.06

1.33

0.00

0.00

0.00

0.00

Muffin

Intervention

0.23

0.46

0.39

0.78

0.07

0.14

0.05

0.11

0.07

0.15

(1 muffin ~ 75g)

Group

0.14

0.28

0.38

0.76

0.06

0.12

0.00

0.00

0.00

0.00

Oat cereal

Intervention

0.72

1.80

0.15

0.38

0.03

0.07

0.05

0.13

0.07

0.18

(30g)

Group

0.63

1.58

0.14

0.35

0.02

0.05

0.00

0.00

0.00

0.00

Pancake

Intervention

0.85

0.77

1.13

1.03

0.08

0.07

0.05

0.05

0.07

0.07

(3 pancake ~ 30g)

Group

0.76

0.69

1.12

1.02

0.07

0.06

0.00

0.00

0.00

0.00

Salad dressing

Intervention

5.17

12.94

4.95

12.37

1.13

2.82

0.05

0.13

0.07

0.18

(40ml)

Group

5.09

12.73

4.94

12.35

1.12

2.80

0.00

0.00

0.00

0.00

Salsa

Intervention

0.56

1.86

1.32

4.40

0.22

0.73

0.05

0.18

0.07

0.25

(25g)

a

Group

0.47

1.57

1.31

4.37

0.21

0.70

0.00

0.00

0.00

0.00

Soup

Intervention

(1 sachet ~ 85g)

Group

1.02
0.94

1.20
1.10

0.99
0.98

1.16
1.15

0.04
0.03

0.44
0.04

0.05
0.00

0.60
0.00

0.07
0.00

0.09
0.00

a

2

Group

a

Mean value of two separate varieties within this category
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At baseline, at 3-months and at the end of the 6-month intervention, fasting blood
samples were taken by venipuncture for erythrocyte fatty acid and lipid
compositional analysis. Height, weight, waist circumferences (at natural waist when
clearly identifiable or midway between the lower rib and iliac crest) and hip
circumference (at greater trochanter) were measured at each of the three time
points.
5.2.3 Dietary Measurement
A modified Burke style DH (Appendix I) (351) was administered to each subject by
trained dietitians using a standardised tool at baseline, 3-months and 6-months.
Dietitians asked subjects to describe a typical day’s intake, as well as amounts,
frequencies and variations in consumption. Quantities were assessed using
familiar volumes, dimensions or purchasing units, or with food models representing
volumes and serving sizes. A standardised questionnaire was then used to gather
information about the types of meals consumed, the frequency of meals, eating out
and formal entertaining. A daily checklist of foods and brands was also used to
identify or clarify intakes of fatty foods and foods containing n-3 fatty acids. Using
each of these tools, a 7-day pattern of consumption was constructed. In addition,
all subjects, prior to the DH at baseline, completed FR (Appendix J) after 3-months
and 6-months. Subjects kept records of all foods consumed over a period of three
days including two weekdays and one weekend day. All foods were either weighed
by the subjects or listed in common serving or package sizes. Subjects were
instructed to be as detailed as possible when reporting food items, weights and
sizes. FR was checked with each subject by a different dietitian to that which
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performed the DH. Analysis of the DH and FR were performed by an independent
dietitian. Both methods were assessed against erythrocyte fatty acid levels with
strong correlations (particularly with the DH) achieved for EPA, DHA, total LCn-3
and total n-3 at 3 and 6-month time points. As additional measure of compliance
each subject was asked to record the number of study food portions consumed per
day and the average weekly portions consumed were calculated for each subject.
At the conclusion of the study participants were asked to rate the taste of each
product on a 7-point Likert scale ranging from -3 (extremely dislike) to +3
(extremely like) (Appendix K).
DH and FR were entered into the Foodworks™ nutrient analysis software package
(Xyris Software, Highgate Hill, Brisbane Australia, Professional Version 3.2,2002),
using the Australian nutrient database AusNut Rev 0.14 (AusNut 2000, Department
of Human Services and Health, Canberra) and the Australian Fatty Acids Rev 0.6
(Royal Melbourne Institute of Technology, 2002) to produce values for energy and
macronutrient intakes and fatty acids. All study foods (controls and intervention)
were entered into the Foodworks database and nutrient content analysed through
recipe analysis using product information and analytical data from
microencapsulated fish oil powder. Additional foods from interviews that were not
found in the database, were substituted with equivalent food items (352).
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5.2.4 Laboratory procedures5
Fasting venous blood was collected in EDTA tubes and centrifuged at 4000rpm for
10 minutes at 4°C to separate erythrocytes from plasma. Subsequently,
erythrocytes were washed twice with isotonic saline and stored at -80°C prior to
fatty acid extraction. Erythrocytes membrane lipids were extracted into methanol:
toluene (4:1, by vol.) and transmethylated according to the method of Lepage &
Roy (1986). Gas Chromatographic analyses of fatty acid methyl esters (FAME)
were performed using a Shimadzu GC 20A (Shimadzu Corporation, Kyoto, Japan)
fitted with a FID and a 50m BPX70 cross-linked 70% cyanopropyl
polysilphenylene-siloxane capillary column (0.32 mm ID and 0.25 µm film
thickness, SGE, Australia). Samples were injected at 125°C and held for 1 minute.
Oven temperature was set to increase in a step-wise manner to a final temperature
of 220ºC. The injector and detectors were maintained at 260ºC and hydrogen was
used as the carrier gas. Peak areas and fatty acid percentages were quantified on
an IBM compatible workstation using Shimadzu software. Individual fatty acids
were identified by comparison with known FAME standards (Nuchek Prep Inc,
USA). Results are expressed as percent of total fatty acids.

5

This analysis was conducted by researchers at the University of Adelaide. Results obtained were correlated with dietary

measurements by CP.
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5.2.5 Data Analysis
The statistical analysis focused on changes in dietary variables at three time
points, baseline, 3-month and 6-month. Effects of treatment on dietary intake over
time were assessed by repeated measures ANOVA based on an intention to treat
model of analysis. Demographics and dietary intakes of treatment and control
groups were compared using one-way ANOVA. Non-parametric analysis was
conducted using the Kruskall-Wallis test.
Differences between DH and FR data were assessed using Student’s t-tests and
Pearson’s correlation coefficients were estimated to view relationships. The
plausibility of estimated intake (EI) was tested against energy expenditure (EE). As
EE was unavailable, we used the EI:basal metabolic rate (BMR) ratio and
compared this to EE:BMR or physical activity level (PAL). Comparing the sample
EI: BMR ratio to the PAL level at which life is not sustained, the level of
underreporting for both individuals and groups could be determined. The
calculations were derived by Goldberg et al (353) and Black et al (354).
Underreporting of energy was determined by taking a group mean reported energy
intake (EIrep) to basal metabolic rate (BMR) ratio and applying the Goldberg cut-off
limits of 1.52 for diet histories and 1.50 for food records. These Goldberg cut-off
were determined using the equation suggested by Black et al (354), using the
group sample size, number of days dietary reporting as well as a physical activity
level (PAL) value. The sample size of n = 86, 86 & 74 was used for the time points
0, 3 & 6-months respectively. The number of days was 3 for food records and 14
for diet history. Using the World Health Organisation (WHO) recommendations for
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energy requirements (355) we made a judgment that a PAL of 1.55 would be used,
based on self reported exercise frequency, duration and intensity.
To assess the quality of dietary data, data obtained from diet history interviews and
food records were compared at 0, 3 and 6 months using Bland-Altman plots (343).
The ranges for the limits of agreement were set at 840kJ, 2% energy and 1g for
reported energy, macronutrients and total n-3 fatty acids respectively. Evidence of
systematic bias was observed if a significant correlation was found between the
difference (DH-FR) and mean (DH-FR/2) values. SPSS V11.0 (Version 11.0.0;
19/09/01, SPSS Inc., Chicago, IL, USA) was used for all statistical analyses, with a
statistical significance level of P < 0.05.
5.3

Results

Eighty six men and women commenced the trial. The intervention and control
groups were well matched for weight, height, BMI, age, daily total energy, protein,
fat and carbohydrate intake (Table 5-2). There were no withdrawals at 3-months
whereas at 6-months 12 withdrew (8 in the intervention and 4 in the control group),
leaving a group randomisation of 36 in the control group and 38 in the intervention
group. Body weight increased significantly in both groups at the end of 6-months
by 2.7kg ± 4.7 in the intervention group and 1.4kg ± 2.4 in the control group (P <
0.001), with no difference detected between the groups.
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Table 5-2 Baseline characteristics

Control

Intervention

P-value

(n = 22 M, 22 F)

(n = 19 M, 23 F)

Age (y)

50.2 ± 9.4

50.4 ± 14.5

0.943

Height (cm)

170.4 ± 9.8

172.3 ± 10.9

0.379

Weight (kg)

94.6 ± 17.2

93.0 ± 17.6

0.667

BMI (kg/m2)

31.9 ±4.4

31.2 ± 5.2

0.242

Waist-to-hip ratio

0.91 ±0.08

0.93 ±0.09

0.495

Total Energy (kJ/day)

11244.2 ±3136.6

11657.9 ±3805.8

0.574

Protein (g/day)

115.0 ±31.6

117.3 ±33.2

0.746

Fat (g/day)

96.6 ±34.0

103.6 ±34.3

0.333

Carbohydrate (g/day)

322.9 ±105.0

337.6 ±135.5

0.565

5.3.1 Dietary data
Dietary intakes of macronutrients and key fatty acids were estimated using the DH
interview data (Table 5-3). Protein as a percent of energy intake, alcohol and fibre
intake decreased over the course of the study, but there were no significant
differences between the two groups. There were no significant changes in total fat
(%E), SFA (%E) and MUFA (%E) after 6-months but there was a significant
difference between the groups at each time point. Dietary intake of PUFA (%E)
increased in the treatment group (≈12%) whereas it decreased in the control group
(≈5.5%). AA intake was significantly different between groups, but this did not
change over time, nor was there a significant interaction between the two groups.
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There were significantly different changes in intake between the control and
intervention for ALA (≈75%, 25%; P < 0.01), EPA (≈490, -58%; P < 0.001), DHA
(≈370%, -60%; P < 0.001), LCn-3 (≈365%, -55%; P < 0.001), n-6:n-3 ratio (≈-51%,
-11%; P < 0.001) and total n-3 (≈122%, 9%; P < 0.001) respectively.
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Table 5-3 Subjects’ daily intake as estimated by diet history analysis Mean (± s.d.)

Baseline

3 months

6 months

Total energy (kJ)

P-value

0.910

a

Intervention

11716.0 ±3912.0

11132.6 ±3107.8

11473.7 ±2764.7

0.760

b

Control

10946.6 ±2922.7

11539.7 ±2703.2

11268.0 ±2592.0

0.419

c

0.845

a

Carbohydrate (% E)
Intervention

45.54 ±6.02

46.11 ±4.81

44.74 ±5.86

0.115

b

Control

46.97 ±6.44

47.21 ±5.76

47.44 ±6.44

0.448

c

0.050

a

Protein (%E)
Intervention

16.56 ±2.58

15.70 ±2.18

16.14 ±2.10

0.774

b

Control

16.60 ±2.53

15.54 ±1.78

15.90 ±2.18

0.622

c

0.071

a

Alcohol (%E)
Intervention

7.96 ±15.18

7.35 ±13.45

6.77 ±14.41

0.437

b

Control

11.03 ±15.14

9.61 ±14.74

8.85 ±11.62

0.595

c

0.038

a

Fibre (g)
Intervention

33.33 ±11.8

28.00 ±8.5

29.92 ±8.3

0.428

b

Control

32.33 ±7.9

32.50 ±9.6

30.44 ±8.3

0.542

c

0.071

a

Cholesterol (mg)
Intervention

360.5 ±325.9

392.3 ±159.8

402.0 ±141.2

0.722

b

Control

324.9 ±122.3

342.2 ±102.0

383.8 ±112.8

0.330

c

0.613

a

Fat (% E)
Intervention

33.20 ±5.80

32.79 ±5.58

34.00 ±5.07

0.005

b

Control

30.58 ±5.86

30.98 ±5.53

30.62 ±5.54

0.656

c

0.509

a

SFA (% E)

‡

Intervention

12.93 ±3.03

12.70 ±1.46

12.86 ±2.26

0.012

b

Control

11.29 ±3.26

11.92 ±2.28

11.87 ±2.31

0.400

c

0.084

a

MUFA (% E)
Intervention

12.45 ±2.89

12.66 ±2.00

13.41 ±2.47

Control

11.48 ±2.92

12.18 ±2.77

12.05 ±3.08

PUFA (% E)

b

0.049
c
0.659
0.466

a

Intervention

5.03 ±1.56

5.53 ±0.91

5.65 ±1.32

0.046

b

Control

5.07 ±1.59

5.12 ±1.37

4.79 ±1.18

0.055

c
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PUFA:SFA ratio

0.412

a

Intervention

0.413 ±0.17

0.440 ±0.09

0.451 ±0.13

0.499

b

Control

0.500 ±0.27

0.442 ±0.12

0.419 ±0.14

0.025

c

0.000

a

n-6:n-3 ratio
Intervention

8.88 ±4.2

3.43 ±0.8

4.31 ±1.6

0.000

b

Control

8.57 ±3.6

6.40 ±1.6

7.59 ±2.4

0.001

c

0.722

a

LA
Intervention

12.92 ±5.59

12.79 ±4.46

14.07 ±5.16

0.470

b

Control

12.46 ±5.56

13.52 ±4.83

11.93 ±4.36

0.336

c

0.261

a

AA
Intervention

0.14 ±0.08

0.10 ±0.06

0.14 ±0.07

0.035

b

Control

0.14 ±0.12

0.14 ±0.08

0.18 ±0.07

0.247

c

0.000

a

ALA
Intervention

1.34 ±0.69

2.60 ±1.19

2.33 ±1.18

0.011

b

Control

1.25 ±0.60

2.11 ±1.09

1.56 ±0.65

0.011

c

0.000

a

EPA (mg)
Intervention

73.0 ±45.8

474.0 ±173.6

428.2 ±140.0

0.000

b

Control

83.0 ±70.1

49.0 ±48.7

35.3 ±28.6

0.000

c

0.000

a

DHA (mg)
Intervention

144.0 ±120.1

775.1 ±296.2

675.7 ±239.8

0.000

b

Control

186.6 ±166.7

94.3 ±78.8

80.5 ±74.8

0.000

c

0.000

a

LCn-3 (mg)
Intervention

258.2 ±179.7

1339.6 ±503.0

1195.7 ±401.0

0.000

b

Control

313.4 ±248.9

177.6 ±137.3

146.3 ±119.2

0.000

c

0.000

a

§

Total n-3 (g)

Intervention

1.59 ±0.67

3.94 ±1.55

3.53 ±1.48

0.000

b

Control

1.57 ±0.63

2.28 ±1.16

1.71 ±0.68

0.000

c

0.695

a

Total n-6 (g)
Intervention

13.08 ±5.62

12.94 ±4.52

14.25 ±5.18

0.346

b

Control

12.63 ±5.62

13.68 ±4.87

12.14 ±4.39

0.484

c

Values significant at P < 0.05; a significant differences observed over time, b significant differences
observed between treatment group, c significant difference with time and treatment group.
‡

SFA, saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated acids; LA,

Linoleic acid, AA; Arachidonic acid; ALA, α –linolenic acid; EPA eicosapentaenoic acid; DHA,
docosahexaenoic acid. § Includes ALA + EPA + DPA (Docosapentaenoic acid, 22:5 n-3) + DHA.
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5.3.2 Relative Validity
Energy reported using DH correlated significantly with that reported in the FR (r =
0.55, P < 0.001) at baseline. Significant correlations were also found between the
DH and FR for all macronutrients and fatty acids (with the exception of PUFA (%E)
and n-6:n-3 ratio at baseline) at all time points, including protein (%E),
carbohydrate (%E), fat (%E), SFA (%E), MUFA (%E) and PUFA (%E) as well as
the P:S ratio, n-6 PUFA, n-3 and EPA + DHA. Correlation coefficients are listed in
Table 5-4.

118

Table 5-4 Correlation coefficients of dietary variables using the diet history and 3-day food
record

Baseline

3 month

6 month

Total energy (kJ)

0.55**

0.70**

0.64*

Carbohydrate (% E)

0.56**

0.55**

0.48**

Protein (%E)

0.24*

0.34**

0.48**

Alcohol (g)

0.71**

0.86**

0.71**

Fibre (g)

0.49**

0.49**

0.42**

Fat (% E)

0.50**

0.49**

0.38**

SFA (% E) ‡

0.59**

0.35**

0.35**

MUFA (% E)

0.36**

0.40**

0.29*

PUFA (% E)

0.18

0.52**

0.33**

PUFA:SFA ratio

0.60**

0.38**

0.32**

n-6 (g)

0.40**

0.47**

0.22

n-3 (g)

0.28**

0.65**

0.62**

EPA + DHA (g)

0.35**

0.82**

0.71**

n-6:n-3 ratio

0.13

0.68**

0.59**

Pearson’s correlation coefficient; * P < 0.05; **P < 0.01.
‡

SFA, saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated acids;

EPA eicosapentaenoic acid; DHA, docosahexaenoic acid.
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5.3.3 Underreporting
Underreporting was more common in FR than DH. However, both methods
reported plausible energy intakes when compared to the Goldberg cut-off at all
time points (Table 5-5).

Table 5-5 Group mean reporter EIrep:BMR and Goldberg cut-off as an indicator of under
reporting

Record

Time-point (month)

Group Mean EIrep:BMR

Goldberg cut-off

DH

0

1.84

1.52

FR

0

1.60

1.50

DH

3

1.89

1.52

FR

3

1.65

1.50

DH

6

1.83

1.52

FR

6

1.57

1.50

5.3.4 Bias
No systematic bias was detected using Bland-Altman plots for all macronutrients
and fatty acids, and at all time points. Only baseline data for total fat and LCn-3 are
presented (Figures 5-1 & 5-2). The DH data compared well with FR as the mean
difference between the two methods was close to zero for each variable, and the
range for the limits of agreement lay within the acceptable values. Site differences
for each dietary assessment method were determined and showed that BMI was
significantly different between the sites at baseline (P = 0.024) and 3-months (P =
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0.048). After adjusting for BMI, only site differences were observed for the 3-month
assessment of total n-6 (P = 0.031) and total n-3 (P = 0.034) using the DH.
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Figure 5-1 Bias of fat versus mean fat (g/day) intake at baseline
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Figure 5-2 Bias of LCn-3 versus mean intake (mg/day) at baseline
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5.3.5 Compliance
Daily log books revealed the consumption of study foods decreased over time
(Figure 5-3). There was no significance between the groups, with both groups
consuming on average between 6 and 7.5 serves of enriched foods per day
(~750mg – 940mg LCn-3 per day)

9
8.5
8

Serves/day

7.5
7

Control

6.5

Omega

6
5.5
5
4.5
4
1

2

3

4

5

6

Month

Figure 5-3 Daily mean (± s.d.) number of study food serves consumed
Values significant at P < 0.05; * significant differences observed over time, but not between groups
using repeated measures ANOVA.

5.3.6 Food pattern analysis
Table 5-6 shows the contribution of different food groups to the overall LCn-3
intake. After 6-months, the major sources of LCn-3 in the intervention group were
enriched milk, cereal and bread. All other enriched products combined contributed
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a further 28.2% of the total LCn-3. In contrast, the major sources of LCn-3 in the
control group were fish (fatty and white) (approximately 1 serve per week) and
meat.

Table 5-6 Major food group contributors to overall LCn-3 intake (% contribution to total LCn3)

Baseline (n = 86)

6-month (n = 74)

Control

Intervention

Control

Intervention

Fatty fish (36.7%)

Fatty fish (52.3%)

Fatty fish (32.4%)

Enriched milk (13.8%)

Chicken (19.3%)

Meat (12.6%)

White fish (22.8%)

Enriched cereal (12.1%)

Meat (14.8%)

White fish (12.1%)

Meat (19.3%)

Enriched bread (11.3%)
Fatty fish (9.9%)
Enriched biscuit (8.1%)
Enriched chocolate (7.5%)
Enriched dip (6.4%)
Enriched margarine (6.3%)

Total - 70.8%

Total - 77.0%

Total - 74.5%

Total – 75.4%

LCn-3 intake – 0.3g/d

LCn-3 intake – 0.3g/d

LCn-3 intake – 0.1g/day

LCn-3 intake – 1.2g/day

5.3.7 Food preferences
At the conclusion of the study, participants in the intervention group rated the oats
and milk slightly favourable (1.4 and 0.5 respectively; items scored between -3 to
+3) whereas they rated the bread as relatively unfavorable (0.3) which was
significantly different (P < 0.05) from the control group (1.1). Apart from the salad
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dressing, all other food items were rated as tasting favorable with no reported
significant differences between the groups (Figure 5-4).
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Figure 5-4 Mean (± s.d.) taste ratings of study foods (scores ranged from unfavourable (-3)
to favourable (+3))

5.3.8 Dietary Biomarkers
There were significant increases in the proportions of EPA, DHA, LCn-3 and total
n-3 in the intervention group by 96%, 79%, 59% and 25% respectively (Table 5-7).
A significant difference in the proportion of n-6 between the groups was observed
at 3-months, but not baseline or at 6-months.
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Table 5-7 Plasma fatty acid biomarkers at each time point for each group (% total fatty
acids)†

Baseline

3 months

6 months

LA‡

*0.058

Intervention (n=34)

6.72 (1.37)

6.93 (0.732)

7.00 (0.71)

**0.144

Control (n=40)

6.98 (1.22)

7.24 (0.97)

7.27 (0.99)

***0.951

AA

*0.254

Intervention (n=34)

10.20 (4.61)

11.08 (2.89)

11.61 (2.33)

**0.138

Control (n=40)

11.64 (2.98)

12.24 (2.23)

11.49 (3.69)

***0.162

ALA

*0.429

Intervention (n=28)

0.390 (1.582)

0.110 (0.026)

0.111 (0.026)

**0.305

Control (n=31)

0.100 (0.030)

0.111 (0.028)

0.136 (0.076)

***0.278

EPA

*0.000

Intervention (n=35)

0.594 (0.386)

0.984 (0.382)

1.165 (0.338)

**0.000

Control (n=40)

0.617 (0.240)

0.619 (0.176)

0.683 (0.286)

***0.000

DHA

*0.000

Intervention (n=35)

3.314 (1.339)

5.058 (1.438)

5.927 (1.178)

**0.000

Control (n=40)

4.109 (1.394)

4.044 (0.913)

3.921 (1.078)

***0.000

LCn-3

*0.000

Intervention (n=35)

5.933 (2.185)

8.339 (2.101)

9.411 (1.870)

**0.000

Control (n=40)

6.824 (2.126)

6.864 (1.418)

6.708 (1.695)

***0.000

Total n-3

*0.022

Intervention (n=35)

8.93 (4.85)

10.39 (2.60)

11.16 (1.81)

**0.001

Control (n=40)

8.64 (1.86)

8.70 (1.17)

8.45 (1.55)

***0.007

Total n-6

†

P-value

*0.087

Intervention (n=35)

20.76 (6.40)

21.96 (3.48)

22.15 (2.68)

**0.007

Control (n=40)

22.91 (4.86)

24.00 (3.24)

24.02 (4.39)

***0.839

Mean (s.d.)

‡

LA, Linoleic acid, AA; Arachidonic acid; ALA, α – linolenic acid; EPA eicosapentaenoic acid; DHA,

docosahexaenoic acid. *significant differences observed over time, ** significant differences
observed between treatment groups, *** significant difference with time and treatment groups. Twoway repeated-measures ANOVA.
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5.3.9 Relationship between dietary intake and dietary biomarkers
The correlation coefficients (r) between dietary intake as recorded by DH and
erythrocyte membrane was significant at 3-months and 6-months for EPA, DHA,
LCn-3 and total n-3 (Table 5-8). The correlation coefficients between the FR and
erythrocyte membrane EPA, DHA and LCn-3 showed a similar trend, but weaker
relationship. In addition the total n-3 was only correlated at 6-months and there
was a small but significant correlation between dietary intake recorded by FR and
erythrocyte membrane linoleic acid (LA) at 3-months.
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Table 5-8 Pearson’s correlation between reported dietary intake and equivalent plasma fatty
acid biomarkers†

Variable

Baseline

3 months

6 months

Diet history

0.024 (0.825)

0.084 (0.445)

0.124 (0.328)

Food record

-0.016 (0.883)

0.335 (0.002)***

0.080 (0.506)

Diet history

0.110 (0.318)

0.172 (0.117)

0.070 (0.582)

Food record

-0.001 (0.995)

0.115 (0.308)

-0.097 (0.420)

Diet history

-0.052 (0.672)

0.022 (0.842)

0.036 (0.785)

Food record

0.154 (0.203)

0.002 (0.985)

-0.041 (0.739)

Diet history

0.123 (0.259)

0.463 (0.000)***

0.743 (0.000)***

Food record

-0.131 (0.228)

0.374 (0.001)***

0.555 (0.000)***

Diet history

0.151 (0.166)

0.418 (0.000)***

0.663 (0.000)****

Food record

0.095 (0.384)

0.288 (0.010)**

0.497 (0.000)***

Diet history

0.101 (0.354)

0.421 (0.000)***

0.641 (0.000)***

Food record

0.050 (0.645)

0.305 (0.006)***

0.450 (0.000)***

Diet history

-0.164 (0.132)

0.341 (0.001)**

0.515 (0.000)***

Food record

-0.018 (0.871)

0.202 (0.720)

0.266 (0.240)*

LA‡

AA

ALA

EPA

DHA

LCn-3

Total n-3

†

Mean (s.d.). ‡LA, Linoleic acid, AA; Arachidonic acid; ALA, α – linolenic acid; EPA

eicosapentaenoic acid; DHA, docosahexaenoic acid. * P < 0.05; **P < 0.01; ***P < 0.001

127

5.4

Discussion

This study demonstrated that replacement of foods with n-3 enriched equivalent
foods for 6 months significantly increased total n-3, LCn-3, EPA and DHA intake as
verified by analysis of FR and DH completed by participants. These findings may
be important as an increased n-3 fatty acid intake has been associated with a
substantially reduced risk of death in subjects with existing coronary heart disease
(CHD) (82, 108) and epidemiological evidence has demonstrated a reduced risk of
CHD mortality in those who eat fish regularly (79, 95, 99, 100). With a large
number of the population unable to consume enough of these essential fatty acids
from fish alone (18), enriched processed foods may have positive public health
implications. In addition to the total intake of LCn-3, the ratio of n-6:n-3 is also
important as it may be associated with improved health outcomes (347, 356)
whereas excess amounts of LA and associated eicosanoids may promote
thrombosis and inflammation (160). This study showed a reduction of the ratio of n6:n-3 to 3:1 and increased the daily intake of n-3 in the intervention group. In
addition there was no alteration of the PUFA, MUFA, SFA or the PUFA:SFA ratio
which are also important when considering the overall dietary affect on heart health
risk (14).
Detailed analysis of the dietary data indicated a sense of confidence in these
findings. Strong positive correlations were found between both measures of dietary
intake for energy and major macronutrient intakes reported using DH and FR and
within the range of coefficients found in other studies of similar-aged subjects (309,
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357, 358). The weakest, although still significant, correlation was found in reported
intakes of PUFA. It can be speculated that this weak correlation was due to overreporting of PUFA in the DH as this was a focal point of questioning. Subjects were
asked specific questions about intakes of foods that were good sources of PUFA,
and may have over-reported their intakes as they interpreted these to be healthy or
desirable foods (359). Although significant correlations can suggest that two dietary
assessment methods possess relative validity, there is still considerable
unexplained error within each of the methods. Correlations are used to
demonstrate the strength of association between two methods, but provide no
guide as to the accuracy or precision of the methods (359).
Both over- and underestimation has been reported in other studies (307). The level
of underreporting in this study was considerably smaller than, or similar to, that
found in previous studies (309, 314, 315, 357, 360-362). The proportion of underreporters was considerably less in the DH than the FR, indicating that the DH is a
better method of estimating energy intake in this study population. Underconsumption may be more likely than underreporting in the FR, since recording all
food consumed for more than one day is known to modify behaviour to reduce
intake (307). However, while some studies show that the DH over-estimates intake
relative to the FR, others have shown using metabolic studies that both the DH and
the FR underestimated intake (313). Rothenberg et al (1998) showed that energy
expenditure reported in activity diaries matches energy intake reported in DH, but
doubly labeled water tests concluded that both must have been underreported
(363). This may explain why we observed a significant weight gain over the study
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period with no apparent increase in reported energy intake. Both methods may
have overestimated intake of LCn-3. A dose response study into EPA + DHA
intake and subsequent rises in erythrocyte fatty acids found that this index rose
from 4.7 ± 0.9% to 7.9 ± 1.7% with supplementation of 0.5g/day (P < 0.001), to 9.9
± 2.9% with 1g/day (P < 0.001), and 11.6 ± 2.4% with 2g/day (P = 0.02) (9). Based
on the estimated dietary intake of 1.2g/day an expected increase in erythrocyte
fatty acid level of > 8% would be expected, whereas an increase of 7.1 ± 1.9% was
reported. Results from the food logs also suggest that the intake of LCn-3 may
have been lower.
There are other components of error relevant to the DH and FR in an intervention
trial in addition to under-reporting. These include random error, error in portion size
estimates and method-related bias resulting in consistent over- or underrepresentations (359). Method-related bias was addressed using Bland-Altman
plots. No systematic bias was found in this study, indicating that any misreporting
was random in nature and does not indicate specific error in reporting of
macronutrients in the DH relative to the FR. This may in part be attributed to
standard study food portion sizes as well as using well-trained research dietitians
to collect the data. In addition, apart from n-6 and n-3 intake at 3-months, there
were no significant differences between the sites in reported intake using the DH
after adjusting for BMI. Others have reported that the diet history is subject to
observer bias, with the bias appears to be macronutrient specific with energy, fat
and SFA consistently underreported (310).
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The question of validity can be addressed by comparing both dietary assessment
methods to fatty acids accumulated in the erythrocytes. The correlation between
the dietary intakes measured by DH of EPA, DHA, LCn-3 and Total n-3 and the
equivalent erythrocyte fatty acid was stronger that that observed using the FR. This
relationship ranged from 0.34-0.46 at 3-months to 0.52-0.74 at 6-months for the
DH and 0.29-0.37 at 3-months to 0.27-0.55 at 6-months for the DH. This is the first
study to investigate the relationship of the DH with erythrocyte fatty acids. Parra et
al (2000) exploring the relationship between FFQ and usual dietary patterns in
Mexican women reported modest correlations with erythrocyte ALA, DHA and EPA
against their dietary counterparts (r = 0.32, 0.35 and 0.36 respectively) (322).
Others have investigated the relationship between FR and serum fatty acids for
LCn-3 with reported correlations of between 0.49-0.75 (364, 365), and between
FFQ and serum fatty acids for LCn-3 (r = 0.49-0.51) (366, 367). Results at 3 and 6months are comparable with these studies; however no significant correlations at
baseline were found. Study design and population characteristics may explain
these differences. Anderson et al, reported strong correlations on LCn-3 at
baseline using a larger sample than ours (n = 579) men and women (365),
whereas cross sectional studies reporting strong correlations were conducted in
Japan where fish intake is habitually high (364, 366, 367). In this study, baseline
habitual intake of LCn-3 (~200mg/day) was not correlated to the equivalent
erythrocyte fatty acid, however once the LCn-3 enriched study foods were added to
the diet this relationship emerged. Finally, there is an apparent anomalous
correlation with LA to the equivalent fatty acid in the erythrocyte membrane at 3months as reported by the FR which may be explained by the difference in dietary
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assessment methods or a statistical artifact. Interestingly, this result was mirrored
by an equally anomalous absence of correlation for total n-3 using the same
assessment method at the same time point. It is important to be aware that the
biochemical marker used can be confounded by the fact that they reflect relative
percentage and not absolute amounts (322). The method of collection, sampling
site and analytical technique may also influence the results (322).
Through the consumption of enriched novel foods an increase in EPA + DHA
levels from 4.09% at baseline to 7.10% was observed. Harris and von Shacky
propose that a combined EPA + DHA level of ≥ 8% is associated with the greatest
cardioprotection, compared to ≤4% (9). However, an unintended negative impact of
this study was the increase in body weight in the intervention group. Weight gain
has the potential to worsen all elements of the cardiovascular risk profile, including
blood pressure, dyslipidemia, glucose tolerance, left-ventricular hypertrophy,
hyperuricaemia, and fibrinogen levels (368). As the design of this study was to
simply replace food items in an ad libitum fashion, ‘whole of diet’ advice was not
provided upfront, and only discussed once any weight gain was detected. A whole
of diet approach considers advice of the number of portions of all food groups and
may be necessary to ensure energy balance as well as controlling for the
background diet in supplemental studies (369). The finding reinforces the need for
caloric consideration in the design of novel foods as well as education about how
the whole diet may emerge when such foods are incorporated.
This study also provides an insight into how consumers may use novel enriched
foods. Although providing a wide range of food products, we found that staple
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foods such as milk, cereal and bread were the most significant contributors to the
overall LCn-3 intake in the intervention group. This finding is consistent with
qualitative research suggesting that consumers prefer staple foods as potential
vectors for this functional ingredient (370). Of particular note was the finding that
participants in the intervention group rated the taste of the bread as being
unfavourable, with comments suggesting that it tasted ‘fishy’. Despite this, the
enriched bread was the third most significant contributor to the increase in LCn-3
intake and suggests that improving the taste of this product has the potential for it
to be an important vector for delivery of LCn-3.
In conclusion, the dietary intakes of LCn-3 were significantly increased, reaching
recommended targets (145), through the use of enriched novel foods in overweight
subjects. The validity of the dietary data was confirmed; however unintended
weight gain has the potential to nullify any positive cardiovascular benefits of an
increase in dietary LCn-3. The ability to extrapolate results from these studies to a
population approach is limited by the controlled nature of the study design.
Therefore, the compliance levels observed in this study may not be achieved
outside of the confines of such a controlled environment highlighting the need to
study consumer behaviour. Therefore, an investigation into consumer beliefs and
attitudes about n-3 functional foods will be presented.
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CHAPTER 6

CONSUMER BELIEFS ABOUT FUNCTIONAL FOODS INFLUENCE UPTAKE6

6.1

Introduction

For n-3 functional foods to be effective in the primary prevention of CHD
widespread consumer acceptance and dietary inclusion would be required. To date
the understanding of consumer beliefs and attitudes towards this concept has
received very little research effort. This is confounded by the fact that there is no
universally accepted definition for functional foods and they seem to fall into a grey
area, somewhere between foods and medicines, with the precise boundaries on
either side far from clear (371). From the viewpoint of nutrition education, the
functional food category does not fit straightforwardly into any of the longestablished food educational models and there are concerns relating to consumer
acceptability and perception (25). With evidence showing that food choice affects
dietary quality as measured by intake (372, 373), it seems appropriate that greater

6
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Patch CS, Tapsell LC, Williams PG. Overweight consumers' salient beliefs on omega-3 enriched functional foods in
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attention be given to the factors that facilitate or constrain the use of functional
foods.
The field of behavioural psychology suggests that the best predictor of human
behaviour is a person’s conscious decision to perform the behaviour. The Theory
of Planned Behaviour (TPB) provides a model that can help explain consumers’
purchase intentions to use functional food products. A person’s behavioural
intention is determined by the attitude they hold towards the behaviour, the degree
of social pressure felt by the person to perform or not perform the behaviour, and
the degree of control that the person feels they have over performing the behaviour
(19). These three factors in turn are determined by a number of beliefs and
subsequently how each is evaluated. It has been demonstrated that the TPB, or
modified versions of it, is applicable in explaining consumers’ food choice (20-22),
including supplement use (23) and genetically modified products purchasing (24).
However, to date this model has not been applied to understanding consumer
behaviour regarding the use of functional food products.
Focus groups can be used to access a diverse range of opinions and viewpoints
and determine salient beliefs. These may then be tested on a larger sample in
quantitative surveys to access their generalisability. A focus group discussion is
defined as “a carefully planned discussion designed to obtain perceptions on a
defined area of interest in a permissive, non threatening environment” (329). This
approach is suggested by Ajzen & Fishbein (1980) as the method of choice to
determine salient beliefs about the topic area of interest (19.). In the present study,
the utility of the method was strengthened by focusing on specific products rather
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than investigating functional food products in general (19.). In addition, consumers’
attitude toward functional food could be expected to be influenced by general
attitudes such as attitude toward technology or food neophobia (374), beliefs about
the production process, perceived healthiness (288) and beliefs about the quality of
the resulting product. This is particularly relevant as the range of n-3 functional
foods entering the market place is increasing.
The aim of this study was to gain an understanding of the salient beliefs underlying
Australian consumer attitudes and purchase intentions with regard to n-3 enriched
functional foods. Using focus group discussions, consumer beliefs and attitudes
were determined for the purpose of developing a survey instrument to test the
generalisability of these opinions in a larger population sample.
6.2

Methods

Focus group interviews examining salient beliefs and attitudes regarding functional
foods were conducted with a cross-section of adult consumers in the Illawarra
region of New South Wales (NSW), Australia. Compared to the NSW average, the
population residing in the Illawarra is more socially disadvantaged and
hospitalisation rates from coronary heart diseases in the Illawarra were 20% higher
in men and 14% higher in women than the state average in 2001 (375). The study
employed a qualitative research design, with overweight participants recruited via
media release (Appendix L). This group reflects a potential target population for
functional foods enriched with n-3 due to their likelihood having a high
cardiovascular risk.
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6.2.1 Participants
Participants were recruited through general advertising in local media. Fifty
potential participants expressed interest in the study and all were invited to attend
one of six focus group discussions. An information sheet and a consent form were
mailed to each potential participant. Each participant was offered a small payment
(AUS$20) to offset any inconvenience that might have resulted from involvement in
the study. Approval for the conduct of the study was provided by the University of
Wollongong / Illawarra Area Health Service Human Research Ethics Committee
(Appendix M).
6.2.2 Focus group procedure
The focus groups were conducted between July and August 2002. All groups were
conducted in a community centre located in the Illawarra region. Focus groups
were audio taped and later transcribed to allow systematic analysis of the
discussion. Each focus group ran for approximately one hour and was conducted
by a moderator and an observer. To ensure consistency between the groups the
same trained moderator ran each group and all groups were monitored by an
independent observer for quality assurance purposes (329). An interview guide
was developed by the research team (CP, LT, PW) following the general guidelines
provided by Krueger (1994) (329). Using the TPB theoretical framework, 10
questions were devised to determine consumer awareness, beliefs, attitude and
barriers to using n-3 fatty acid functional foods (Figure 6-1). The question guide
was pre-tested using undergraduate nutrition students and reviewed by the
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research team. At the beginning of each session instructions were provided to the
group, the purpose of the interviews was outlined and it was emphasised that there
were no right or wrong answers. During the sessions, participants were
encouraged to speak until no more views were expressed, and then the moderator
probed and clarified points. In short, probes were primarily used to encourage
participants to clarify meanings or explain points of incongruence in their answers.
To introduce the concept of functional food, sample products were provided as
prompts for discussion (Questions 1 – 5)-, Flora’s Pro-activ® and Meadow Lea’s
Logicol™ (margarines with added plant sterols), Yakult’s fermented milk drink (a
probiotic beverage) and Buttercup’s Wonder White® bread (with high-amylose
resistant starch). Specific n-3 enriched food products were used as prompts for
discussion (Questions 6 – 10) - Tip Top’s Up™ bread and Meadow Lea’s Hi
Omega® margarine (both enriched with n-3 fatty acids).

139
1. Have you seen these foods and what do you think of them? [Probe: Has anyone used them and
why? If no one has, do you know anyone who has? Do you think they are useful and necessary?]
2. What do you see as the difference between these foods today and the foods of yesteryear?
[Probe: Do you think we should be going back to foods with fewer additives or less technology?]
3. Do you think you can improve your health by choosing foods with health benefits? Why?
4. How would you decide if you were going to use these products?
[Probe: Would you be influenced by other people’s view –professional, family, and friends?]
5. Why wouldn’t you use these products?
[Probe: Cost factors, availability in supermarket]
6. What do you think about this new margarine/bread (Meadow Lea n-3 and Tip Top Up)?
[Probe: Who do you think should use this?]
7. What health conditions should we be designing new foods for?
[Probe: Would it be better to add these health-promoting ingredients to food or make them into a
supplement? Have you taken supplements before?]
8. We all buy food for lots of different reasons; do you specifically buy foods for your health? Why?
[Probe: increase performance, reduce cholesterol, bowel health]
9. Do you believe what you read on the labels about the products?
[Probe: Do you think they will do what they claim to do? What else would help convince you that
they really work?]
10. If you were convinced that they work would you still buy these products?
[Probe: explore the ‘it depends’ issues]

Figure 6-1 Moderator question guide for salient beliefs focus groups
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6.2.3 Data Analysis
Each focus group discussion was tape-recorded and transcribed, producing on
average 30 pages of transcript. A computer software package for qualitative
research analysis, NVivo 2.0 (2002, QSR International Pty Ltd), was used for data
management and coding (334). Using the TPB model, transcribed conversation
was categorised into one of the three areas of belief related to behaviour:
behavioural beliefs, which are assumed to influence attitudes toward the
behaviour; normative beliefs, which constitute the underlying determinants of
subjective norms; and control beliefs, which provide the basis for perceptions of
behavioural control. Content analysis was carried out and sub-categories were
developed to capture the emerging themes. An iterative process of
subcategorisation was conducted as suggested by Knodel (1993) (376). After the
preliminary analysis by a single coder, two other members of the research team
assessed the categorisation of conversation as well as the content of each
category and sub-category. All three members of the team discussed areas of
disagreement and a consensus was reached. Because the purpose of this study
was exploratory, with an aim to elicit salient beliefs about functional foods,
quantification (e.g. frequency counts) was not undertaken; rather, examples from
the discourse are presented to illustrate the interpretive frames that emerged,
along with the corresponding themes (377).
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6.3

Results/Discussion

Of the 109 people who responded to media advertisements 50 agreed to attend a
focus group; however 8 people failed to attend on the day leaving a final number of
42. Of those who originally expressed interest and subsequently declined to
participate, the major reason cited was that they expected to be involved in a
dietary intervention trial. Six focus groups were scheduled and conducted at the
same venue. Each focus group included between 6-9 participants and lasted
between 50 and 80 minutes. The mean age of participants was 48 years with the
majority being female (65%). Fifty seven percent of participants were married, 27%
single and 16% living in a live in relationship. Group characteristics are shown in
Table 6-1.
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Table 6-1 Focus group characteristics

Focus group number
1

2

3

4

5

6

Total

9

9

6

7

6

5

42

Males

6

0

2

2

3

0

13

Females

3

9

4

5

3

5

29

Age (years)

49

42

47

50

51

51

48 (Mean)

Single

2

3

3

2

0

1

11

Live in relationship

2

2

0

0

2

0

6

Married

5

4

3

5

4

4

25

50

80

60

65

60

55

-

Number of participants
Gender (n)

Marital status (n)

Focus group duration (min)
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6.3.1 Salient Behavioural beliefs

Table 6-2 Categories of salient behavioural beliefs related to the use of n-3 enriched
functional foods

Category

Sample Quote

Speaker

Provide long term
health benefits

But do you think, if we started eating healthy, things like this [omega
enriched bread], as young as [name] is, then it would make a
difference over time, instead of starting when you’re older!

Group3, F

Help to manage
chronic disease

I’ve got heart disease and n-3 oil is good if you have heart disease.

Group 1, F

Well as you get older the fish oil definitely helps your arthritis. In a lot
of people the fish oil helps arthritis.

Group3, M

Because I heard it’s good for asthma, arthritis…It’s for a whole range
[of conditions] not just for lowering cholesterol. So I am pretty happy
that these are on the market now that I can give to him.

Group 2, F

Well I know that it’s a very good brain food and it keeps us
functioning and the brain needs n-3. But also possibly, people that
suffer or a suffering from Alzheimer’s.

Group 4, M

Otherwise deliver the
health benefits of fish

Because of the fact that I’ve got two boys that won’t eat tuna - one of
them will eat a bit of fish - and this is a way of supplementing that
then [yeah].

Group 4, F

Have an advantage
over supplement

Put it this way, I would rather not take it in tablets whatsoever, I’d
rather not take any stuff like that in tablets, my wife does, but none of
my children [do].

Group 5, F

May undermine the
concept of a healthy
diet

But we get two different messages. We get a message that everyone
should be eating a balanced diet and exercise and the other
message were getting is, hey, you don’t need to, [because you can
take this instead] yeah, because you can take this instead. So many
people won’t eat a balanced diet.

Group 3, F

May be at risk of
overexposure or
inadequate intake of a
nutrient

If they’re putting in enough to be beneficial [n-3], you could get to a
point where you are taking too much…particularly if it’s being put into
nearly every food or if you can never get to a stage where you are
taking too much, therefore they are not putting in enough to be
useful.

Group 1, F

I take my own supplements and that way I would know how much I
am taking. I am not having my food doctored up and not knowing
exactly the levels I am taking.

Group 1, F
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Categories of statements displaying behavioural beliefs, or outcomes beliefs
relating to using n-3 enriched foods, are outlined in Table 6-2. Most participants
indicated they believed that n-3 fats were good for them, often describing them as
being good for general health. In addition, there was strong agreement that most
people, from children to the elderly, could gain health benefits from including more
n-3 fats in the diet. When participants were asked about their beliefs about eating a
diet high in n-3 (or foods high in n-3 or foods enriched with n-3) a most prevalent
view was that they had a role in the prevention and treatment of heart and vascular
disease. There was confusion about the mechanism of action, with a number of
participants stating that n-3 fatty acids were important in lowering cholesterol;
however this did not detract from the believed importance of this nutrient in the
diet. In addition a number of participants were strong advocates of the benefits in
ameliorating inflammatory diseases, most notably arthritis. The importance of n-3
fatty acids in improving visual function and asthma was a belief held by relatively
few participants. There was a belief expressed by some individuals that n-3 fatty
acids had both a brain health promoting role, as well as a therapeutic role in the
treatment of Alzheimer’s disease.
There was a commonly expressed view that the health benefits of dietary n-3 fats
were only achievable when they were included in the diet over a long period of
time. However, there was also a prevailing belief that the ongoing use of these
products was largely determined by how effective these products were for the
individual; that is, did they alleviate symptoms or make the individual feel better
and did these benefits take long to be observed? Many people expressed the view
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that functional foods enriched with marine n-3 fatty acids were a good way of
delivering this nutrient in the diet, particularly as an alternative to fish, and more
specifically, a fish alternative for children. In general, participants saw functional
foods as a logical dietary option (e.g. fibre is good for you and children prefer white
bread, therefore white high fibre bread is a sensible innovation). Also, these foods
were seen to overcome other barriers to good nutrition such as access to fresh fish
products.
Research in the US has suggested that CHD remains the largest health concern
for consumers. Moreover, after CHD, Americans were concerned with eyesight,
cancer and joint pain (378). Research has shown positive associations with beliefs
about n-3 intakes and all of these health concerns (123, 379-381). These results
reflect this, with participants acknowledging the wide range of health benefits of n-3
fatty acids. Despite this, participants still demonstrated some reservation over
whether these health benefits could be extrapolated to novel foods enriched with
this ingredient.
Some participants raised the concern that n-3 enriched functional foods may not
contain enough of the functional ingredient to be effective and the dosage would
need to be clearly stated for use. This was the reason that supplements had
greater appeal for some over functional foods. However, the opposite was
apparent when considering the nutritional needs of children. Functional foods were
seen as a more practical and appropriate option than supplements for children and
adolescents and the elderly, a finding that has also been reported elsewhere (382).
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From the literature it is known that companies selling functional food products and
nutritional supplements share a similar market place and therefore compete for
market share. Reports have indicated that the market for ‘natural’ or ‘organic’
produced foods equals the growth of functional foods and may exceed it when
there is a reported food scare (383). It is also known that the perceived
wholesomeness of the overall product is also an important factor in food purchase
behaviour (384). Previous research into health behaviours shows that consumers
regard “healthy” eating as eating natural foods and “unhealthy” eating in terms of
eating manufactured or processed food (384) and our study suggests this may also
be the case when considering functional foods. Participants indicated that foods
that were not perceived as being healthy (e.g. chocolate or soft drink) were
regarded as less acceptable carriers for n-3 fatty acids despite acknowledging the
logical argument for the contrary – a finding which has been reported elsewhere
(382).
Overall this data showed a strong support for the concept of functional food
products as a convenient and logical way to achieve a healthy diet. Some
participants expressed concerns that functional foods had the potential to
undermine a person’s ability to achieve a healthy diet by creating confusion about
what constitutes a healthy food and that a total diet approach was preferred.
Concerns were also raised about the risk of overexposure of active ingredients. For
example, if recommended daily doses were provided in a typical number of daily
serves, an excessive intake of the food may lead to overexposure and potentially
undesirable side effects. Overall though, functional foods were viewed as an
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important part of a total diet approach by providing consumers with more healthy
food options.
6.3.2 Salient Normative beliefs

Table 6-3 Categories of salient normative beliefs related to the use of n-3 enriched
functional foods

Category

Sample Quote

Speaker

Family members

With different products, we just see if it’s one the family
will like

Group 4, F

Friends

It’s my best mate that told me about fish oil for arthritis.

Group 3, M

Medical practitioner

If a doctor or medical person said that it would improve
my health, I’d have a serious look at it. But advertising
[by] itself wouldn’t influence me.

Group 1, F

Nutritionist

It’s not just these people [food industry] making the claim,
it’s the nutritionists and all that across the country and
across the world are making the same claim.

Group 2, F

Scientists

And the other thing too is who did the research?
Because if they do their own research it doesn’t mean
that it’s honest.

Group 5, F

Food Industry

There are lots of loopholes in the labelling of foods they
[Food industry] can get around the legislation.

Group 5, F

Normative beliefs
generated with reference
to:

Table 6-3 outlines the major normative beliefs affecting the use of n-3 fatty acid
enriched functional foods as expressed by participants. Communication between
family members was important in spreading the word about new or novel foods
entering the market. Furthermore, the incorporation of these foods into the diet
depended on overall acceptance by the family unit. Similarly the opinions

148
expressed by friends appeared to be an important factor in at least exposing
consumers to novel food products. Medical and health professional opinion was
also an important factor in influencing participants’ behaviour in using functional
foods as a part of an overall health strategy, with nutritionists being regarded as an
independent credible source of information. Participants considered the
independence of health professional advice as being very important along with a
proven scientific basis to the claims, even though they found it difficult to interpret
and evaluate scientific results. There was a general belief that scientists and
scientific evidence was inconsistent, confusing and probably biased. These beliefs
were amplified when related to functional food products and industry-sponsored
research. In general participants were very skeptical of advertising campaigns as a
result of being more informed and less inclined to be coerced into purchasing.
Also, there was apparent distrust of labelling and the legislation controlling claims
on food packages.
The normative influences on participants’ use of functional foods such as family,
friends, food companies, health professionals and scientists revealed in our study
are consistent with the results of other studies that have investigated other more
general health related behaviours (23). The high level of trust in the opinion of
nutritionists compared to scientists and medical practitioners, when it came to
matters of nutrition, was of interest. The major factor contributing to this view was
their perceived level of independence. Conversely, food companies and their
advertising were not valued very highly. However, there was acknowledgement of
the need to inform the market of new food innovations through advertising.
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Participants place trust in family and friends and their advice affects willingness to
try a new product.
6.3.3 Salient Control beliefs

Table 6-4 Categories of salient control beliefs related to the use of n-3 enriched functional
foods

Category

Sample Quote

Speaker

Availability at the
supermarket and lack of
control over purchasing

I do most of my shopping at Woolies or Coles,
and if it’s not there I’m not going to buy it am I!

Group 3, M

Taste/Texture

No! [I would not eat these products] because of
my fish hate, I’d be turned off [laughter]
Supposing I didn’t have that fish taste maybe yes
I’d buy it.

Group 1, F

Lack of clarity in dosage
and effect

I’d like to know the difference. If I was going to
start taking some n-3 tablets…I want to know
what my benefits are going to be. If I don’t feel
any different next week, how long will it take?

Group 5, F

Lack of time to read labels

I honestly don’t have time to get there and read
labels and decipher all this stuff as you say and
every time you buy a product…

Group 1, F

Cost

…a discussion came up about them [functional
foods] at work day, and one of the comments was
the cost, because they are expensive and a lot of
people because of their financial situation have to
take that into consideration [mmm]…I think with
the food supply that if it is generally proved to do
what they claim then the next avenue to go would
be to lower them down to everybody’s reach. If
that’s their claim, that they’re doing it not for profit
or only partially for profit and for the good of
peoples health and the average family, they
should lower it down to everybody’s reach

Group 1, M

Salient control beliefs
based on perceptions of:
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Stated control beliefs, or factors out of the control of participants that could be
barriers to the purchase of functional foods, are listed in Table 6-4. It has been
shown that socially disadvantaged families disproportionately live in areas where
there are fewer large supermarkets (385). Other food outlets typically stock a
limited range of foods where prices are higher thus limiting access to functional
foods (385). However, there was little evidence that this is a real concern held by
the participants. Likewise, lack of control over purchasing is another potential
barrier, but only minor reference was made to this as a legitimate concern for
individuals within the groups. Taste and texture was fundamentally important to all
food purchasers. There was no evidence to suggest that participants would trade
taste for health and they expressed the view that if the tastes weren’t at least equal
to comparable products then they would not buy them, which is consistent with
many studies investigating dietary habits (386). Some participants expressed the
view that a major barrier that prevented them from purchasing functional food
products was the fact that they had little time during shopping to decipher the
positive and negative attributes of various products and to determine the
appropriate place for them within their own diet. Of all the discussion areas, cost of
products generated the most discussion as well as consistent attitudes. Most
participants believed that foods promoted as having health benefits cost more. This
cost was not always seen as worth the investment, particularly if the health claims
were not believed or ambiguous.
As an adjunct to the TPB model utilised in this analysis, participants’ views about
which were the potential products that could best be used as carriers of n-3 fatty
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acids were also investigated. The responses were consistent, with participants
framing the importance of the wholesomeness of the products as an important
factor. Also, participants felt that is was better for everyday products such as milk,
bread, margarine and yoghurt to be the carriers of this functional ingredient,
although participants also expressed the belief that snack and occasional foods
would also be appropriate carriers of functional food ingredients. Further probing
revealed that although this may be logical (people don’t eat enough n-3 fat but
people drink diet coke, therefore the addition of n-3 fatty acids in diet coke is
logical), overall participants were suspicious of this strategy and viewed it as a
gimmick, rather than a legitimate health proposition. Participants believed that the
overall health proposition of the functional foods should be consistent with other
health messages, i.e. low fat, low salt, low sugar.
6.3.4 General beliefs about functional foods
There was no evidence of negative salient beliefs related to healthiness of
functional foods, which was surprising. Compared to conventional foods, functional
foods are often processed with a relatively high degree of technological
manipulation, which has parallels with the manufacturing of genetically modified
(GM) foods. Attitudinal studies into consumer views of GM foods have indicated
that this is a factor attributable to the general resistance to use of these products
(387). Furthermore interactions between enrichments and product types of
functional foods were found to be important determinants of consumers’
perceptions of the healthiness in a cross-national study of Danish, Finnish and
American consumers (288). The authors of that study described prevailing cultural
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values of ‘mastery’ or ‘harmony’ that help to explain these attitudes (288). People
or cultural values that can be described as high in mastery emphasise active
mastery of the social and natural environment through self-assertion. These people
tend to view functional foods positively (288). On the other hand, ‘harmony’ refers
to values that co-exist with nature and deference of the technological manipulation
of natural resources, therefore would most likely oppose the use of functional
foods. It is possible that participants in our study were not aware of the level of
technical manipulation involved in the development of these products – as there
was national media coverage from the market release of several n-3 enriched
products in Australia preceding the interviews which may have attributed to an
understanding and acceptance of the concept– or that Australians in general (or at
least those that self selected for focus group interviews) have a value system that
can be described as high in ‘mastery’.
In the past food purchasing behaviour has formed the focus of many promotion
and health education campaigns with the aim of improving food and nutrient
intakes (388). With the emergence of functional foods there is a need to develop
education campaigns and design behaviour change models to ensure that those
segments of the population who can benefit the most from these novel products
actually use them (389). To this end understanding consumer beliefs and attitudes
toward functional foods is critical to both commercial success and achieving
positive health outcomes from the introduction of enriched functional foods.
However, more targeted research is required, as these results alone provide
limited value in guiding education and marketing disciplines alike. In this study we
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uncovered the salient beliefs in relation to n-3 enriched functional foods from a selfselect Australian sample and therefore caution is required in interpreting these
results. The nature of this focus group study was exploratory and these results
were next used to expand on the TPB theoretical model to help examine consumer
behaviour in relation to the use of n-3 enriched products. These salient beliefs
formed the basis for question development for a quantitative survey tool which was
used in the following study.
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CHAPTER 7

ATTITUDES AND INTENTIONS TOWARDS PURCHASING FUNTIONAL FOODS
PREDICT UPTAKE7

7.1

Introduction

Although understanding consumer beliefs and attitudes provides interesting
insights, it is the ability to predict purchasing behaviour that will ultimately assist in
the promotion of this primary prevention strategy. Functional food products are
distributed through traditional food markets and to be effective must first be
purchased, and then incorporated into an individual’s eating pattern. This presents
unique challenges to health educators when considering the ability and potential of
functional foods to deliver population health benefits. Efforts to increase intake
depend, in part, on understanding the factors determining selection and intake.
With this knowledge health promotion strategies can be targeted to maximise their
effectiveness.

7
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The reasons for consuming functional foods are likely to be multifactorial, with a
combination of social, psychological, knowledge based and economic factors.
Earlier market segmentation studies in the US described the average functional
food user to be female, well educated, with a higher income, aged between 35-55
years old and actively interested in health as a result of illness (390). More
recently, Bech-Larsen and Grunert (2003) examined attitudes relating to perceived
healthiness of functional foods across different cultures (288). They found that
different processing methods, the use of different health claims, types of
enrichments and types of products were determinants of consumers’ acceptance of
functional foods. Some studies have investigated demographic characteristics of
users and non-users, however, they note that characteristics are specific to the
functional food under study (391). Overall, research into factors that determine
choice of functional food is limited and no studies to date have investigated the
specific factors affecting the use of foods enriched with n-3 fatty acids.
One model that has been used to explain health related behavior in the past is the
Theory of Planned Behavior (TPB) (19). It has been applied to food-related
behaviors such as supplement use (23), genetically modified foods (387), dairy
product intake (326) and organic vegetable consumption (392). According to the
theory, behavior is directly predicated by intention to perform this behavior, as well
as control factors, when behavior is not under complete volitional control. Intention
in turn is determined by attitudes (A) toward the behavior, subjective norms (SN)
and perceived control over the behavior (PBC). Intention can be viewed as the
conscious plan to carry out a particular behavior and the motivation to perform it.
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Each of these determinants is formed from a set of referent beliefs. Attitudes are
determined by a behavioural belief about performing a particular behavior. This is
the combination of strength of the belief (BS) combined with the belief that
performing a particular behavior will result in the outcome (OE). Also, Subjective
Norm is determined by the social pressure and beliefs held by significant others, or
normative beliefs (NB), combined with the motivation of the individual to comply
with this pressure (MC). Perceived behavioural control is determined by the
likelihood of various factors outside of direct control to facilitate or inhibit a certain
behavior. Therefore, a person who has a positive attitude toward a behavior,
perceives social pressure to perform the behavior and believes that they have
control over their decision to perform the behavior is more likely to carry out that
behavior. The aim of this study was to identify the nature, strength and relative
importance of influences on intention to purchase foods that are enriched with n-3.
7.2

Methods

7.2.1 Questionnaire development
Survey questions were developed using results obtained from focus group
interviews, as recommended by Ajzen & Fishbein (1980) (19). The details of those
interviews are described in Chapter 6 (370). Each focus group was tape-recorded,
transcribed and content analysed using NVivo 2.0 (2002, QSR International Pty
LTD). Sub-categories were developed to capture emerging themes. These formed
the basis of the questions used in the questionnaire. A draft of the questionnaire
was pre-tested on 10 subjects who were representative of the study sample.
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Comments attained resulted in minor changes being made to the final
questionnaire (Appendix N). Example foods enriched with n-3 fatty acids were
included in the instructions on filling out the questionnaire.
Behaviour (B) - Use of foods enriched with n-3 was assessed 2 weeks after
implementation of the questionnaire. A question was asked: Did you eat any of the
following foods high in n-3 over the previous 2 weeks (canola margarine, enriched
bread, milk, enriched eggs, enriched bread etc)?
Intention (I) - The dependent variable was measured by a global question using a
seven point bipolar differential scale as suggested by Ajzen and Fishbein (1980)
(19). Respondents could choose extremely unlikely, quite unlikely, slightly unlikely,
neither, slightly likely, quite likely or extremely likely (+3 to -3) to the statement: I
intend to eat one or more foods with added omega-3 oils over the next two weeks.
Attitude (A) - The independent variable, attitude, was also directly measured by a
global question using a seven point bipolar differential scale. Respondents could
choose favourable to unfavourable (+3 to -3) responses to the statement: Overall,
my attitude toward my eating foods with added omega-3 oils over the next two
weeks is.
Belief strength (BS) - Eleven independent variable statements were used to assess
belief strength towards purchasing foods enriched with n-3 fatty acids: provide
long-term health benefits, importance of obtaining the health benefits, may be at
risk of inadequate intake of nutrient, may be at risk of over exposure of this
nutrient, importance of scientific proof, developing new ways to make it easier to
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choose a diet high in n-3, provide heart health benefits, provide brain health
benefits, provide eye health benefits, improve arthritis and improve asthma. Each
statement was anchored on a bipolar differential 7-point scale ranging from
extremely important to extremely not important.
Outcome evaluation (OE) - The TPB assumes that having a positive attitude
towards a behavior is based on believing that the behavior will be likely to lead to
positively evaluated outcomes, or will be unlikely to lead to negatively evaluated
outcomes. Therefore for each of the BS there was an equivalent outcome
evaluation statement. Each statement was anchored on a bipolar differential 7point scale ranging from extremely likely to extremely unlikely.
Beliefs relating to n-3 functional foods were transformed into consequences of
purchasing by multiplying the belief strength by the outcome evaluation (BS X OE)
and a mean computed (possible range +9 to –9) and reflect an overall behavioural
belief scale.
Subjective Norm (SN) - The TPB assumes that normative factors are based on
perceptions of whether specific significant others believe you should perform the
behavior or not (Normative Belief), and the motivation to comply with the wishes of
these significant others. Therefore beliefs relating to n-3 functional foods were
transformed into consequences of purchasing by multiplying the normative belief
by the motivation to comply and a mean was computed (possible range +9 to –9).
This reflects an overall subjective norm scale (SN). The independent variable,
subjective norm, was also measured by a global question using a seven point
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bipolar differential scale. Respondents could choose extremely likely to extremely
unlikely (+3 to -3) to the statement: most people who are important to me think I
should eat foods with added omega-3 fats.
Normative beliefs (NB) - Groups or individuals whose views might influence
functional food use were also explored. Seven normative beliefs (NB) were
assessed: family, friends, medical practitioners, nutritionists, scientists and food
industry. For example one statement is “most members of my family think that I
should eat foods with added omega-3 oils” (extremely likely – extremely unlikely).
Normative belief statements were scored from +3 to –3.
Motivation to comply (MC) - Motivation to comply with the beliefs of significant
others was also determined. For each of the NB there was a question relating to
the motivation to comply. For example one statement is “Generally speaking, I
want to do what my family thinks I should do.” Motivations to comply statements
were scored from +3 to –3. Each statement was anchored on a bipolar differential
7-point scale ranging from extremely likely to extremely unlikely.
Perceived Behavioural Control (PBC) – Factors which might facilitate or inhibit
functional food use, are termed control beliefs (CB). Included in our questionnaire
were availability at the supermarket, control over shopping, cost, taste, time, and
suitability for the family. In addition a global question of control was included: “how
much control do you have over whether you do or do not eat foods with added
omega-3 oils” (seven point scale: complete control - very little control). Unlike other
determinants of intention, CB does not correspond with measures of intention. The
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TPB assumes that the higher CB would be found in those intending to purchase
functional foods. In this case it was expected that a high CB would result in both
intention to purchase or not to purchase functional foods, whereas a lower CB
would result in no intention to purchase. For this reason CB was transformed into
a binomial scale. The transformation involved estimating whether motivation was
either positive or negative from the determinant variables, therefore placing PBC
as either (a) having control over purchasing or not purchasing, or (b) no control.
7.2.2 Sample
This study was conducted in the Illawarra region of New South Wales, Australia. At
the time of the study health claims on food products were prohibited, however a
regulatory system for health claims is currently being developed. Two sub-samples
were surveyed via questionnaire: general consumers who responded to media
advertisement and subjects with Type 2 diabetes participating in an intervention
trial. These sub-samples were selected as we wanted to investigate if there were
differences in intention and attitude between those with an existing disease (in this
case type 2 diabetes mellitus) and those without, as suggested by Childs (1997)
(390). General consumers were recruited from advertisements in the local media.
Potential participants phoned in their contact details to a study-specific answering
service and these calls were returned and a brief outline of the study was
explained. They were screened and excluded if they were undergoing treatment for
chronic illness. Those expressing interest were sent an information sheet and
consent form to sign and return. Once consent was obtained a questionnaire was
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sent via post. Questionnaires not returned after 2 weeks were followed up via
telephone communication.
Subjects were recruited from advertisements in the local media and on local
institutional email networks (University and Technical College). Potential
participants phoned in their contact details to a study specific answering service
and these calls were returned with a screening questionnaire. Inclusion criteria
were: aged 35-75yrs, diagnosed with type 2 diabetes mellitus for at least one year
and generally well. Exclusion criteria were: on insulin therapy (or with HbA1c >9%),
BMI > 35kg/m2, with major debilitating illness, food allergies or food habits
inhibiting their participation in the study, illiteracy and inadequate conversational
English. Subjects at the first clinic appointment of this 6-month trial completed the
questionnaire. Approval for the conduct of the study was provided by the University
of Wollongong / Illawarra Area Health Service Human Research Ethics Committee
(Appendix O).
Using the database of eligible consumers responding to the local media
advertisement, 134 questionnaires were sent out. After 3 weeks (including a
reminder call after 2 weeks) 79 were returned representing a response rate of
61%. Fifty-five adults with type-2 diabetes who had volunteered separately for
participation in a dietary intervention trial were asked to fill out the questionnaire
and five declined to participate. The final sample size of the two sub-samples was
129.
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7.2.3 Data Analysis
Internal consistency reliability of the scales used to measure the variables was
determined by calculating the Chronbach’s alpha and questions with an alpha <
0.3 were deleted. All variables that constituted attitude were included in the
analysis, and the alpha value was 0.89. The questions relating to the influence of
friends and food companies were deleted as they showed a low level of internal
reliability (0.222 and 0.204 respectively). Chronbach’s alpha for SN in the final
analysis was 0.77. Control over food choice also showed a low level of internal
reliability and once deleted the Chronbach’s alpha value for PBC increased from
0.71 to 0.74.
There were no significant differences between the two sub-samples in both
demographic parameters and measured variables (apart from the proportion
reporting a chronic illness); therefore the results were combined for analysis.
Respondents were dichotomised into intenders (47.7%) and non-intenders (52.3%)
(Positive scores were classified as intenders; neutral and negative scores were
classified as non-intenders). Independent t-tests where used to compare mean
scores of TPB components and other continuous variables. Non-parametric data
were compared using Mann Whitney U-tests. Correlations between the variables
were measured using both Pearson’s and Spearman’s correlation coefficients. The
influence of the TPB components of use of n-3 enriched functional foods was
investigated by multiple logistic regressions. The determinants of intention as per
TPB were investigated using multiple linear regressions. According to the TPB,
Attitude, Subjective Norm and Perceived Behavioural Control are direct
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determinants of intention. The first step involved entering global measures of
attitude, subjective norm and perceived behavioural control into the model. The
second step involved the addition of the attitudinal beliefs, normative beliefs and
control beliefs. This allows us to determine if beliefs are mediated through attitude.
Additional demographic variables (age, income and education) were added to the
model to investigate any associations. Estimates were computed at the overall
means for the data set. All analyses were carried out using SPSS for Windows
version 7.0 (SPSS Inc.)
7.3

Results

The mean (± s.d.) age of the participant sample was 53 (± 12.8) years (range 17 –
80 years) and the mean body mass index (BMI) 28.6 (± 6.6) kg/m2. Two thirds of
the participants were female (66.7%) and the majority of subjects were currently in
a relationship with no children under the age of 18 living at home (75.2%). Ninety
four percent of participants were the main shopper in the household, or shared the
shopping in the household. Income range was relatively evenly distributed between
the five income brackets – 22.6% earned < $20K per year, 19% earned between
$20K-$40K per year, 13.9% earned between $41K-$60K per year, 16.1% earned
between $61K-$80K per year and 12.4% earned between $81K-$100K per year.
The smallest number (7.3%) earned greater than $101K per year. The highest
level of education of participants was 0.8% finished primary school, 31% finished
high school, 24.8% finished technical college and 38.8% graduated from
University.
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Spearman’s or Pearson’s correlation between the various TPB components and
those above 0.3 are reported. Attitude (r = 0.56; P = 0.01) and Subjective Norm (r
= 0.41; P = 0.01) were correlated to Intention. In turn, each set of beliefs was
correlated with the corresponding global measure. For example BB X OE
correlated strongly with attitude (r = 0.75; P = 0.01) and NB X MC correlated
strongly with Subjective Norm (r = 0.48; P = 0.01). Perceived behavioural control
beliefs did not correlate with any of the variables under investigation.
There were no differences between the two sub-samples in intention to use
functional foods or any of the determinant variables. Table 7-1 summarises the
differences between intenders and non-intenders of n-3 enriched functional foods.
Perceived behavioural control and control beliefs were not different between
intenders and non-intenders. Those who intended to use these products had a
more positive attitude toward them and perceived normative pressure to use them.
Similarly scores on belief items also showed the same trend. There were no
difference in age, income or education between the intenders and non-intenders.
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Table 7-1 Comparison of variable rating scores between those intending or not intending to
use n-3 enriched products in the following two weeks [mean ± s.d.]

Intenders
(n = 61 [47.7%])

Non Intenders
(n= 67 [52.3%])

Significance
(P- value)

Attitudeb

2.2 (0.6)

-0.5 (1.5)

0.00

Behavioural beliefs (BS x OE) c

4.2 (1.9)

1.6 (2.5)

0.00

Subjective Norm b

0.8 (1.4)

-0.2 (1.5)

0.00

Normative beliefs (NB x MC) c

1.9 (2.0)

0.7 (1.6)

0.00

Perceived behavioural control b

2.2 (1.1)

1.9 (1.4)

0.13

Control Beliefs (CB)b

0.5 (1.1)

0.4 (1.2)

0.95

a

a

Student’s t- test between intenders and non-intenders.

b

Scores are from +3 to –3

c

Scores are from +9 to –9

The results (Table 7-2) showed that the first step intentions were a significant
predictor of n-3 enriched food use, with overall 78.5% of subjects correctly
classified as users or non-users based on intentions and PBC. Twenty-nine
percent of the variation in behaviour was explained by the regression (R2 = 0.298;
P < 0.001). The odds of using n-3 functional foods increased 0.75 fold for every
increase of one unit in intention score. PBC was not a significant predictor of use.
At the second step, the addition of attitude and SN the predictive power slightly
decreased and none of the variables were significant. Thus as predicted by the
TPB, the effects of attitude and subjective norm on behaviour were mediated by
intention. At the third step, the predictive power of the model decreased to 75.3%
with none of the variables being significant. Thus as predicted by TPB, the belief
components have no unmediated effects on behaviour.
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Table 7-2 Logistic regression of behaviour onto TPB componentsa,b

Variablec

Odds ratio

95% CI

Significance

Intention

0.75

0.14

P = 0.04

Perceived behavioural control (PBC)

1.03

0.26

P = 0.92

Intention

0.65

0.32

P = 0.65

Perceived behavioural control (PBC)

1.03

0.26

P = 1.03

Attitude

1.33

0.39

P = 1.33

Subjective Norm

0.84

0.26

P = 0.84

Intention

0.51

0.38

P = 0.78

Attitude

1.03

0.28

P = 0.93

Subjective Norm

1.66

0.44

P = 0.25

Perceived behavioural control (PBC)

0.77

0.29

P = 0.36

Behavioural beliefs (BS X OE)

0.99

0.18

P = 0.97

Normative beliefs (NB X OE)

0.60

0.31

P = 0.09

Control beliefs (CB)

1.25

0.21

P = 0.28

Step 1

Step 2

Step 3

a

Non significant variables were retained in the model to determine the effect of the additional

variables when existing TPB variables were taken into account; b R2 = 0.298 (P < 0.001);c Percent
correctly classified: step 1 78.5%; step 2 = 77.9%; step 3 = 75.3%;

A further question is the extent to which intentions are predictable. By entering the
direct predictors of intention (attitude, subjective norm, PBC) at the first step and all
the other beliefs at the second we are able to test whether the effects of belief
components are mediated by other TPB variables. At step 1 in the development of
the linear regression model of intention, attitude was significantly positively
associated with intention, whereas SN and PBC was not significant (Table 7-3).
Thus stronger intentions to use n-3 enriched foods were associated with having
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positive attitudes toward the use of these foods. Overall the equation accounted for
72.4% of the variance of intentions (P < 0.001). Assumptions of multiple
regressions were validated using residual plots. At step 2, the belief variables
explained a marginal amount of variation in intentions 72.5% (P <0.001). Thus as
predicted by TBP, the effect of belief components have no unmediated effects.
Therefore, the next phase was to examine how beliefs about the consequences of
using n-3 enriched foods were associated with intention to use.
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Table 7-3 Linear regression of intentions onto TPB componentsa

Variable

B

Beta

SE

Significance

Attitude

1.01

0.85

0.07

P < 0.001

Subjective Norm

0.02

0.01

0.07

P = 0.82

Perceived behavioural control (PBC)

0.02

0.01

0.08

P = 0.87

Attitude

0.97

0.81

0.07

P < 0.001

Subjective Norm

-0.05

-0.04

0.09

P = 0.57

Perceived behavioural control (PBC)

-0.01

-0.01

0.09

P = 0.88

Behavioural beliefs (BS X OE)

0.06

0.07

0.06

P = 0.32

Normative beliefs (NB X OE)

0.08

0.07

0.06

P = 0.22

Control beliefs (CB)

0.00

0.00

0.09

P = 1.00

Step 1

Step 2

a

B = regression coefficient; SE = standard error; R2 = 0.724 (P < 0.001) for Step 1, R2 = 0.725 (P <

0.001) for Step 2.

Based on the dichotomised categorisation of self-reported intention to use,
differences in responses to each belief question between intenders and nonintenders were examined using independent t-tests (Table 7-4).
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Table 7-4 Mean scores for belief items: comparison of intenders and non intenders [mean ± s.d.] (n = 126)
Variable

Intenders

Non-intenders
a

Intenders

Non-intenders

Outcome evaluation(OE)

BS X OE

2.85 (0.40)
†††
2.48 (0.57)
†††
2.41 (0.70)
1.32 (1.81)
2.82 (0.50)

2.74 (0.82)
1.43 (1.33)
1.28(1.46)
1.16 (1.69)
2.52 (1.19)

2.1 0(0.65)
†††
2.15 (0.64)
††
1.7 (0.10)
0.98 (1.72)
††
1.80 (1.14)

†††

0.92 (1.32)
0.92 (1.41)
0.48 (1.45)
0.42 (1.60)
1.05 (1.44)

6.08 (2.15)
†††
5.49 (2.40)
†††
4.42 (2.99)
1.21 (4.45)
†††
5.14 (3.37)

†††

1.51 (1.20)
2.76 (0.46)
2.69 (0.55)
2.68 (0.58)
2.68 (0.53)
2.69 (0.50)

1.69 (1.09)
†††
1.97 (0.62)
††
1.32(1.32)
0.98 (1.32)
††
1.39 (1.10)
††
0.91 (1.26)

†††

0.45 (1.6)
0.86 (1.40)
0.63 (1.39)
0.55 (1.36)
0.63 (1.39)
0.23 (1.40)

4.34 (3.03)
†††
5.64 (2.02)
††
3.73 (3.95)
2.81 (3.77)
††
3.98 (3.09)
††
2.67 (3.58)

2.43 (0.62)
2.85 (0.36)
2.82 (0.39)
2.79 (0.45)
2.74 (0/48)
2.83 (0.38)

a

Normative beliefs(NB)

Family
Friends
Dietitians
Doctors
Scientists
Food companies

Non-Intenders
a

Belief strength (BS)

Importance of general health
Importance of health benefits n-3
Contain enough n-3 to be useful
Little risk of over exposure
Food development based on
science
New ways to make n-3 intake easy
Improving heart health
Brain health
Eye health
Improving Arthritis
Asthma

Intenders

†††

0.75 (1.41)
†††
0.53 (1.39)
†
1.47 (1.24)
†
1.26 (1.36)
††
1.43 (1.33)
1.14 (1.60)

-0.56 (1.60)
-0.52 (1.51)
0.92 (1.52)
0.69 (1.44)
0.78 (1.39)
1.20 (1.40)

Motivation to comply(MC)

0.56 (1.76)
-0.03 (1.68)
†††
1.80 (0.93)
†
1.80 (1.01)
††
1.30 (1.13)
-0.72 (1.64)

0.18 (1.70)
-0.38 (1.52)
0.98 (1.57)
1.34 (1.36)
0.63 (1.41)
-1.09 (1.63)

a

b

†††

2.48 (3.9)
2.05(3.19)
1.35 (2.94)
-0.09 (3.58)
2.43 (4.41)

†††

1.59 (3.12)
1.97 (4.10)
1.78 (4.01)
1.54 (3.90)
1.86 (3.88)
0.85 (3.67)

b

NB X MC

†

1.88 (2.89)
1.05 (2.92)
†
3.14 (3.05)
††
3.12(2.91)
††
2.43 (2.91)
-0.47 (4.10)

0.51 (3.20)
0.97 (3.01)
1.83 (2.90)
1.33 (2.90)
0.88 (2.50)
-1.42 (3.92)

a

Control beliefs(CB)

Availability at the supermarket
Control over purchase
Cost
Taste/texture
Time required to find
Suitability for family
†

†

-0.25 (1.77)
††
1.16 (2.25)
0.28 (1.93)
0.49 (1.76)
0.64 (1.85)
0.38 (1.88)

0.19 (1.5)
1.51 (1.68)
0.06 (1.87)
0.52 (1.66)
0.22 (1.73)
0.04 (1.91)

P < 0.05; †† P < 0.01; ††† P < 0.001 equal variances not assumed; a Items scored between +3 to -3; b Items scored between +9 to –9
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7.3.1 Behavioural beliefs
Intenders differed from non-intenders in 3 behavioural beliefs; “importance of the
health benefits of omega-3 fats”, “that foods enriched with omega-3 contain
enough of this nutrient to be of benefit” and “how important is it that we make new
ways to make omega-3 intake easy”. When considering how each group evaluated
these outcomes on n-3 enriched food intake, intenders differed significantly in 9 of
the 11 beliefs. With the multiplicative measure of belief strength and outcome
evaluation (BS X OE) there was a significant difference between intenders and
non-intenders for the 9 beliefs. These results suggest that intenders are more likely
to believe that eating n-3 enriched products specifically will provide a variety of
health benefits despite the fact there was little difference between how intenders
and non-intenders rated the overall importance of these effects.
7.3.2 Normative beliefs
Normative beliefs differed between intenders and non-intenders for 5 of the 6
variables. Differences were observed for family members, friends, dietitians,
doctors and scientists with more positive ratings for intenders. This was consistent
when considering motivations to comply as well as the multiplicative value of NB X
MC, with all variables except for family members (MC) differing. There were no
differences between the groups in the normative belief relating to food companies,
with both groups responding negatively when rating motivation to comply with their
recommendations.
7.3.3 Control beliefs
Only 2 out of the 6 control beliefs differed significantly between intenders and nonintenders: availability in the supermarket and control over purchasing. Interestingly,
intenders did not perceive availability as being a barrier to purchase (indicated by
the negative response), whereas non-intenders believed that this was a barrier.
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Non-intenders were more likely to believe that a lack of control over purchasing
was a significant reason for not purchasing these products.
7.4

Discussion

Using a questionnaire based on the TPB, the model explained 72.5% of the
variance of intention to use n-3 enriched foods. This result is comparable with other
studies investigating intentions to use genetically modified foods and supplements,
using the TPB, which have reported R2 = 0.35 and 0.75 respectively (23, 387).
These results, in light of this earlier work, highlight the importance of studying
specific food products, processing techniques and health effects in order to
understand the complex nature of food selection. For example, whilst these results
are valid in understanding consumer behavior in selecting n-3 enriched foods, they
do not translate to an understanding of the use of fish oil supplements, nor n-3
enriched products enriched using GM technology.
These findings into the determinants of intention extend on previous work using the
TPB. In relation to n-3 enriched foods, attitude was found to be the sole
determinant of intention to eat these products and was the sole significant
predictor. It was found that both normative beliefs and control were not significant
determinants of intention to eat these products in this study. It is apparent from the
literature that the relative importance of these factors is variable and is dependent
on the behavior, demographic and particular food under investigation. For
example, dairy product use by the elderly is predicted by both attitudes and control
beliefs, whereas the use of genetically modified foods is predicted by attitude,
control beliefs as well as subjective norms (326, 387). This adds weight to the
importance of investigating single action, specific behaviors as suggested by Azjen
and Fishbein (19).
It appears that selection of n-3 enriched foods remains largely a personal choice.
Although marketers, health professionals and family members may suggest the
use of these novel products, ultimately use is an individual decision having minimal

172
influence from normative factors. Similarly as perceived behavioural control was
not predictive of intention to eat n-3 functional foods in our sample; it can be
speculated that selection of these products is under volitional control, although
control factors may act directly on behavior. In summary, the selection of n-3
functional foods appears to be a cognitive process based on underlying beliefs,
leading to overall attitudes which in turn have a significant impact on food choice.
The incorporation of functional foods into the diet has the potential to improve
individual and population health (393). A survey of American dietitians found that
over three quarters had recommended the use of functional foods in the last year
(394). Results from this study can be used in a practical sense with the upstream
determinants of attitude providing nutrition educators with cognitive targets that can
be used to improve the specificity and assist in the development of nutrition
education programs. Intenders had a greater belief in the importance of n-3 fats
and their associated health benefit and a belief that it is important to provide these
novel foods on the market, but insisted it was important that they contain enough of
the active ingredient to be useful. Most significant was the belief that eating foods
enriched with n-3 fats specifically would lead to a number of health benefits.
Subjects believed in a wide range of health benefits attributed to n-3 enriched
foods despite varying degrees of empirical scientific evidence to support these
claims. However, both intenders and non-intenders alike rated the importance of
these health parameters similarly. This would suggest that changing individual
beliefs about the importance in health issues alone will not translate into the use of
these foods. Efforts to influence consumers may best be channeled into
demonstrating and communicating a cause and effect relationship between a
specific product and a health parameter or benefit. Therefore, the role of health
claims might be important in promoting these foods. However, more research is
required to determine the effectiveness of this approach in increasing the use of
omega-n-3 functional foods.
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There are a number of limitations to this study. Despite the lack of differences
between our two sub-samples, the combined sample was not representative of the
general population and was both time and context specific. In addition, these study
participants were more likely to be interested in nutrition than the general
population. Intention to use n-3 functional food was high (54%) and may have been
a result of the recent product launches which coincided with the study. Also, this
study provides a static view of attitudes towards n-3 enriched foods and follow-up
over time, as more of these foods enter the market, would be useful. Another
limitation was that the questionnaire did not account for more general beliefs to do
with healthfulness, naturalness and altruism, which previous studies have been
shown to be significant determinants of GM food selection (387). However, these
issues did not emerge as salient beliefs from earlier focus group work (370). This
implies a more general limitation to the TPB.
In summary, to be initially effective in maintaining and encouraging positive
intentions and behaviour, a likely strategy for promoters of n-3 enriched functional
foods would be to direct their promotions towards changing attitude, and
specifically belief in the effectiveness of enriched products in achieving specific
health benefits. Independently, environmental factors are also important in
determining the attitudes of consumers towards n-3 functional foods. For example,
consumer beliefs can be affected by the way n-3 functional foods are portrayed in
the media, which in turn is a product of the level of stakeholder agreement or
disagreement. The final study of this thesis investigated the stakeholder beliefs and
attitudes that may impact on the consumer environment.
7.5
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CHAPTER 8

STAKEHOLDER BELIEFS AND ATTITUDES DISPLAY MIXED IDEOLOGIES
THAT MAY HAVE AN IMPACT ON THE CONSUMER ENVIRONMENT8
8.1

Introduction

To ensure the success of functional foods in the market place, an active
collaboration of all stakeholders in the promotion of these novel foods is required to
ensure a positive consumer attitude (395). McConnon et al (2002) have argued
that a dissonance in ideology, beliefs, views and motivations between stakeholders
could lead to a consumer lack of confidence in this concept, and ultimately
undermine the potential for both commercial success and public health gain (25).
To increase a favourable public perception they propose that the future of
functional foods is dependent upon communication and trust between the
stakeholders and warn how misperception can threaten their potential (25). The
real challenge is to create an environment for the development and promotion of
functional foods through collaboration between the various stakeholders (294).
The area of functional foods has attracted interest from a wide range of
stakeholders, including government personnel, consumers, and members of the
food industry, scientists and health professionals. The rising popularity of functional
foods has resulted from the concomitant advances in food technology, nutrition
science and consumer awareness in health and wellbeing (396, 397). The

8
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landscape of the food supply is changing at an unprecedented rate, with the
emergence of novel functional foods in most food categories thus creating many
business opportunities for the food industry (383, 398). Equally as exciting is the
advanced emphasis on preventing chronic illness and disease as well as
promoting better health and wellbeing through an improved food supply (399).
Because the topic of functional foods is relatively new, there remains confusion
amongst stakeholders surrounding this concept (395). Areas of confusion and
debate include the lack of a clear definition and categorisation of functional foods,
the lack of inclusion of functional foods in established nutrition education models as
well as concerns relating to consumer perceptions and acceptability (25), social
and cultural differences (288) and regulatory concerns about health claims (25,
400). This confusion amongst stakeholders has the potential to erode consumer
confidence and dissipate the potential benefits if not managed effectively (27).
There is evidence to suggest that with appropriate legislation, good scientific
support and effective marketing, it is quite possible that any general consumer
skepticism can be overcome (401). Many countries either have health claim
legislation in place or are currently in the process of review (402). In addition,
attempts are being made at an international level by the Codex Alimentarius
Commission to establish guidelines for health claims about foods (403). However,
there is continuing disagreement in these policy developments which is often
fuelled by the interests of a range of stakeholders who seek to exert control over
the marketing and product landscape of the food supply (26).
Stakeholders can be conceptualised as networks of human beings, actors or
agents with diverse interests and somewhat bound by their role (404, 405). This
metaphor highlights the problematic notion of rational decision-making as the sole
basis for matters such as functional food evaluation, strategic direction and policy
development. For consumer interests to be placed at the centre of policy direction
it is essential that stakeholders come to an agreement free from restraint due to
their roles. It has been suggested that this emancipation can be achieved by
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recognising and challenging ideology (405). In this sense ideology can be defined
as ideas that are so commonplace and familiar that they are taken for granted as
objective fact or truth (406). Ideology becomes a coherent and widely accepted set
of ideas that permeate a group and has a role in shaping political activity, often in
an unconscious way (407). By surfacing and challenging underlying assumptions
and making ideologies explicit, emancipation may be possible (405). The aim of
this qualitative investigation was to explore the beliefs and attitudes and ideologies
of different stakeholders toward the development and communication of functional
foods and attempt to categorise underlying ideological positions.
8.2

Method

8.2.1 Participants
Semi-structured interviews were undertaken by using purposive sampling. Twenty
potential participants were identified from a database of contacts to the recently
created National Centre of Excellence in Functional Foods (NCEFF) (408). This
centre was funded by the Australian government to provide leadership for
functional foods in Australia, with an emphasis on integrating science and business
interests. Twenty individuals representing general practitioners (GPs), nutritionists,
industry, media, regulatory bodies and authoritative health organisations from
various States were contacted initially via e-mail and an expression of interest to
participate was requested. Quotas were set for each category, priority lists
compiled (Table 8-1) and each individual contacted via e-mail. For those
interested, an information sheet and a consent form were mailed to each potential
participant, and interviews were conducted at a mutually convenient time.
Forecasted quotas were not reached for the GPs and journalists. The interviewees
included two nutrition researchers, two food industry marketers, two public health
nutritionists, one general practitioner, two clinical dietitians, two nutrition
consultants, one prominent spokesperson, one journalist, one research consortium
executive, two food policy experts, one food legislation enforcer and one food
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industry lobbyist. The proportions of females and males were 50% each and all
States and Territories (except Northern Territory) were represented.
Table 8-1 Profile of interviewees

Stakeholder group

Quota

State/territory

Gender

General practitioners

2

South Australia, Queensland

Male, Female

Nutrition Researchers

2

Western Australia, Victoria

2 Males

Food Industry
Marketers

2

Western Australia, New South Wales

Male, Female

Public Health
Nutritionist

2

Queensland, Victoria

2 Males

Clinical Dietitian

2

New South Wales, Victoria

2 Females

Industry consultants

2

New South Wales

Male, Female

Prominent
spokesperson

1

New South Wales

Female

Journalist

2

Queensland, New South Wales

2 Female

Research Director

1

New South Wales

Female

Policy expert

2

Victoria, New South Wales

Male, Female

Industry lobbyist

1

Australian Capital Territory

Male

Regulatory enforcer

1

New South Wales

Male

Total

20

10 Males; 10 Females

Details of the participants and organisations have been suppressed in order to
maintain confidentiality in view of the sensitive issues involved. Approval for the
conduct of the study was provided by the University of Wollongong / Illawarra Area
Health Service Human Research Ethics Committee (Appendix P).
8.2.2 Study context
In qualitative research, transparency of the study context is an important aspect of
validity (409). The study context comprised the current regulatory framework, the
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positions of the authors and those of the stakeholders interviewed. The authors did
not receive financial gain from the study. One of the authors (CP) was in receipt of
an Australian Research Council scholarship through a linkage grant co-funded by
Goodman Fielder Ltd, Sydney, Australia with the scholarship provided by
government funds. In addition the Smart Foods Centre is part of a consortium that
forms the National Centre of Excellence in Functional Foods that has received
Federal Government funding. LT is the Director of this Centre and PW is the
Regulatory Affairs Cluster coordinator within this organisation. All three authors
hold Accredited Practicing Dietitian status. In December 2003, the Australian and
New Zealand Food Regulation Ministerial Council agreed to a policy guideline on
nutrition, health and related claims. The policy guideline provided the policy
principles to underpin the regulation of nutrition, health and related claims which
included the regulatory system. At the time this study was conducted, the initial
assessment report on a proposal for Nutrition, Health and Related Claims
(Proposal P293) was drafted by Food Standards Australia New Zealand (FSANZ)
and released for public comment (410).
To enhance the quality and credibility of qualitative analyses there is a particular
need to highlight the professional and social pressures on the author which may
have an effect on the reporting of these results (409). Further, as this study
interprets attitudes and beliefs from the perspective of ideology, it is important to
state the author’s own political ideology. To date our research is based on the
belief that a functional-food led intervention is effective in ameliorating many lifestyle diseases. Our own liberal view transcends a purely scientific view that tends
towards promoting functional food within the food supply, but does not preclude
objectivity at the expense of ideology.
8.2.3 Semi-structured interview procedure
The interviews were conducted during the months of April to June 2004. Interviews
were pre-arranged and carried out over the telephone (except for two face to face
interviews given the proximity with the interviewer’s location). Interviews were
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audio taped and later transcribed to allow systematic analysis of the discussion. An
interview guide was developed following the general guidelines provided by
Krueger (329). Using the theoretical framework proposed by McConnon et al
(2002) (25), as well as reviewing the literature pertinent to this area (26, 27), ten
open-ended questions were devised to determine stakeholder awareness, beliefs
and attitudinal issues regarding the development and promotion of functional foods
(Figure 8-1). After a definition of functional foods was provided, interviewees were
asked for their views on the processing and production of functional foods, the
ability of functional foods to improve health, evidence supporting functional foods
and resultant claims, the regulatory environment, intellectual property and
propriety, and finally, the perceived roles of stakeholders. During the interview,
participants were encouraged to speak until no more views were expressed, and
then the moderator probed and clarified points. In short, probes were primarily
used to encourage participants to clarify meanings or explain points of
incongruence in their answers.

180

General impression about these foods
1. Given the definition of functional foods we have provided;
We have seen the emergence of a number of foods with added health benefits such as foods
enriched with plant sterols and foods enriched with fish oils…what do you think about these?
[Probe: Is this something that we should be doing to our food supply?]
Processing/Production
2. What do you see as the important factors when considering the development and promotion of
functional foods in the food supply?
[Probe: Environmental concerns, production/processing technologies etc[
Ability to achieve health benefits
3. Do you believe that functional foods have the potential to improve health or promote health?
4. Do you see any alternative to the promotion of functional foods in the food supply in improving
public health?
[Probe: Do you see this as a realistic approach? What do you consider as being the ideal balance
between functional foods and the alternative approach?[
Determining evidence
5. What do you see as the type of scientific evidence that would be required to substantiate claims
for functional foods?
[Probe: Consider draft discussion paper on levels of evidence.]
6. Do you believe that consensus can be reached about the scientific evidence about the effect of
a food?
Regulatory environment
7. Do you believe that consensus can be reached about the scientific evidence about the process
of approval or regulation regarding functional foods and claims?
8. Which body should ultimately be the authority for substantiating, authorisation of claim wording?
[Probe: Should this be a national body, ‘competent’ body or self-regulation? [
9. Who do you see as being responsible for post-launch surveillance of these novel products?
Intellectual property
10. Should evidence for a health claim be available to the public? How could the intellectual
property of the claimant be protected? Do you think that this is an important issue?
Perceived role of stakeholder
11. What do you see as your role in the area of functional foods and claims about these foods?

Figure 8-1 Moderator question guide for stakeholder interviews
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8.2.4 Data Analysis
Each interview was tape-recorded and transcribed, producing on average 6 pages
of transcript. A computer software package for qualitative research analysis, NVivo
2.0 (2002, QSR International Pty Ltd), was used for data management and coding
(334). Content analysis was carried out by CP and sub-categories were developed
to capture the emerging themes. An iterative process of subcategorisation was
conducted as suggested by Knodel (376). After the preliminary analysis, other
members of the research team (LT and PW) assessed the content of each
category and sub-category. Because the purpose of this study was exploratory,
with an aim to elicit salient beliefs about functional foods, data were presented as
examples from the interview discourse that illustrated the interpretive frames that
emerged, and the corresponding themes (377). The analysis attempted to
represent the full spectrum of beliefs within the study sample.
8.3

Results/Discussion

From the initial sampling frame (n = 20), 16 key stakeholders agreed to participate
(representing a participation rate of 80%). None of the initially targeted GP’s or
journalist’s agreed to participate. A further five people were approached from each
of these two groups with only one from each group agreeing to participate,
resulting in a final number of 18 interviews.
As a way of introduction into the interview participants were asked about their
overall impression of functional foods. As would be expected diverse views were
expressed ranging from positive and supportive of functional foods to negative in a
number of areas (Table 8-2)

182
Table 8-2 Views expressed on functional foods

Supportive views

Non-supportive views

•

Functional foods have a role where
there is strong evidence

•

Functional foods are problematic due to
conflicting industry and health goals

•

Functional foods are a necessary and
logical development of the food supply

•

Functional foods may be seen as a
magic bullet approach to a very complex
public health issue

•

Functional foods provide innovative
solutions to deliver health benefits to the
community

•

There is ambiguity over the definition of
functional foods

•

Functional foods provide the potential to
increase the healthy choices of the
population

•

The success of functional foods will
ultimately be determined by consumer
acceptance

•

There is potential for functional foods
only to be available to those who can
afford them

The notion that functional foods are at odds with public health goals is one that has
been expressed in the literature. Some believe that functional foods will undermine
the most important determinants of public health by making them out of reach of
those that need it most (389, 411) because of issues such as price (412), and
access (412). Like the assumption that functional foods will contribute to public
health gains, neither is substantiated by strong evidence. Both of these positions
need to be tested, monitored and reviewed.
A range of views were expressed on matters concerning processing and
production, achievement of health benefits, determining evidence, regulatory
issues and intellectual property (Table 8-3 to 8-7). With respect to processing and
production, concerns about the use of GM technology, shelf stability, safety and
environmentally sound practices (Table 8-3) have been found by others in relation
to personal predictors of consumers’ food and health concerns and are generally
well described factors (413). However, the notions that these foods should be
produced with a justifiable health need in mind as well as the need for functional
ingredients to be bioavailable appear to be unique to functional foods. Whilst
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stakeholders expressed concerns regarding the scientific validity of functional food
claims, consumers are more concerned with honesty in food labelling and disease
concerns in general (413). In this way a scientific paradigm expressed by
stakeholders is expressed in a different way to consumer concerns. The link
between the two creates a challenging territory for those working in the field of
functional foods.
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Table 8-3 Key issues identified by stakeholders relating to processing and production of
functional foods

Major sub-category

Exemplar Quote

Technological considerations (e.g. GM
technology)

It’s [GM technology] an area where you should look at
research and what can be done with it

Justifiable need

Well I would want to approach it [functional food
production] from a public health perspective

Shelf stability

They’ve got to be shelf stable

Safety

No dispute over safety, that has to be there

Bioavailability

My perspective is that if these products are informed
by clinical trials and they’ve got some powerful
evidence that they have an impact on, say biomarkers
in a certain population group, then you would expect
that when it’s produced it actually retains the qualities it
was tested for

Environmentally sound practices

…much more consideration of the whole food chain.
What might turn out to be the most important functional
food might be organically grown.

The ability of functional foods to deliver health benefits lies at the heart of their
production and promotion. Those who held the belief that these foods would have
a positive impact on public health also believed that this impact would only be in
certain individuals who also had a specific medical condition and would be
conditional upon there also being an education program about use of these foods
(Table 8-4). Others believed that the negative impacts outweighed the potential
public health gains. For example the risks of unintended overexposure, misleading
and confusing labelling and inappropriate advertising were all seen as having a
potentially negative effect on public health. Other stakeholders appeared less
concerned, indicating that energy balance is the current key issue for promoting
widespread public health, so unless functional foods could address this issue, their
effects would be insignificant. Some believed cost barriers and the inability to prove
the benefit would undermine the widespread use of these foods. A final view
expressed was that the effort (human and financial) invested in the research,
development, promotion and regulation of these novel foods would be better spent
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in alternative public health campaigns such as mass education, mandatory
fortification where there is a demonstrated benefit, promotion of minimally
processed foods and promoting more politically risky approaches such as taxing
‘unhealthy’ foods.
Despite the assertion that the production and promotion of functional foods has the
potential to promote public health benefits (266, 269), these data suggest large
dissention in particular stakeholder categories. These respondents believe that
functional foods are best targeted to those with specific health concerns rather than
mass markets, a point discussed in the position paper of the American Dietetic
Association (414) and an Australian review paper on dietetics and functional foods
(415). This issue is clearly debatable, making further research specifically
addressing effectiveness of a functional food led intervention of benefits desirable.
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Table 8-4 Stakeholder beliefs about a functional food-led intervention and the promotion of
public health benefits

Major sub-category

Minor sub-category

Exemplar Quote

Positive impact

In conjunction with education

‘[regarding plant sterol margarines] I
doubt that it will have an impact
unless a person at the same time
reduced the saturated fat in the diet,
knows what cholesterol is and gets
it monitored, measures their blood
pressure and tries to increase
exercise and lose weight’

For certain individuals with specific
medical concern

Neutral (insignificant
impact)

Negative impact

Energy balance is the real concern

‘I believe that in certain
circumstances some of them may
help individuals. I am not convinced
that they will have a wide spread
public health benefit’
‘The modern lifestyle diseases are
largely related to too much food and
not enough exercise. I am not sure
that any sort of functional food will
address that’

Those in need are least likely to use
due to cost barriers

‘ I suspect that the population
groups that are likely to use these
things are least likely to need them’

Unable to prove or disprove the
public health benefit

‘Whether they [functional foods]
have a protective effect for the
whole of the population and one
which is unproblematic, I think has
never really been tested’

Unintended exposure of added
functional ingredient

‘…I think plant sterols [products] is
a good one because we know that
there are a number of groups that
might not benefit from the
consumption of these foods’

Misleading and confusing labelling

‘…I’ve written a bit about food
labelling and there’s a lot of room to
interpret. For instance what ‘lite’
might mean’

Misleading marketing and
promotion

‘Well the negatives from my
perspective are it the information
that’s used to promote these foods
is misleading or inaccurate so that
consumers get the wrong message’

Promoted in inappropriate context

‘I think that on that issue that to me
is the way in which food is
developed as a drug for a specific
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group. And is then promoted
broadly to people that do not have a
particular problem’
Lost opportunity cost alternative Public
health strategies

Mass education (dietary guidelines
and fruit/veg messages)
Mandatory fortification where
benefit clear
Promotion of minimally processed
foods
Political approaches (such as taxing
of unhealthy foods)

‘I think it is a fantastic alternative to
treating people when they are
sick…I think it is under the umbrella
of wellness’
‘I mean if it is established that
calcium enrichment is important
than it should be in all milk’
‘My personal belief is that as the
first line of defense I would be
promoting natural foods first’
‘I’d be arguing for a more public
health model which is look at
dismantling the barriers to people
choosing healthy food’
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Because the most distinctive feature of functional foods is their claimed “health
benefit”, health claims are often used to distinguish between functional foods and
ordinary foodstuffs (27) and the establishment of a legal framework for the
management of claims is seen as imperative. Stakeholders identified a range of
regulatory issues and the organisations for dealing with them that should be
responsible (Table 8-5). The views on the latter ranged from a competent body to a
suitable government agency such as FSANZ or a body set up by government,
models described to varying degrees in other countries (333). There was less
variation in the opinions about an appropriate body to authorise wording of health
claims with most believing this should lie under the auspices of FSANZ. However,
there was a strong view from some that there should be involvement from
communications and marketing experts to help establish and manage the process.
Views about who should be responsible for post-launch surveillance were diverse.
In part this was due to the expressed lack of experience and knowledge in this
area. One statement was made that the problem with post-launch surveillance lies
with the current legislation that the health authorities in each state are working with,
not the absence of mandate. In fact it was suggested that the current regulatory
structure, which now primarily deals with food safety, could easily be extended
(given appropriate guidelines and funding) to the monitoring of functional foods.
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Table 8-5 Opinions on the regulatory environment for substantiation, claim wording and
monitoring of health claims

Major sub-category

Organisation responsible

Authority for substantiation

Food Standards Australia New Zealand (FSANZ)
Government body
Independent body
Authoritative body
Competent body

Authority for wording of claims

Food Standards Australia New Zealand (FSANZ)
Expert panel (communication experts)

Post-launch surveillance

Food Standards Australia New Zealand (FSANZ)
State/Territory health authorities
Australia Competition and Consumer Commission
Consumer Association
Australia Food & Grocery Council and peers
Independent body

Removal of regulatory hurdles
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Despite there being insufficient data on the possible influences of health claims on
eating behaviour (416) there is a demand for health claims, particularly from the
food industry (27), whereas others warn of the potential threat they may pose to
public health (417). Not surprisingly then, in this study, a range of stakeholder
beliefs regarding the level of evidence required for the substantiation health claims
was found (Table 8-6). Putting the relative merits to one side, it was widely
accepted by participants that evidence is required to support health claims.
However, details regarding the level of evidence required and the type of evidence
varied. It was apparent from the interviews that a clearly articulated structured
approach to the assessment of evidence is warranted. The consideration of
functional foods within the context of the total diet of the intended population was
also regarded as an important consideration. Participants expressed the need to
consider the totality of the evidence relevant to the proof of claim. Policy related to
the establishment of evidence for health claims needed to address the challenge of
determining the appropriateness of extrapolating evidence from a controlled
research environment to the general population, an issue already debated in the
literature (10).
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Table 8-6 Categories of evidence identified as required for substantiation of health claims
for functional foods

Major subcategory

Minor subcategory

Exemplar Quote

Cochrane-type
review

Established
evidence

‘What I have a lot of respect for are Cochrane reviews and
the reason I have a lot of respect for those is that they give
you the criteria under which they are reviewing’

Food modelling
studies

‘Food is not drugs. There is a whole lot of contingencies
associated with this and the main one is the reference to the
whole diet and the variation that occurs within usual dietary
pattern and somehow we need to get a grip on that as well’

Totality of the
evidence

‘certainly human experimental research is essential but then
there is the issue in terms of substantiating the link between
the claim and the functioning of that particular food’

Effectiveness trials

‘The testing and the efficacy of those foods are often
undertaken through clinical trials. Often using fairly small
groups and then through really a slight of hand they are then
promote it to wider populations outside the clinical trials
themselves’

Bioavailability

‘…but its important that it actually works in that product
because it might be that one product would bind the active
ingredient and that it would not be bio-active anymore’

There was unanimous agreement that evidence used to support a health claim
should be available to the public, however the timing of this availability was an
issue (Table 8-7). In order to gain first to market benefits, some suggested that the
evidence should only be made available once communication commenced. This
raises the larger issue of claimant protection. There were disparate views ranging
from the belief that claimant protection only served the interest of industry, whilst
undermining public health goals, to a fundamental requirement of the legislation to
support innovation. In addition, some believed that while patenting legislation, trade
marks and fair trading legislation provide some protection for innovation,
procedural changes to the review process would assist claimant protection.
Disparity between stakeholders emerged on the necessity of claimant protection.
Some stakeholders believed that protection was unnecessary and that the benefit
for the greater good (through decreased competition and increased process) would

192
be compromised if there was significant claimant protection, whereas others
believed that company investment should be protected to ensure continuing
investment in innovation. One way to view this disparity is to investigate these
beliefs as a function of ideology. According to Eccleshall et al (2003) (407),
recurrent controversies through several centuries of Western thought reveal a
polarity that extends from extreme “left-wing” humanism to an extreme “right wing”
normative position. Here the desire for a greater good can be viewed as a
humanist feature and claimant protection of rights as a normative feature.
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Table 8-7 Categories of responses on intellectual property

Major subcategory

Minor sub-category

Exemplar Quote

Evidence
available to
the public

Evidence provided to the
public unconditionally

‘Absolutely, because for people like me who
are interested in it you want more information’

Evidence provided to the
public conditionally

‘I think [evidence available to the public] once
a company starts to talk to consumers about
it’

Claimant
protection

Unnecessary

‘…the public health outcome is the greater
good and if there is a copycat product out
there in the market then there is a greater
opportunity for consumers to take advantage
of these benefits [bringing cost down] we
should support that’

Covered under IP
regulation

Need to protect investment
and promote innovation

Change of FSANZ act on
public comment

Has potential to undermine
Public Health goals

8.4

‘…I think in terms of intellectual property there
are things like patenting or identifying an
actual process of manufacturing [which] could
potentially be patented, rather than the actual
ingredient or formulation’
‘if you were sinking hundreds of millions of
dollars which some of them do, it is
reasonable that if you’re first to market you
should get some protection’
‘… a company produces a new product but
they’re restricted from putting it on the market
until they go through a rigorous consultation
process where all their IP is made publicly
available before the product is launched’
‘Public health [and the public] would probably
benefit more if it [IP]was accessible to
anybody or any company so it can be more
widely distributed for cheaper’

Conclusion

The findings of this research need to be interpreted in the context of the limited
sample frame of stakeholders, with the omission of ‘average consumers’ noted.
There is also solely an Australian perspective on an issue that is legislated in
partnership with New Zealand. A cautionary note is also required on the
examination of ideology. In an effort to draw out insights of ideology from beliefs
expressed by participants the clear link between stakeholder views and the
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ideologies they represent needs to be considered in terms of everyday realities.
For example, to assume that the ideology of a normative position can be drawn
neatly from the beliefs expressed by those who represent the food industry is to
reduce the complexity of both normative ideology and food industry politics to
banal caricatures. Also, despite the characterisation of the humanist and the
normative orientations as opposites, at an individual level they are often
orthogonal, that is, both can be held by the same person when considering
different aspects of the topic of functional foods.
This research has revealed that there are a number of areas of agreement
between stakeholder positions. Stakeholders in this study agreed that there was a
role for functional foods in specific cases where the evidence supported the use.
There were consensus that these functional foods should be safe, stable, and the
bioactive agent available in the products. There was also agreement amongst
stakeholders that regulation was required, and there was a need for evidence to
substantiate claims. One feature of this research is that it also started to distinguish
areas of disagreement. The most significant incongruity between stakeholders was
related to the beliefs about the process of substantiation and regulation of health
claims, as well as the evidence required for substantiating these claims.
Interestingly the areas of disagreement are often characterised by the lack of clear
scientific evidence available to inform stakeholder views. Examples included the
beliefs expressed that plant sterol foods are only effective with adjunct education,
contrasted with an alternative belief that they may be harmful for certain subgroups. Stakeholders thus sometimes rely on pre-existing ideology to form beliefs
and attitudes and this is in stark contrast to the stated beliefs regarding evidence
for claims. We have categorised these ideologies as examples of “humanism” vs.
“normative”. Emancipation from these ideologies is required to ensure consumer
interests, from both a public health and market demand perspective, remain at the
heart of decision making on functional foods.
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In the formulation of regulation in relation to functional foods it may be tempting to
hold off decision making until conclusive evidence is available. With this being
unlikely, the process is inevitably political, and in making political decisions the
concept of emancipation from ideologies is a very useful one. The clarification of
differences and their ideological bases can help find common ground between
stakeholders and lead to different approaches to the problem. The issue of political
uncertainty thus can be managed by transparency of decision making (333). In
countries like Australia where current legislation is under review, it is important that
policy is founded on dialogue that is responsible and reflective, genuinely inclusive
and free from domination from any one stakeholder group.
The effectiveness of the functional food concept as a means for primary prevention
of CHD ultimately relies on consumer acceptance and the main priority of all
stakeholders should be the protection of consumer interests. Differences in beliefs,
attitudes and ideologies of stakeholder groups potentially distract from this goal.
When stakeholders are relying on ideology rather than evidence they do not
always make this explicit and sometimes people do not use evidence to support
their arguments in a rigorous way. It is suggested that the next step from this
exploratory work should be to focus on the identified areas of disagreement and
attempt to examine in more detail those issues using a scientific approach.
Particularly there needs to be an understanding about what evidence there is (or is
lacking) about how consumers are likely to understand and use health claims. Also
there needs to be agreement from stakeholders with differing views about what the
key consumer questions are and what study methods would be appropriate to
answer them. Some consensus meetings to do this might help inform national
research priorities.
8.5

Acknowledgements

I would like to thank all the participants who took part in this study and
acknowledge Lyn Politis for her help in transcribing the taped interviews.

196
CHAPTER 9

CONCLUSION
9.1

Summary

This research set out to examine the effectiveness of a functional food-led
intervention in the primary prevention of CHD by addressing the question: ‘can the
use of functional foods be used to help overcome a person’s natural aversion to
dietary change in a way that results in an observable health benefit?’ Analysis of a
variety of data collected through dietary trials, focus group interviews, surveys and
in-depth interviews suggest that it can. In the context of clinical practice where
patients present with clear diagnosis of hypercholesterolaemia, the dietary
prescription of plant sterol enriched margarine leads to clear improvements in
biochemical markers, without compromising the whole of the dietary profile.
However, targeting individuals with identified risk factors is only one part of the
solution, targeting healthy populations is also an important aspect of primary
prevention. As the chapter on increasing LCn-3 through enriched foods indicates,
functional foods can overcome LCn-3 deficiency as indicated by dietary analysis
and erythrocyte fatty acid fractions, but further benefits may be masked by the
unintended weight gain. It is important to stress that an attempt to investigate the
biological effects still leaves us wondering about the true ‘effectiveness’ of such an
approach. The chapters on consumer beliefs and attitudes not only provide
evidence for a relationship between beliefs, intention and behaviour, but also
demonstrate a complex picture of consumer use of n-3 enriched foods that
involves cognitive processes above and beyond taste and convenience which are
often regarded as primary determinants of food related behaviour. Factors affecting
beliefs about the effects of LCn-3 are not clearly understood, but it is believed that
negative publicity as a result of conflict between stakeholders is an important
factor. The final chapter on stakeholders argued that significant incongruence in
beliefs and attitudes lie not in the notion of functional foods per se, but the way in
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which they are promoted and advertised. Effective health claim legislation lies at
the heart of functional food promotion. If policy fails to consider consumers’
interests the potential public health gains could be negated through diminished
consumer confidence caused by conflict between stakeholder groups.
9.2

Theoretical significance

The findings of this study support the hypothesis that a functional food-led
intervention can be an effective preventative health strategy, but a note of caution
is required at this point lest their significance be extrapolated inappropriately. More
specifically, a functional food-led intervention using a single food, in a clinical
context, with the support of a health professional, supports the hypothesis that this
approach was more effective than usual practice. However, there are three main
considerations which may limit the applications in healthy populations. Firstly, the
nutritional composition of the vector or carrier of the functional ingredient needs to
be considered. It may be the case that vectors are high in fat and energy
concentration which may contribute to weight gain, which is counterproductive to
all nutrition interventions. Secondly, concentrations of the functional ingredient
must be incorporated into the vector in large enough quantities to be consumed
readily, otherwise an excess in energy intake is required to consume the desirable
intake. A final cautionary note concerns the way the functional food will be
consumed and therefore the effect on other foods in the diet and the ultimate diet
matrix. Subtle shifts in individual foods in the diet can lead to a dietary imbalance
when the entire diet profile is considered. This is exemplified by the importance of
the n-6 to n-3 ratio on CHD risk independent on total n-3 intake.
Notwithstanding the difficulties mentioned above, this research supports the claims
of behavioural theorists who argue that the merits of the Theory of Planned
Behaviour can be applied to food related behaviour, including the use of functional
foods enriched with LCn-3. Given the complex nature of human behaviour, this
gives us a method of prediction that again supports the theory that this approach
will be supported through individual changes in diet.
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The significance of this research is not, however, confined to the narrow realm of
utility of behavioural theory. Identifying stakeholder belief incongruence also
illuminates the wider theoretical issue of social power. This confrontation usually
takes place around the formation of health claim legislation. Underlying the
arguments are significant differences in ideology between the profit motives of the
food industry and the public health motives of health professionals. The
environmental context is an essential part of the epidemiological triad and is
essential in the effectiveness of primary prevention interventions (418).
9.3

Limitations and areas for further research

As the cautionary note above suggests, there are some limitations to this study, the
principal one being, as with all primary prevention interventions, the lack of
definitive evidence for the effect on mortality and morbidity in the population. In
low-risk populations without identifiable risk factors the likelihood of clinical events
is infrequent, necessitating a larger study group to achieve statistical power in
detection. Even when investigating at-risk individuals, large, expensive trial designs
are required to show any positive effect. This raises the question of the degree to
which conclusions about the effectiveness of this functional food approach can be
applied to primary prevention based on causal inference. In the absence of
definitive clinical trials cohort studies and population follow up may be the only way
to determine the ultimate effectiveness of this approach.
Another limitation concerns the quality of evidence obtained from behavioural
research. At best, models that have attempted to explain human behaviour have
only managed to explain up to 30% of the behaviour under investigation.
Therefore, most of the reasons for human behaviour cannot be explained through
questionnaire sampling and quantitation. Compared to the precision of biochemical
measurements, one cannot be as confident of conclusions based on these
sources.
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Although pre-clinical research into functional ingredients is well established,
research into the application of this knowledge is in its infancy and further research
is warranted. Not only is this needed to offset some of the limitations, but also to
pursue some important theoretical questions arising from this research.
Concerning dietary trials three studies are suggested. First, conducting an
intervention in patients within a clinical context, again using plant sterols, but this
time incorporating functional foods to reach n-3 targets. In addition this would need
to include a larger sample which would probably require a multi-centre trial. A
second trial, again using healthy subjects, could be designed to incorporate LCn-3
enriched functional foods but with greater emphasis placed on achieving fatty acid
targets with fewer foods (higher LCn-3 concentrations). By basing the intervention
on staple foods, and considering the energy and fat contribution to the overall diet,
the likelihood of observing positive effects in cardiovascular biomarkers would be
improved. In addition, due to the wide inter-individual variation in biomarkers (such
as lipid and lipoprotein) responses to dietary change, and the impact of the
presence of hypo and hyper-responders, which is related to genetic variation,
methodologies from the fields of nutrigenomics and nutriproteinomics will emerge
as an important component of this research (419). Thirdly, the logical conclusion to
these studies is to test the effectiveness of a portfolio approach to dietary
interventions incorporating functional foods – i.e. low fat, high sterol, high cereal
fibre, high folate, high n-3 fatty acids, low GL. This has also been suggested by
others (281).
Also, further research is required to pursue the nature of human behaviour in
relation to the use of these novel foods. Having identified cognitive targets for
intervention, research efforts could be focused on evaluating the effect that both
education campaigns and health claim on labels have on the beliefs, intentions and
ultimately behaviour of consumers. Also, this model could be extended to include a
wider range of psychosocial variables to build a more comprehensive picture of the
factors affecting consumer behaviour in relation to these foods. Finally, the
approach used in this research focused specifically on n-3 enriched functional
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foods. It would be worth researching the utility of this model with other functional
food ingredients, thus devising a range of product specific behavioural models
relating to functional food choice.
9.4

Policy implications

CHD remains a significant cause of chronic disease, our scientific understanding of
nutrition is expanding, innovation in the food supply leading to novel foods is
increasing and governments around the world are managing this through
legislative changes. These are immovable facts. It is clear that despite the lack of
definitive evidence on the effectiveness of primary prevention strategies, action is
required. It is necessary for the practical immediate application of the existing
knowledge regarding functional foods. Given the current legislative changes in
Australia it is timely that we look at the policy implications of this research. At the
centre of these suggestions is the consideration of consumer interests. As argued
earlier, despite the best scientific and technologic intent, without consumer
confidence the potential health benefits will be eroded.
The scientific design of these dietary trials provides a good model for the
substantiation of health claims. Often the launch of a functional food is preceded by
a body of animal, mechanistic, epidemiological, clinical trials. However, as argued
earlier the translation of results in the controlled context does not necessarily
translate into the free-living context. This is a point that is often overlooked. In
establishing evidence for the substantiation of health claims consideration should
be given to the demonstration of the effect in the proposed food, where trials in a
‘free-living’ context and with due consideration given to the effect on the whole diet.
With the knowledge that we can never replicate the true nature of human
behaviour in a study design, it is important to gather intelligence on consumer
beliefs and attitudes. For example, the widespread backlash against the
introduction of GM foods might have largely been averted by an understanding of
consumer attitudes. This has meant that the potential gains obtained from this
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technology will not be realised for a much longer time frame. Traditionally much
information about consumer views has been gathered by food companies with very
little being published and peer reviewed. It is in the interest of all stakeholders that
this information be available and should constitute part of the evidence required
when evaluating health claims.
Methods of communicating the functional efficacy of foods may be needed to
provide end users with a more accurate and complete view of the health effects of
foods than can be provided by health claims or food composition alone in view of
the complexity of the whole diet and whole foods (420). The health related effects
of foods are often so dependent on food properties that the effects cannot be
adequately represented by food composition alone (420). As a result, nutrient data
can be unhelpful, or even misleading to end users, and there is a need for
measures of functional efficacy that can be used to accurately guide evidencebased food choices for health (421).
Thus the balance between education and confusion is a fine one, and one that
requires continual assessment. Stringent monitoring and disincentives for thin or
misleading claims is one measure. Another is the research of consumer reactions
to claims built from widespread intelligence gathering of consumers. What is
suggested here is not that dissimilar to what is already known to industry but not in
the scientific domain. Equally important is a regulatory environment that supports
innovation and building incentives that reward innovation and protect industry
investment needs to be considered.
A functional food-led intervention is no longer a futuristic approach to ameliorating
lifestyle diseases. A new paradigm for diet, nutrition and lifestyle can be developed
utilising the social capital available within the interested stakeholders. Through the
development of scientifically based new functional foods, as well as education of
the public about their role in a healthy diet, the potential to reduce the burden of
lifestyle disease is great. The introduction of functional foods into the market place
must be accompanied by extensive evaluation of functional foods, from both a
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scientific effectiveness standpoint as well as a consumer standpoint. It is in the
interest of all that regulatory policy should be founded on dialogue that is
responsible and reflective, genuinely inclusive and free from domination by any
single stakeholder group. In addition there is a responsibility of all stakeholders to
advise on public health policy and the best ways of translating new science into
practical information to ensure that these new foods enter the market in an
equitable way that supports the health of both high-risk individuals and the
population at large.
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APPENDIX A
STEROL/STANOL STUDY RECRUITMENT ADVERTISEMENT

WANTED
Patients with hyperlipidaemia who are considered
candidates for cholesterol lowering medication.
The joint ethics committee of the Illawarra Area Health Service and the University of
Wollongong has approved a dietary intervention ‘field’ trial to be held at Port Kembla
Hospital. The aim of the study is to measure the effectiveness of a novel dietary
strategy in improving dietary compliance and improving biochemical parameters in
patients with hyperlipidaemia.
How to access the study
• Patients can be referred to the Port Kembla Dietitian clinic; Phone outpatients on
42238202
• Patients who do not fit the inclusion criteria or do not wish to participate in the
study will undergo routine nutritional assessment and counselling
• Written consent will be obtained prior to commencement of the study and
participation is voluntary
• In referring patients to the clinic, GP’s are asked to ensure information is included
on serum lipids, routinely assessed in clinical practice: total serum cholesterol;
LDL cholesterol; HDL cholesterol; triglycerides. This information will be required
at first referral and again after 3 months follow up.
Cost
• Free
Who will be conducting the research
• Mr Craig Patch, a qualified clinical Dietitian and PhD student
• supervised by Associate Professor Linda Tapsell from the Department of
Biomedical Science at the University of Wollongong
Benefits to General Practitioners
• Nutritional assessment and counselling of patients considered candidates for
cholesterol lowering medication
• Individual patient progress reports provided to the GP
• Results of study circulated to the members of the Illawarra Division of General
Practice
For further information contact:
• Craig Patch, Dietitian (PhD student), Port Kembla Hospital; phone: 42238166; email: patchc@iahs.nsw.gov.au
• Associate Professor Linda Tapsell, Director Smart Food Centre, Department of
Biomedical Science, University of Wollongong; phone: 42213152; e-mail:
linda_tapsell@uow.edu.au
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APPENDIX B
STEROL/STANOL STUDY LETTER TO TARGETED GP’S

Dr Frank Goderie
Woonona Medical Practice
380 Princess Hwy
Woonona 2517
10 May 2002

Dear Dr Goderie
Re: Patients with hyperlipidaemia wanted
As part of our efforts to develop quality dietetic services, we have recently started a dietary
lipid clinic at Port Kembla Hospital. This not only extends our services to the community,
but also enables us to evaluate models of effective dietetic practice in lowering blood lipids.
We feel this service is also important to general practitioners, in view of the recent budget
announcement aimed at raising prescriber awareness on trialing dietary therapy prior to
commencement of lipid-lowering medication.
Patients referred to our clinic for lipid management will be invited to participate in a research
trial. This study involves a prospective, randomised, dietary intervention trial. The aim of the
study is to measure the effectiveness of a novel dietary strategy in improving dietary
compliance and thereby biochemical parameters in patients with hyperlipidaemia. We will
be comparing dietary prescription of plant-sterol enriched margarines with standard dietary
practice. Patients that decline will receive dietary assessment and counselling as per standard
practice.
Dietary intake patterns will be monitored using research methodologies, and clinical
outcomes will include dietary and weight change and biochemical parameters, routinely
provided in referrals by GP’s in clinical practice include: total serum cholesterol; LDL
cholesterol; HDL cholesterol; triglycerides. The joint ethics committee of the Illawarra Area
Health Service and the University of Wollongong has approved the research.
Details of the study as well as access details are attached. Please feel free to refer any of your
patients with hyperlipidaemia.
Regards

Craig Patch MBA APD
PhD Candidate
Smart Foods Centre
University of Wollongong
Northfields Av, Wollongong NSW 2522. Australia

Phone: +61 2 42214232
Fax: +61 2 42214844
Mobile: 0408 266832
Email: csp03@uow.edu.au
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APPENDIX C
STEROL/STANOL STUDY PATIENT CONSENT AND INFORMATION FORM

UNIVERSITY OF WOLLONGONG & ILLAWARRA AREA HEALTH
SERVICE INFORMATION FORM
The efficacy of functional food prescription in free-living subjects with Hyperlipidaemia,
Craig Patch APD
The positive aspects of nutrition and heart health are very well established. A lot of
media attention is focussed on telling people what to eat; however the information is
often confusing. Helping people achieve an optimal dietary intake‐ that is good for
your heart‐ is the primary role of a dietitian. This study aims at investigating the best
strategy for achieving a healthy diet. In taking part of this study you will undergo the
following procedure. The first interview will involve the dietitian collecting
information about your usual food intake via a dietary history and a 3‐day food
record; Instructions measuring equipment (scales, measuring spoons, measuring
cups) will be provided. This will be followed up with dietary advice and counselling
based on the National Heart Foundation’s dietary guidelines. You will be allocated
into one of two groups. One month after your first appointment you will be reviewed
and further dietary advice will be provided. At three‐months and six‐months, a
follow‐up dietary history and 3‐day food record will again be performed. Your GP
will also follow your progress at this stage and will order a blood test. A phone call
reminder will be made one week prior to remind to start your food record and a time
will be made for a follow‐up appointment. Dietary advice will be provided as
necessary and follow‐up negotiated. Extensive work is involved in participating in
the study.
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UNIVERSITY OF WOLLONGONG & ILLAWARRA AREA HEALTH
SERVICE CONSENT FORM
The efficacy of functional food prescription in free-living subjects with Hyperlipidaemia,
Craig Patch APD

This project is being conducted as part of a Doctor of Philosophy (PhD). The research
is supervised by Assoc Prof Linda Tapsell, Smart Food Centre, University of
Wollongong.
Your participation in this research is voluntary, you are free to refuse to participate
and you are free to withdraw from the research at any time. Your refusal to
participate or withdrawal of consent will not affect your treatment in any way/your
relationship with Port Kembla Hospital, the Department of Nutrition & Dietetics or
your relationship with the University of Wollongong. All results and information is
confidential and your name will not be used. All data will be collected by me and
stored (confidentially) in the department. If you would like to discuss this research
further please contact Craig Patch on 4223 8166 or Assoc Prof Linda Tapsell on 4221
3152. If you have any enquires regarding the conduct of the research please contact
the Secretary of the University of Wollongong, Human Research Ethics Committee on
4221 4457.
I,..................................................................................(Participant’s name) consent to
participate in the research conducted by Craig Patch as it has been described to me in
the information sheet. I understand that the data collected will be used for research
and I consent for the data to be used in this manner.
Signed Date
......................................................................................

......../......../.........
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APPENDIX D
STEROL/STANOL – CONTROL & INTERVENTION MEAL PLANS

Eating for a Healthy Heart
Suggested Meal Plan
BREAKFAST
Breakfast cereal with Low fat milk
Fresh, tinned, dried fruit or juice
Toast with margarine with a scrape of Peanut butter, honey etc
LUNCH
Wholemeal bread or roll or flat bread with Margarine
Add salad or vegetables with a low fat or olive oil or avocado
Add a small serve of lean meat, chicken or fish (twice a week)
Finish meal with fruit (fresh, dried, tinned or pureed)
EVENING MEAL
An optional start to the meal - soup (broth, vegetable or creamed - use low
fat evaporated milk instead of cream)
Select starchy vegetables (potato, sweet potato or corn), rice, pasta or
legumes (eg kidney beans, lentils)
Add salad or vegetables with a low fat or olive oil or avocado
Add a medium serve of lean, eats (fat trimmed from pork, lamb or beef) or
skinless poultry (chicken or turkey) or fish, fresh or tinned (eg Tuna in
water, spring water or drained of oil) or egg or reduced fat cheese.
Finish meal with fruit based dessert- fresh or tinned served with low fat ice
cream or yoghurt
When dining out, limit deep-fried, battered or pastry based foods
AT MID MEAL SNACKS
Choose from a small tub of low fat yoghurt fruit or plain, or a piece of fruit,
or a slice of raisin toast with Margarine or a glass of low fat milk or a couple
of plain biscuits, scones etc.

Department of Nutrition & Dietetics
Port Kembla Hospital
PO Box 21 Warrawong 2502

ARC Key Centre of Teaching and Research
University of Wollongong
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APPENDIX E
STEROL/STANOL STUDY DIET HISTORY QUESTIONNAIRE
The University of Wollongong
Metabolic Research Centre
Illawarra Dietary Intervention Studies
Name of study: The Efficacy of functional food prescription in free‐living
subjects with hyperlipidaemia

Research Diet History

Participant code:

260

261

262

263

264

265

266

267
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270
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272

273

274

275

276

277

278
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APPENDIX F
STEROL/STANOL STUDY FOOD RECORD QUESTIONNAIRE
The University of Wollongong
Metabolic Research Centre
Illawarra Dietary Intervention Studies
Name of study: The Efficacy of functional food prescription in free‐living
subjects with hyperlipidaemia

3‐Day Food Record

Please record everything that you eat and drink for 3 days (two
consecutive weekdays and one weekend day)

Participant code:

280

281

282

283

284

285

286

287
APPENDIX G
OMEGA STUDY INFORMATION FORM AND CONSENT
versity Department of Medicine
dical Research Foundation Building
el 4, Rear 50 Murray Street
h, Western Australia 6000

Dr Trevor A Mori
Telephone
61 8 9224 0273
Facsimile
61 8 9224 0246
Email
tmori@cyllene.uwa.edu. au

SUBJECT INFORMATION SHEET

DEVELOPMENT AND EVALUATION OF NOVEL FOODS ENRICHED WITH
VERY LONG CHAIN OMEGA-3 FATTY ACIDS
Purpose of the Study:
There is considerable evidence that omega-3 fats found mainly in fish and fish oils have
wide-ranging health benefits. Consequently, the National Heart Foundation of Australian,
health authorities and nutritionists, now recommend that we eat more omega-3 fats.
Increased consumption of omega-3 fats may reduce heart disease and stroke by
improving blood pressure and heartbeat disturbances, by reducing blood clotting, and
favourably altering blood fats (i.e. reducing triglycerides and increasing HDL-cholesterol,
the “good” fraction of cholesterol).
Most Australians consume less omega-3 fats than recommended by health authorities.
This means that the majority of Australians do not receive the potential benefits of
dietary omega-3 fats. While fish remains the best source of omega-3 fats, Australians
consume relatively little fish. One possible reason for the failure to achieve the dietary
recommendations for omega-3 fats is the limited range of readily available foods that can
deliver these nutrients. A potential solution is the development of novel foods enriched
with omega-3 fats. We propose to develop foods enriched in omega-3 fats and test the
effectiveness of these foods on heart risk reduction.
Subjects and Groups:
40 non-smoking men and women, aged 20-65 years, who are overweight (i.e. have a
body mass index > 25 kg/m2, a waist circumference > 100 cm, a waist/hip ratio > 1), and
have elevated blood triglycerides (>1.6 mmol/L), but are otherwise healthy, will be
recruited from the general community. People not eligible include those with diabetes,
recent symptomatic heart disease, a history of heart disease or stroke, peripheral vascular
disease, major surgery within the last 3 months, high blood pressure (>170/100 mmHg),
liver or kidney disease, regular users of non-steroidal anti-inflammatory drugs, drugs for
high cholesterol or high blood pressure control, and those eating more than one fish meal
per week or regularly taking fish oil supplements.
Procedures:
A. At the beginning of the study volunteers will attend the University Department of
Medicine Research Unit at Royal Perth Hospital (Murray St) for 1 visit (approx 30-45
minutes).
At the screening visit volunteers will:
1. Complete a lifestyle questionnaire;
2. Complete a brief medical history questionnaire;
3. Have height, body weight and waist circumference recorded;
4. Have blood pressure measured sitting, at 1 min intervals for 5 minutes;
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1.

Provide a small blood sample (~10 ml). A blood donation at the blood bank is ~500
ml. This procedure may cause mild bruising at the site where the blood is taken.

B. Volunteers who meet the entry criteria will be invited to participate in the study. Over a 2
week period they will be asked to attend our Department for 2 visits (approx 30-45
minutes each). At each visit, volunteers will be required to fast (water is allowed) for 12
hours prior to their visit. They will:
1.
2.
3.
4.
5.
6.

7.

Maintain usual diet and drinking habits;
Have measurements of body weight taken at each visit;
Complete a lifestyle questionnaire detailing alcohol consumption and physical
activity at one visit;
On one occasion, complete 24 hour dietary diaries on 3 separate days of the week;
Provide a small blood sample (~50 ml) at one visit;
Have blood pressure measured by an automated recorder at each visit. Volunteers
will be rested for 10 minutes, then blood pressure and heart rate will be measured
every 2 minutes for 20 minutes while lying down and every minute for 5 minutes
while standing.
Undertake assessment of blood vessel function. This is a non-invasive test that is
similar to having your blood pressure taken. The test measures stiffness of the blood
vessels determined from an artery in the arm.

C. Volunteers will then be randomly allocated (i.e. by chance) to one of two groups, either:
(1) a treatment group, that will be consuming a range of omega-3 fatty acid enriched
foods (the total amount of fish oil-derived omega-3 fats consumed will be approximately
1g per day), or (2) a control group, that will consume the same quantity of test foods as
the treatment group, but versions of these foods will not contain omega-3 fatty acids.
Low fat, moderate sodium intakes will be advised for both groups, in keeping with
Australian dietary guidelines. Individual dietary intake will be determined at baseline
ensuring minimal change from usual eating patterns but accommodating the test foods. A
list of foods will be provided to enable variety within constraints of desired macronutrient
consumption patterns. All participants will be asked to continue their usual lifestyle and
physical activity throughout the 6-month intervention period.
D. At the end of 3 and 6 months, volunteers will be asked to attend our Department for 2
visits (approx 30-45 minutes each) during which they will have all measurements as
outlined in B.2-7 above repeated.

Participants are free to withdraw from the study at any time and their records will be
destroyed, unless otherwise agreed by the participant. Any medical treatment needed
during the trial will not be prejudiced. All personal information collected in this study
will be kept strictly confidential. Your participation in this study does not prejudice any
right to compensation, which you may have under statute or common law. The Human
Research Ethics Committee at the University of Western Australia has given approval for
this study. Any concerns regarding the project can be directed to the Secretary, Human
Research Ethics Committee, Registrar’s Office, University of Western Australia, 35
Stirling Highway, Crawley, WA 6009 (telephone number 9380-3703). Any questions
concerning the study can be directed to Dr Trevor Mori or Professor Ian Puddey of the
Department of Medicine, Royal Perth Hospital on Telephone: 9224 0273 or 9224 0252.
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versity Department of Medicine
dical Research Foundation Building
el 4, Rear 50 Murray Street
h, Western Australia 6000

Dr Trevor Mori
Telephone
61 8 9224 0273
Facsimile
61 8 9224 0246
Email
tmori@cyllene.uwa.edu.au

CONSENT FORM

DEVELOPMENT AND EVALUATION OF NOVEL FOODS ENRICHED WITH
VERY LONG CHAIN OMEGA-3 FATTY ACIDS
1. I have read a summary of the study and its nature has been fully explained to me. I
consent to take part.
2. During screening I will be required to attend the University Department of Medicine
Research Unit at Royal Perth Hospital (Murray St) for 1 visit (approx 30-45 minutes).
I will be asked to:
(a) Complete a lifestyle questionnaire;
(b) Complete a brief medical history questionnaire;
(c) Have height, body weight and waist circumference recorded;
(d) Have blood pressure measured sitting at 1 min intervals for 5 minutes;
(e) Provide a small blood sample (~10 ml). A blood donation at the blood bank is ~500
ml. This procedure may cause mild bruising at the site where the blood is taken.
3. If eligible for participation in the study, I will over a 2 week period be asked to attend the
UDM Research Unit at RPH for 2 visits (approx 30-45 minutes each) during which I will:
(a) Maintain usual diet and drinking habits;
(b) Have measurements of body weight taken, at each visit;
(c) Complete a lifestyle questionnaire detailing alcohol consumption and physical
activity, at one visit;
(d) On one occasion, complete 24 hour dietary diaries on 3 separate days of the week;
(e) Provide a small blood sample (~50 ml) at one visit;
(f) Have blood pressure measured by an automated recorder at each visit. I will rest for
10 minutes, and then blood pressure and heart rate will be measured every 2 minutes
for 20 minutes while lying down and every minute for 5 minutes while standing.
(g) Undertake assessment of blood vessel function at each visit. This is a non-invasive
test that is similar to having blood pressure taken. The test measures stiffness of the
blood vessels determined from an artery in the arm.
I understand that I will be randomly allocated (i.e. chance) to one of 2 groups, a control group
or a treatment group. I may be required to either: (1) consume a range of omega-3 fatty acid
enriched foods (the total amount of fish oil-derived omega-3 fats consumed will be
approximately 1g per day), or (2) consume the same quantity of test foods as the treatment
group, but versions of these foods will not contain omega-3 fatty acids. Low fat, moderate
sodium intakes will be advised for both groups, in keeping with Australian dietary guidelines.
My dietary intake will be determined at baseline ensuring minimal change to my usual eating
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3. patterns, but accommodating the test foods. I will receive a list of foods to enable variety
within constraints of desired macronutrient consumption patterns. I will be asked to
continue my usual lifestyle and physical activity throughout the 6-month intervention
period.
4. At the end of 3 and 6 months, I will be asked to attend the University Department of
Medicine Research Unit at Royal Perth Hospital for 2 visits (approx 30-45 minutes each)
during which I will have all measurements as outlined in 3 (a)-(g) above repeated.

I have read the Subject Information Sheet and the information above, and any questions I
have asked have been answered to my satisfaction. I agree to participate in this activity,
realising that I may withdraw at any time without reason and without prejudice, or without
prejudice to my future medical treatment.
I understand that all information provided is treated as strictly confidential and will not be rele
I agree that research data gathered for the study may be published provided my name or other

_____________________________

______________

Signature of Participant

Date

_____________________________

______________

Signature of Investigator

Date

The Human Research Ethics Committee at the University of Western Australia requires that all
participants are informed that, if they have any complaint regarding the manner, in which a research
project is conducted, it may be given to the researcher or, alternatively to the Secretary, Human
Research Ethics Committee, Registrar’s Office, University of Western Australia, 35 Stirling Highway,
Crawley, WA 6009
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APPENDIX H
OMEGA STUDY DIET SHEET AND OMEGA LOG

Study Diet Sheet
Diet
guidelines

•
•
•
•
•
•

Eat your usual diet and substitute the test foods in to your usual eating
pattern.
Consume a total of at least 8 omega points per day (You may have
additional test foods as desired)
Limit to one fish meal per week – this includes tuna sandwiches and
anchovies on pizza
Avoid omega enriched foods other than the study foods
Foods are only to be consumed by study participants
Try not to overeat so that you do not put on weight

Suggested Omega Plan

Consume your usual diet to include:
Muesli or oats plus 250ml milk
or
2 Toast with 4 tsp spread
or
1 Toast with 2tsp spread plus 2 eggs
or
3 pancakes with 20g spread

Morning Tea

Le Snak or muffin or Biscuits or dip or 250 ml
milk

1

Lunch

2 slices bread with 20g spread
plus
Egg or soup or Caesar dressing or
250ml milk

3

Afternoon Tea

Le Snak or muffin or 2 Biscuits or dip or
250ml milk or 3 pancakes

1

Dinner/Supper

Caesar dressing or 2 chocolates or Le Snak
or dip or 250ml milk

1

Test food

Omega point
system

Omega
points

Breakfast

Bread
Spread
Milk
Cereal
Soup
Biscuits
Eggs
Le Snak
Chocolate
Dip
Muffin
Pancake
Caesar Dressing

Serve size

2

Omega points

2 slices
20g (4 tsp)
250ml
1 packet
1 packet
2 biscuits (1pkt)
2 eggs
1 serve (dip)
2 serve
1 serve
1 (as per directions)
3 (as per directions)
40ml (2Tbs)

1
1
1
1
1
1
1
1
1
1
1
1
1
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Additional information
___________________________________________________
___________________________________________________
___________________________________________________
___________________________________________________
___________________________________________________
___________________________________________________
___________________________________________________
___________________________________________________
___________________________________________________
___________________________________________________
___________________________________________________
___________________________________________________
___________________________________________________
___________________________________________________
___________________________________________________
___________________________________________________
___________________________________________________
___________________________________________________
___________________________________________________
___________________________________________________
___________________________________________________
___________________________________________________
___________________________________________________
___________________________________________________
___________________________________________________
___________________________________________________
___________________________________________________
___________________________________________________
___________________________________________________
___________________________________________________
___________________________________________________
___________________________________________________
___________________________________________________
___________________________________________________
___________________________________________________
___________________________________________________
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Food item

Bread
Margarine
Cereal
Milk

Serve size = 1
omega point
2 slices
20g (4tsp)
1 packet
250ml

Biscuits

2 biscuits

Soup

1 packet

Eggs

2 eggs

Le Snak

1 packet (dip)

Chocolate

2 items

Dip

1 packet

Muffin

1 as per
directions

Pancake

3 as per
directions

Dressing

40ml (2Tbs)

Mon
__/__/__

Tue
__/__/__

Wed
__/__/__

Thu
__/__/__

Fri
__/__/__

Sat
__/__/__

Sun
__/__/__
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APPENDIX I
OMEGA STUDY DIET HISTORY QUESTIONNAIRE

Code:
Date:
Site:

diet history
questionnaire

Return to:
Smart Foods Centre
University of Wollongong
Northfields Av, Wollongong NSW 2522. Australia
Phone: +61 2 42214232
Fax: +61 2 42214844

ARC Key Centre of Teaching and Research
University of Wollongong

© dhq 2002. Tapsell LC, Patch CS.
diet history (Base) 2042

…/1
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Interviewer: _________________
DOB:
Ht:

_________________
____________cm

BMI: ___________ _

Age: ____________

Weight: ______________
BMR:

_______________

Medications: ___________________________________________________________
History of health conditions: _________________________________________________
Supplements: _____________________________________________________________
Physical activity level: _______________________________________________________

Core Food Choices: Please indicate the type of foods you select in these
categories
Food group
Milk (full fat,
skim)

Type

Food group
Spread (margarine
etc)
Oils (olive, canola)

Bread (white,
grain)
Drinks (sweetening)

Type
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Part 1: Breakfast
How often do you eat this meal?_____________________Home_______________Away_________

Breakfast Cereals/Porridge
Type

Amount

Frequency

Amount

Frequency

Amount

Frequency

Amount

Frequency

Milk with cereal
Sugar with cereal

Toast/Bread/Muffins etc (including toppings)
Type

Spread with toast
Topping on toast

Eggs and other cooked dishes
Type

Oil/fat

Other Foods (including drinks, fruit, yoghurt)
Type
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Part 2: Light Meal.

Lunch or Dinner (Circle)

How often do you eat this meal?_____________________Home_______________Away_________

Sandwiches/Rolls
Description (include all components)

Amount

Frequency

Amount

Frequency

Amount

Frequency

Other foods (including drinks, fruit, takeaway meals, cakes)
Description
Amount

Frequency

Spreads
Added salt
Salads
Description (include all components)

Dressings
Soups
Description (include all components)

Soup mix
Added salt
Bread
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Part 3: Main Meal.

Lunch or Dinner (Circle)

How often do you eat this meal?_________________________Home_______Away___________

Main dishes (include all components)

Oils/spreads
Dressings
Sauces

Amount

Frequency
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Other foods (include drinks, bread, side dishes, desserts, fruit)
Type
Amount

Frequency

Part 4: Foods consumed outside meals
How often do you eat snacks?_____________________Home_______________Away_________

Type

Amount

Frequency
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Part 5: Food Frequency Checklist
Food category
Bread/crumpet
Biscuits
Crispbreads/crackers
Cakes/scones/muffins/pastries
Pancakes
Beans/legumes
Fruit
Fruit juice
Soft drinks/cordials
Chocolate/lollies
Chips
Alcohol
Milk
Yoghurt
Ice cream
Cheese
Dip/cream cheese/cheese spread
Soy milk
Soy yoghurt
Eggs/omega eggs
Salmon/tuna (fresh/canned)
Sardines/Mackerel
White fish varieties
Oysters
Walnuts
Pecans
Other nuts
Seeds

Amount

Frequency
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Part 6: Food Preparation Practices
6.1 Butter/Margarine _
What type do you usually use?
Butter
Dairy blend
Margarine - polyunsaturated, regular
Margarine - polyunsaturated, reduced fat
Margarine - monounsaturated, regular
Other_____________________________
6.2 Oil/Fat in cooking
What type of oil/fat do you use in cooking?
Butter
Dairy blend
Margarine - polyunsaturated, regular
Margarine - polyunsaturated, reduced fat
Margarine - monounsaturated, regular

Olive oil
Canola oil
Soybean oil
Gold’n Canola
Other _________________________

6.3 Fat on Meats/Chicken________________________________
How much fat is trimmed from meat before cooking/eating?
a) None
b) 25%
c) 50%
d) 75%
e) All
How much of the skin on chicken to you remove before cooking/eating?
a) None
b) 25%
c) 50%
d) 75%
e) All
Other, please specify: ___________

…/1
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APPENDIX J
OMEGA STUDY 3-DAY FOOD RECORD QUESTIONNAIRE

Code:
Date:
Site:

3-day food record

Study centre to return to:
Craig Patch MBA APD
PhD Candidate
Smart Foods Centre
University of Wollongong
Northfields Av, Wollongong NSW 2522. Australia
Phone: +61 2 42214232
Fax: +61 2 42214844
Mobile: 0408 266832
Email: csp03@uow.edu.au

ARC Key Centre of Teaching and Research
University of Wollongong

© fr 2002. Tapsell LC, Patch CS.
food record (Base) 2040

…/1
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Date:___________________

Breakfast and Morning Tea
Checklist
Cereal
Bread
Eggs
Cream cheese
Milk drinks
Soup mix
Caesar
dressing

Biscuits
Le Snak
Dip
Muffins
Pancakes
Chocolate

Food

Amount
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Date:___________________

Lunch and Afternoon Tea
Checklist
Cereal
Bread
Eggs
Cream cheese
Milk drinks
Soup mix
Caesar
dressing

Biscuits
Le Snak
Dip
Muffins
Pancakes
Chocolate

Food

Amount
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Date:___________________

Dinner and Supper
Checklist
Cereal
Bread
Eggs
Cream cheese
Milk drinks
Soup mix
Caesar
dressing

Biscuits
Le Snak
Dip
Muffins
Pancakes
Chocolate

Food

Amount
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APPENDIX K
OMEGA STUDY FOOD PREFERENCE QUESTIONNAIRE

Code:
Date:
Site:

Food preference questionnaire

Directions
Thank you for completing this questionnaire. This should only take a couple of
minutes. Please answer all questions. Please do not identify your name on any part
of the questionnaire.
For each study food listed answer the five questions (a,b,c,d & e).

Margarine:
a. Please rate the taste of the study food:
Dislike '
'
extremely quite

'

'

'

slightly neither slightly

'
quite

'

Like

extremely

b. Comment

____________________________________________________________________
c. I consume this food ____ times a week
d. Do you intend to continue to consume this product over the next three months?

e. For you to be able to include this product in your diet did you:

'
'

Yes
No

' substitute a similar product already eaten, or
' add this product to your normal diet

Bread:
a. Please rate the taste of the study food:
Dislike '
'
extremely quite

'

'

'

slightly neither slightly

'
quite

'

Like

extremely

b. Comment

____________________________________________________________________
c. I consume this food ____ times a week
d. Do you intend to continue to consume this product over the next three months?

e. For you to be able to include this product in your diet did you:

'
'

Yes
No

' substitute a similar product already eaten, or
' add this product to your normal diet

…/1
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Milk:
a. Please rate the taste of the study food:
Dislike '
'
extremely quite

'

'

'

'

slightly neither slightly

'

quite

Like

extremely

b. Comment

____________________________________________________________________
c. I consume this food ____ times a week
d. Do you intend to continue to consume this product over the next three months?

e. For you to be able to include this product in your diet did you:

'
'

Yes
No

' substitute a similar product already eaten, or
' add this product to your normal diet

Muesli:
a. Please rate the taste of the study food:
Dislike '
'
extremely quite

'

'

'

slightly neither slightly

'
quite

'

Like

extremely

b. Comment

____________________________________________________________________
c. I consume this food ____ times a week
d. Do you intend to continue to consume this product over the next three months?

e. For you to be able to include this product in your diet did you:

'
'

Yes
No

' substitute a similar product already eaten, or
' add this product to your normal diet

Oat temptations (Apple & Sultana):
a. Please rate the taste of the study food:
Dislike '
'
extremely quite

'

'

'

slightly neither slightly

'
quite

'

Like

extremely

b. Comment

____________________________________________________________________
c. I consume this food ____ times a week
d. Do you intend to continue to consume this product over the next three months?

e. For you to be able to include this product in your diet did you:

'
'

Yes
No

' substitute a similar product already eaten, or
' add this product to your normal diet
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Ginger biscuit:
a. Please rate the taste of the study food:

'
Dislike '
extremely quite

'

'

'

slightly neither slightly

'
quite

'

Like

extremely

b. Comment

____________________________________________________________________
c. I consume this food ____ times a week
d. Do you intend to continue to consume this product over the next three months?

e. For you to be able to include this product in your diet did you:

'
'

Yes
No

' substitute a similar product already eaten, or
' add this product to your normal diet

Chicken Laksa soup:
a. Please rate the taste of the study food:
Dislike '
'
extremely quite

'

'

'

slightly neither slightly

'
quite

'

Like

extremely

b. Comment

____________________________________________________________________
c. I consume this food ____ times a week
d. Do you intend to continue to consume this product over the next three months?

e. For you to be able to include this product in your diet did you:

'
'

Yes
No

' substitute a similar product already eaten, or
' add this product to your normal diet

Creamy Vegetable soup:
a. Please rate the taste of the study food:
Dislike '
'
extremely quite

'

'

'

slightly neither slightly

'
quite

'

Like

extremely

b. Comment

____________________________________________________________________
c. I consume this food ____ times a week
d. Do you intend to continue to consume this product over the next three months?

e. For you to be able to include this product in your diet did you:

'
'

Yes
No

' substitute a similar product already eaten, or
' add this product to your normal diet
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Eggs:
a. Please rate the taste of the study food:
Dislike '
'
extremely quite

'

'

'

slightly neither slightly

'
quite

'

Like

extremely

b. Comment

____________________________________________________________________
c. I consume this food ____ times a week
d. Do you intend to continue to consume this product over the next three months?

e. For you to be able to include this product in your diet did you:

'
'

Yes
No

' substitute a similar product already eaten, or
' add this product to your normal diet

Le Snak:
a. Please rate the taste of the study food:

'
Dislike '
extremely quite

'

'

'

slightly neither slightly

'
quite

'

Like

extremely

b. Comment

____________________________________________________________________
c. I consume this food ____ times a week
d. Do you intend to continue to consume this product over the next three months?

e. For you to be able to include this product in your diet did you:

'
'

Yes
No

' substitute a similar product already eaten, or
' add this product to your normal diet

Mint Chocolate:
a. Please rate the taste of the study food:

'
Dislike '
extremely quite

'

'

'

slightly neither slightly

'
quite

'

Like

extremely

b. Comment

____________________________________________________________________
c. I consume this food ____ times a week
d. Do you intend to continue to consume this product over the next three months?

e. For you to be able to include this product in your diet did you:

'
'

Yes
No

' substitute a similar product already eaten, or
' add this product to your normal diet
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Salsa dip:
a. Please rate the taste of the study food:
Dislike '
'
extremely quite

'

'

'

slightly neither slightly

'
quite

'

Like

extremely

b. Comment

____________________________________________________________________
c. I consume this food ____ times a week
d. Do you intend to continue to consume this product over the next three months?

e. For you to be able to include this product in your diet did you:

'
'

Yes
No

' substitute a similar product already eaten, or
' add this product to your normal diet

Cracked pepper dip:
a. Please rate the taste of the study food:

'
Dislike '
extremely quite

'

'

'

slightly neither slightly

'
quite

'

Like

extremely

b. Comment

____________________________________________________________________
c. I consume this food ____ times a week
d. Do you intend to continue to consume this product over the next three months?

e. For you to be able to include this product in your diet did you:

'
'

Yes
No

' substitute a similar product already eaten, or
' add this product to your normal diet

Orange & Poppy seed muffin:
a. Please rate the taste of the study food:
Dislike '
'
extremely quite

'

'

'

slightly neither slightly

'
quite

'

Like

extremely

b. Comment

____________________________________________________________________
c. I consume this food ____ times a week
d. Do you intend to continue to consume this product over the next three months?

e. For you to be able to include this product in your diet did you:

'
'

Yes
No

' substitute a similar product already eaten, or
' add this product to your normal diet
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Pancake:
a. Please rate the taste of the study food:
Dislike '
'
extremely quite

'

'

'

slightly neither slightly

'
quite

'

Like

extremely

b. Comment

____________________________________________________________________
c. I consume this food ____ times a week
d. Do you intend to continue to consume this product over the next three months?

e. For you to be able to include this product in your diet did you:

'
'

Yes
No

' substitute a similar product already eaten, or
' add this product to your normal diet

Salad Dressing:
a. Please rate the taste of the study food:
Dislike '
'
extremely quite

'

'

'

slightly neither slightly

'
quite

'

Like

extremely

b. Comment

____________________________________________________________________
c. I consume this food ____ times a week
d. Do you intend to continue to consume this product over the next three months?

e. For you to be able to include this product in your diet did you:

'
'

Yes
No

' substitute a similar product already eaten, or
' add this product to your normal diet

Thank you for completing this questionnaire

…/1
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APPENDIX L
FOCUS GROUP MEDIA RELEASE

NEWS RELEASE
RESEARCHERS CONCERNED THAT
CONSUMERS DO NOT EAT ENOUGH FISH

Research suggests that Australians are not eating enough fish. Fish, in particular deep-sea
varieties, are high in omega-3 polyunsaturated fats, which offer a range of heart health
benefits.
Craig Patch – PhD student with the Smart Foods Centre – says the wide-ranging health
benefits of fish oil, which is high in omega-3 polyunsaturated fats, are well documented in
both in the prevention and treatment of cardiovascular disease.
Mr Patch states “Studies reveal that Australians consume on average 1.2 serves per week of
fish with nutrition authorities now recommending up to 3 serves per week. There is a
potential to improve heart health if we can get more people to eat marine omega-3 fats.”
“But not everyone can eat enough fish. Obviously factors such as food preferences and
disposable income affect fish consumption. However, factors such as depleting fish stocks
and distribution across an expansive continent have led to the proposed development of range
of foods enriched with fish oil,” said Mr Patch
Researchers at the University of Wollongong in collaboration with Goodman Fielder,
University of Adelaide and University of Western Australia are now developing and testing a
range of novel food products enriched with fish oil in order to deliver the health benefits of
fish to a wider number of consumers.
Dr Peter Williams, Head of the consumer insights program of the Smart Foods Centre said the
introduction of entire ranges of functional food products has brought with it a whole new set
of issues. “We need to understand what consumers think about new foods with added health
benefits and how to incorporate them into the diet.”
“We are conducting focus group research to find out what Wollongong consumers think about
these proposed changes to the food supply and how they would want new foods to be labelled
and advertised,” said Dr Williams
If you are interested in participating or wish to find out about other studies conducted by the
Smart Foods Centre please phone 42214600 for details on how you can be involved.
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APPENDIX M
FOCUS GROUP SUBJECT CONSENT AND INFORMATION FORMS
UNIVERSITY OF WOLLONGONG & ILLAWARRA AREA HEALTH SERVICE
INFORMATION FORM
Consumer salient beliefs and attitudes with regard to functional foods and food
labelling Craig Patch APD, Peter Williams PhD APD, Linda Tapsell PhD APD, Chung Sau Chan MS
Student
(Research supported financially by Goodman Fielder foods and the Australian Research Council)

The positive aspects of nutrition and health are well established. In response the fo
industry has launched a range of products with added nutrients beyond the norm
ingredients with health promoting affects eg margarine to lower cholesterol. Th
products are termed ‘functional foods’. The properties of these products are adverti
via the food label. It is uncertain how the availability of functional foods or fo
labelling claims affect food choices and it is important to find out what consumers thi
The aim of this study is to investigate the views of consumers toward both functio
foods and food labels.
In taking part of this study you will required to attend a focus group interview with 8
people. This will take approximately one and a half hours. You will be allocated to
of two groups: one will encourage discussion about functional foods and the other w
encourage discussion about low fat food labelling.
All conversations will be tape recorded and later transcribed for analysis. So
information about your age, name and marital status will be collected for purpose
analysis. All comments made during the focus groups will be treated as confiden
and will not be individually identified. While we can ensure confidentiality, the ext
of confidentiality within the focus group cannot be ensured. Record of focus gro
discussions on food labelling will be summarised in a report to Goodman Fiel
(Sponsor) foods and published as a scientific paper. Results from discussions
functional foods will be used in the development of a questionnaire to be used
subsequent research.
We ask consent of all participants to be contacted in the future to participate in a s
administered questionnaire survey. All participants will be reimbursed $20.00 for ti
travel costs and inconvenience. This payment does not depend on continu
participation.
If you would like to discuss this research further please contact Craig Patch on 42214
or Dr Peter Williams on 4221 4085. If you have any enquires regarding the conduc
the research please contact the Secretary of the University of Wollongong, Hum
Research Ethics Committee on 4221 4457.
Thank you for considering this request.
Craig Patch
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UNIVERSITY OF WOLLONGONG & ILLAWARRA AREA HEALTH SERVICE
CONSENT FORM
Consumer salient beliefs and attitudes with regard to functional foods and food
labelling Craig Patch APD, Peter Williams PhD APD, Linda Tapsell PhD APD, Chung Sau Chan MS
Student
(Research supported financially by Goodman Fielder foods and the Australian Research Council)

This project is being conducted as part of a Doctor of Philosophy (PhD). Dr Pe
Williams and Assoc Prof Linda Tapsell, Smart Food Centre, University of Wollongo
supervise the research.
Your participation in this research is voluntary, you are free to refuse to particip
and you are free to withdraw from the research at any time. Your refusal to particip
or withdrawal of consent will not affect your treatment in any way your relations
with Port Kembla Hospital, the cardiac rehabilitation team or your relationship with
University of Wollongong. All results and information is confidential and your na
will not be used. All data will be collected by me and stored (confidentially) in
department.
I,..................................................................................(Participant’s
name)
consent
participate in the research conducted by Craig Patch. Specifically I consent to:
• Participation in a 1.5hrs focus group of 8‐10 people at the University
Wollongong.
• The focus group will be audio taped, analysed and reported upon.
• My identity will remain confidential to the researchers.
I understand that the data collected will be used for research and I consent for the d
to be used in this manner.
Signed Date
...................................................................................... ......../......../.........

Consent to be contacted for subsequent survey

I,..................................................................................(Participant’s name) consent to be
contacted via the phone by Craig Patch to be involved in a survey as it has b
described to me in the information sheet. I understand that this does not compel m
participate in the survey.
Signed Date
...................................................................................... ......../......../.........
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APPENDIX N
FUNCTIONAL FOOD BELIEF QUESTIONNAIRE

Code:
Date:
Site:

functional food belief
questionnaire

Return to:
Craig Patch MBA APD
PhD Candidate
Smart Foods Centre
University of Wollongong
Northfields Av, Wollongong NSW 2522. Australia
Phone: +61 2 42214232
Fax: +61 2 42214844
Mobile: 0408 266832
Email: csp03@uow.edu.au

ARC Key Centre of Teaching and Research
University of Wollongong

© f2bq 2002. Patch CS, Tapsell LC, Williams PG.
f2bq base eatwell2044 2
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Part A – General details

Directions
Thank you for completing this questionnaire. This should only take 10-15 minutes.
Please answer all questions. Please do not identify your name on any part of the
questionnaire.
Once completed please return to the study center.
Part A - Please indicate your personal details by ticking ( ) a box.

a

1. Please indicate your age:
25 or under
26-35
36-45
46-55
56-65
66 or over
2. Please indicate your gender:
Male
Female
3. Please indicate your marital status:
Single/divorced/separated
Married/de facto
4. Do you have Children aged under 18 years old living with you?
No
Yes
5. Which best describes your shopping practices:
I am the main shopper
I share shopping with my partner
I do not shop for food
6. What is your employment status?
In paid work
Un paid work
7. Please indicate the income range of your household:
Less than $20,000 per year
$20,000-$40,000 per year
$41,000-$60,000 per year
$61,000-$80,000 per year
$81,000- $100,000 per year
greater than $101,000 per year
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8. Please indicate your highest level of education:
Primary school
High school
TAFE
University
Other
Please specify _______________
9. Please provide the best estimate of your height and weight:
Weight
____
Height
____
10. Please indicate any chronic condition(s) you have:
Asthma
High blood pressure
Diabetes
Cancer
Heart disease
Lung disease
Arthritis or other rheumatic disease
Other
Please specify _______________
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Part B

Directions
In this part of the questionnaire we are m
ainly concerned with your views toward foods with
added omega 3 oils. Some examples of these products include
Meadow Lea’s Hi-Omega
margarine and Tip Top’s UP bread.
In the questionnaire you are about to fill out we provide both statements and quest
ions which
we would like you to rate on a scale with seven boxes; you are to make tick
( ) in the place that
best describes your opinion.

a

For example, if you were asked to rate “the weather in Wollongong” on such a scale and
you
think the weather in Wollongong is extremely good, and then you would place your mark as
follows:
The weather in Wollongong is.
bad
extremely quite

slightly neither slightly

quite

a

good
extremely

If you think theweather in Wollongong isquite bad, then you would place your mark as follows:
The weather in Wollongong is.

a

bad
extremely quite

slightly neither slightly

quite

good
extremely

11. I intend to eat one or more foods with added omega-3 oils over the next
two weeks:
unlikely
extremely quite

slightly neither slightly

quite

likely
extremely

12. Overall, my attitude toward my eating foods with added omega-3 oils
over the next two weeks is:
unfavourable
extremely quite

favourable
slightly neither slightly

quite

extremely

13. I believe that improving general health is:
Not important
extremely quite

important
slightly neither slightly

quite

extremely
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14. I believe that obtaining the health benefits of omega-3 oils is:
Not important
extremely quite

slightly neither slightly

important
extremely

quite

15. How important is it for foods that have added omega-3 oils to contain
enough of this nutrient to provide a health benefit?
Not important
extremely quite

slightly neither slightly

quite

important
extremely

16. When eating foods with added omega-3 oils how important is it that
there is little risk of overexposure of this nutrient?
Not important
extremely quite

slightly neither slightly

quite

important
extremely

17. How important is it for food companies to base new food development
on good scientific evidence?
Not important
extremely quite

slightly neither slightly

quite

important
extremely

18. I believe that developing new ways to make it easier to choose a
healthy diet high in omega-3 oils is:
Not important
extremely quite

slightly neither slightly

quite

important
extremely

19. I believe that improving heart health for the general population is:
Not important
extremely quite

slightly neither slightly

quite

important
extremely

20. I believe that improving brain health for the general population is:
Not important
extremely quite

slightly neither slightly

quite

important
extremely

21. I believe that improving eye health for the general population is:
Not important
extremely quite

slightly neither slightly

quite

important
extremely
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22. I believe that improving arthritis for the general population is:
Not important
extremely quite

slightly neither slightly

important
extremely

quite

23. I believe that improving asthma for the general population is:
Not important
extremely quite

slightly neither slightly

important
extremely

quite

24. My eating foods with added omega-3 oils will improve my general
health:
unlikely
extremely quite

slightly neither slightly

quite

likely
extremely

25. My eating foods with added omega-3 oils makes it easy to obtain the
health benefits of this nutrient:
unlikely
extremely quite

slightly neither slightly

quite

likely
extremely

26. Foods with added omega-3 fats contain enough of this nutrient to
provide a health benefit:
unlikely
extremely quite

slightly neither slightly

quite

likely
extremely

27. My eating foods with added omega-3 oils puts me at risk of
overexposure of this nutrient in the diet:
unlikely
extremely quite

slightly neither slightly

quite

likely
extremely

28. Foods with added omega-3 oils have been developed and based on a
good understanding of the scientific evidence:
unlikely
extremely quite

slightly neither slightly

quite

likely
extremely

29. My eating foods with added omega-3 oils is an easy way to choose a
healthy diet:
unlikely
extremely quite

slightly neither slightly

quite

likely
extremely
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30. My eating foods with added omega-3 oils will improve my heart health:
unlikely
extremely quite

slightly neither slightly

likely
extremely

quite

31. My eating foods with added omega-3 oils will improve my brain health:
unlikely
extremely quite

slightly neither slightly

quite

likely
extremely

32. My eating foods with added omega-3 oils will improve my eye health:
unlikely
extremely quite

slightly neither slightly

quite

likely
extremely

33. My eating foods with added omega-3 oils will protect me from or
improve arthritis:
unlikely
extremely quite

slightly neither slightly

quite

likely
extremely

34. My eating foods with added omega-3 oils will protect me from or
improve asthma:
unlikely
extremely quite

slightly neither slightly

quite

likely
extremely

35. Most members of my family think that I should eat foods with added
omega-3 oils:
unlikely
extremely quite

slightly neither slightly

quite

likely
extremely

36. My close friends think that I should eat foods with added omega-3 oils:
unlikely
extremely quite

slightly neither slightly

quite

likely
extremely

37. Most dietitians think that I should eat foods with added omega-3 oils:
unlikely
extremely quite

slightly neither slightly

quite

likely
extremely

38. Most doctors think that I should eat foods with added omega-3 oils:
unlikely
extremely quite

slightly neither slightly

quite

likely
extremely
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39. Most scientists think that I should eat foods with added omega-3 oils:
unlikely
extremely quite

slightly neither slightly

likely
extremely

quite

40. Most food companies think that I should eat foods with added omega-3
oils:
unlikely
extremely quite

slightly neither slightly

likely
extremely

quite

41. Most people who are important to me think I should eat foods with
added omega-3 fats:
unlikely
extremely quite

slightly neither slightly

quite

likely
extremely

42. Generally speaking, I want to do what my family thinks I should do:
unlikely
extremely quite

slightly neither slightly

likely
extremely

quite

43. Generally speaking, I want to do what my close friends think I should
do:
unlikely
extremely quite

slightly neither slightly

quite

likely
extremely

44. Generally speaking, I want to do what the most dietitians think I should
do:
unlikely
extremely quite

slightly neither slightly

quite

likely
extremely

45. Generally speaking, I want to do what the most doctors think I should
do:
unlikely
extremely quite

slightly neither slightly

quite

likely
extremely

46. Generally speaking, I want to do what the most scientists think I should
do:
unlikely
extremely quite

slightly neither slightly

quite

likely
extremely

47. Generally speaking, I want to do what the food companies think I
should do:
unlikely
extremely quite slightly neither slightly

quite

likely
extremely
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48. How much control do you have over whether you do or do not eat
foods with added omega-3 oils?
Very little control
extremely quite

slightly neither slightly

quite

complete control
extremely

49. Even if I wanted to eat foods with added omega-3 oils they are often
not available where I buy food:
unlikely
extremely quite

slightly neither slightly

quite

likely
extremely

50. Even if I wanted to eat foods with added omega-3 oils I have no control
over what is bought from the supermarket:
unlikely
extremely quite

slightly neither slightly

quite

likely
extremely

51. Even if I wanted to eat foods with added omega-3 oils the cost prevents
me from buying them:
unlikely
extremely quite

slightly neither slightly

quite

likely
extremely

52. Even if I wanted to eat foods with added omega-3 oils the taste and/or
the texture prevents me from buying them:
unlikely
extremely quite

slightly neither slightly

quite

likely
extremely

53. Even if I wanted to eat foods with added omega-3 oils the time required
searching for these foods prevents me from buying them:
unlikely
extremely quite

slightly neither slightly

quite

likely
extremely

54. Even if I wanted to eat foods with added omega-3 oils if they were not
suitable for the entire family I would not buy them:
unlikely
extremely quite

slightly neither slightly

quite

likely
extremely

Thank you for your participation.
Please return the questionnaire to the st udy center on your next visit.
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APPENDIX O
VALIDATION OF F2BQ INFORMATION FORM AND CONSENT
UNIVERSITY OF WOLLONGONG & ILLAWARRA AREA HEALTH SERVICE
INFORMATION FORM
Development and validation of a questionnaire predict the use of functional foods ‐
Self administered questionnaire
Craig Patch APD, Peter Williams PhD APD, Linda Tapsell PhD APD, Chung Sau Chan MSc student
(Research supported financially by the Australian Research Council)

The positive aspects of nutrition and health are well established. There are a number of
products that claim to have health benefits. The latest range of products has nutrients in
addition to the normal ingredients and claim to have a health promoting effects eg
lowering cholesterol. These products are termed ‘functional foods’.
The aim of this study is to examine consumer beliefs and use of functional foods .

Specifically we will ask you to complete a self

‐administered questionnaire. This will

take approximately 20 ‐30 minutes. Questions will be on beliefs toward food and health
as well as current use of specific functional foods. All questionnaires will be anonymous
and results used for research purposes only. The que stionnaire should be returned as
soon as possible using the self ‐addressed envelope provided. If we do not receive this
within two weeks or we need to clarify answers we will contact you by phone.

If you would like to discuss this research further please contact Craig Patch on 42214232
or Dr Linda Tapsell on 4221 3152. If you have any enquires regarding the conduct of the
research please contact the Secretary of the University of Wollongong, Human Research
Ethics Committee on 4221 4457.

Thank you for co nsidering this request.
Craig Patch
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UNIVERSITY OF WOLLONGONG & ILLAWARRA AREA HEALTH SERVICE
CONSENT FORM
Development and validation of a questionnaire predict the use of functional foods
‐
Self administered questionnaire
Craig Patch APD, Peter Williams PhD APD, Linda Tapsell PhD APD, Chung Sau Chan MSc student
(Research supported financially by the Australian Research Council)

This project is being conducted as part of a Doctor of Philosophy (PhD). The research is
supervised by Assoc ProfLinda Tapsell, Smart Food Centre, University of Wollongong.

Your participation in this research is voluntary; you are free to refuse to participate
. Your refusal to participate
and you are free to withdraw from the research at any time
or withdrawal of c onsent will not affect your treatment in any way/your relationship
with the University of Wollongong. All results and information is confidential and your
name will not be used. All data will be collected by Craig Patch and stored in secure,
confidential holdings within the Department of Biomedical Sciences.

I,..................................................................................(Participant’s name) consent to
participate in the research conducted by Craig Patch. Specifically, I consent to:
• Completing a self‐administered questionnaire on functional foods received in the
mail.
‐addressed envelope provided.
• Returning this in the stamp self
• Being contacted by phone by Craig Patch if any questionnaires are not received
within 2 weeks or if thereis a need to clarify any of my responses.
I understand that the data collected will be used for research and I consent for the data
to be used in this manner.

Signed Date

...................................................................................
... ......../......../.........
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APPENDIX P
STAKEHOLDER STUDY INFORMATION SHEET AND CONSENT FORM
UNIVERSITY OF WOLLONGONG
INFORMATION FORM
Determining stakeholder beliefs and attitudes towards the development of and
communication about novel foods designed to improve or enhance health (functional
foods).
Craig Patch APD, Linda Tapsell PhD APD, Peter Williams PhD APD
(Research supported financially by an Australian Research Council Linkage grant with Goodman
Fielder Foods being the industry partner)
The positive aspects of nutrition and health are well established. In response the food industry has
launched a range of products with added nutrients beyond the normal ingredients with health
promoting affects eg margarine to lower cholesterol. These products are termed ‘functional foods’.
To this end the Australia New Zealand Food Regulation Ministerial Council agreed to a range of
policy initiatives, which included Nutrition, Health and Related Claims to be permitted on food
labels. In addition, the existing code on novel foods will be reviewed. This is a policy shift in
Australia and there are implications for Public Health.
Regulatory bodies often consult stakeholders on policy options, however there are no studies
reporting beliefs and attitudes of Australian stakeholders towards functional foods. Identifying
contrasting beliefs regarding this issue is important if we are to understand how we can use the food
supply to improve the health of the population.
The aim of this study is to investigate views of stakeholders toward the development and
promotion of functional foods and whether this is an appropriate strategy for improving
population health through the food supply.
In taking part of this study you will be required to attend a one-off interview. This will take
approximately one hour. All conversations will be tape recorded and later transcribed for analysis.
Some information about your age, name and workplace will be collected for purposes of analysis. All
comments made during the interview will be treated as confidential and will not be individually
identified. Results from discussions will be published in peer reviewed journal articles. We ask
consent of all participants and signature on the attached form is required.
If you would like to discuss this research further please contact Craig Patch on 42214232 or Prof
Linda Tapsell, on 4221 3152 or Dr Peter Williams on 4221 4085. If you have any enquires
regarding the conduct of the research please contact the Secretary of the University of Wollongong,
Human Research Ethics Committee on 4221 4457.
Thank you for considering this request.
Craig Patch
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UNIVERSITY OF WOLLONGONG
CONSENT FORM
Determining stakeholder beliefs and attitudes towards the development and communication
of novel foods designed to improve or enhance health (functional foods).
Craig Patch APD, Linda Tapsell PhD APD, Peter Williams PhD APD
(Research supported financially by an Australian Research Council Linkage grant with Goodman
Fielder Foods being the industry partner)
This project is being conducted as part of a Doctor of Philosophy (PhD). Prof Linda Tapsell and Dr
Peter Williams, National Centre of Excellence in Functional Foods (NCEFF), University of
Wollongong supervise the research.
Your participation in this research is voluntary, you are free to refuse to participate and you
are free to withdraw from the research at any time. Your refusal to participate or withdrawal of
consent will not affect your treatment in any way your relationship with the NCEFF, the Smart Foods
Centre or your relationship with the University of Wollongong. All results and information is
confidential and your name will not be used. All data will be collected by me and stored
(confidentially) in the department.

I,..................................................................................(Participant’s name) consent to participate in the
research conducted by Craig Patch. Specifically I consent to:
• Participation in a 1 hr interview group either via telephone of mutually agreeable venue.
• The interview will be audio taped, analysed and reported upon.
• My identity will remain confidential to the researchers.
I understand that the data collected will be used for research and I consent for the data to be used in
this manner.
Signed Date
......................................................................................

......../......../.........

